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Abstract 
Rhinovirus (RV) infections are the principal cause of asthma exacerbations. While Th2-
mediated inflammation is clearly implicated in the asthmatic response, it is unknown how 
the immune response to RV infection interacts with Th2 immunity to enhance disease 
pathogenesis. The epithelial-derived cytokine, IL-25, has been identified as an initiator and 
regulator of Th2 immunity and plays a role in asthma pathogenesis. Based on the fact that 
RV infects bronchial epithelial cells, we hypothesized that RV induces IL-25 production 
providing a link between infection and Th2 driven allergic inflammation. 
RV-induced IL-25 expression was measured in human bronchial epithelial cells (HBECs) 
obtained from bronchoscopic brushings from atopic asthmatics and healthy patients. Mouse 
models of RV infection and RV-induced allergic airways disease were also employed to 
examine IL-25 induction in response to RV infection and/or OVA sensitisation and challenge. 
Finally, to define a mechanistic role for RV-induced IL-25, signalling mediated by IL-25 was 
blocked in our model of RV-induced allergic airways disease by neutralising the IL-25 
receptor.  
RV-infected HBECs from asthmatics expressed significantly greater IL-25 gene and protein 
compared with cells from healthy controls. Furthermore, RV infection of mice induced IL-25 
expression in the airway epithelium as well as in inflammatory cells in the airway lamina 
propia. Using a mouse model of RV-induced allergic disease, we demonstrated that RV 
enhanced allergen-driven IL-25 gene and protein expression which was associated with 
increased Th2 inflammation in the lung. Finally, by blocking IL-25 signalling in an RV-infected 
and OVA-sensitised and challenged mouse, several key features of the exacerbation 
phenotype were significantly reduced including airway leukocyte infiltration, BAL Th2 
cytokines and chemokines and Th2 cells.  
These novel findings indicate that RV-induced IL-25 plays an important role in enhancing 
Th2 inflammation associated with the exacerbation phenotype which is mediated by binding 
to the IL-25 receptor.  
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Chapter 1: Introduction 
1.1 Human Rhinoviruses 
 1.1.1.  Disease Burden 
First isolated and cultured in 1953 from subjects displaying cold symptoms, human 
rhinoviruses (RV) have since been identified as the singular greatest cause of the common 
cold, accounting for approximately two-thirds of all acute and upper respiratory tract (URT) 
infections1,2. Non-influenza-related URT infections account for a total healthcare cost of $40 
billion per year in the US, while in the UK, children younger than 5 years of age with URT 
infections  account for 59% of general practitioner visits3,4. Therefore, the extrapolated 
economic burden of RV infections is substantial. 
 
Diagnosis and detection of RVs has improved significantly since the application of 
polymerase chain reaction (PCR)-based techniques for RV screening which had previously 
relied on less sensitive cell or organ culture techniques5. These methods have not only 
allowed discovery of genetically divergent, novel RV strains, including the new species  HRV-
C, but have also enabled higher detection rates than earlier epidemiological studies6,7. 
Notably, using reverse transcription (RT) PCR, investigators were able to confirm a theory 
long suspected by clinicians; namely, that respiratory viruses, most frequently RVs, are the 
principal trigger for asthma exacerbations in the vast majority of children and approximately 
two-thirds of adults8,9. More recently, increasing evidence also indicates a causative role for 
rhinovirus in chronic obstructive pulmonary disease (COPD) exacerbations10.  
While it was previously assumed that RV replication was restricted to the upper airways due 
to its ability to replicate optimally at 33-35oC , it has since become apparent that RVs have 
the ability to infect the lower airway 11. Increasing clinical and epidemiological evidence 
have linked RV infections to bronchitis, bronchiolitis and pneumonia in infants. Further to 
this, asthmatics, immunocompromised patients and the elderly have also been 
demonstrated to have increased susceptibility to lower respiratory tract (LRT) infections12-14. 
Studies in infants also indicate a role for RV in the progression of disease from allergic 
sensitisation to asthma15,16. 
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RV infections, which were previously viewed as self-limiting conditions in the upper airways, 
have the potential to cause severe lower respiratory tract infections, exacerbations and 
potentially induce asthma in susceptible individuals8,15,17.  Mechanisms of how RVs interact 
with these underlying immune conditions to precipitate disease are currently unknown.   
 
1.1.2 Circulation patterns and transmission 
RV infections occur year-round but have a peak incidence in the early fall and to a lesser 
extent in the spring in temperate climates18,19. Higher rates of infection in the young have 
been linked with return from school holidays19,20. On average, pre-school children have 6 RV 
infections per year while the rate of symptomatic infection decreases with age as illustrated 
by a lower incidence of 2-3 infections per year in adults18,21. Whether this is due to acquired 
immunity or lower transmission rates in adults is unknown19,22. Introduction of virus into the 
eye or nose from contaminated fingertips is the predominant route of transmission, though 
aerosolised inhalation can occur23,24.      
 
1.1.3 Classification, structure and life cycle 
RVs belong to the Picornaviridae family within the Enterovirus genus. Approximately 101 
serotypes have been identified which encompass a major group (HRV-A) that makes up 
~90% and a minor group (HRV-B) which accounts for the remaining 10%5,25. These serotypes 
are classified based on the receptor used for host cell entry; HRV-A utilises the intercellular 
adhesion molecule 1 (ICAM-1) while HRV-B binds the low-density lipoprotein (LDL) 
receptor26,27. More recently, a third species classified as HRV-C has been discovered by 
genomic sequencing although its receptor is currently unknown7.   
 
RVs are small, nonenveloped viruses comprised of a single-stranded, positive sense RNA 
genome of ~7200 nucleotides. A single open frame encodes 4 structural capsid proteins 
(VP1-VP4) and 7 non-structural proteins. These non-structural components include an RNA 
polymerase, Vpg (needed for negative strand synthesis), the protease 2A  (serves to shut 
down the translational machinery of the host cells) and the protease 3C/3CD (required for 
post-translational maturation)28. The viral shell is composed of 60 copies of the capsid 
proteins folded into an icosahedron which create characteristic depressions or ‘canyons’. 
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These ‘canyons’ contain ligands to the ICAM-1 receptor which, upon binding, cause 
destabilisation of the capsid29. RV is internalised via receptor-mediated endocytosis and 
uncoating occurs in the endosome allowing transfer of genomic RNA into the cytosol30. Due 
to the positive sense RNA orientation the genome is directly translated by the host cell. 
Utilising an internal ribosome-entry site (IRES) sequence that is located in the 5′ 
untranslated region (5′ UTR), RV is able to initiate a cap-independent mechanism of 
translation.  This, together with RVs ability to inhibit the hosts mRNA translation, enables 
rapid propagation of viral replication and synthesis28. In subjects experimentally infected 
with RV the growth cycle was reported to be approximately 5-7 hours (h) and progeny 
(released by cell lysis) were detectable within 11h post-infection (p.i.)31. The duration of 
onset of viral shedding was similar to conditions in cell culture32. Additional RV inoculation 
studies have demonstrated a peak in viral titres at 48h-72h p.i. while viral shedding can 
persist for up to 20 days p.i. 31,33.  
 
1.1.4 Disease pathogenesis and the host immune response 
RVs primarily enter and propagate within the upper respiratory tract, particularly the 
nasopharynx and nasal mucosa20.  In an otherwise healthy individual, the double-stranded 
viral RNA intermediate is recognised by the host pattern-recognition receptor (PRR), Toll like 
receptor (TLR) 3, which coordinates with melanoma differentiation associated gene-5 
(MDA5) and retinoic acid inducible gene (RIG-I),  to trigger a cascade of proinflammatory 
cytokines including the antiviral type I (IFN-β and IFN-α) and type III interferons (IFN-λ) 34,35. 
One of the most well characterised pathways is the induction of neutrophil-recruiting 
chemokine, CXCL8/IL-8, by RV-induced nuclear factor (NF)-κB activation which results in 
nasal obstruction via increased neutrophilia36,37. Congestive symptoms are related to nasal 
epithelial oedema, mucus hypersecretion and vascular permeability20. In a healthy 
individual, proinflammatory mediators including IL-1, IL-6, CCL5/RANTES, IFN-γ and TNF-α 
have been demonstrated to be induced by RV infections. This is characteristic of a T helper 
(h) 1 response and has been shown to be associated with enhanced viral clearance and 
shortened symptoms38,39. Cellular inflammation during RV infection involves neutrophil and 
T cell infiltration into the lung which in certain susceptible individuals (such as asthmatics) 
may be enhanced, worsening symptoms and affecting lung function. Bronchial CD4+ and 
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CD8+ T lymphocyte infiltration have also been observed at the height of cold symptoms in 
experimentally infected patients40. Due to RV’s limited cytotoxicity and damage of the 
mucosal epithelium, clinical symptoms of disease are largely thought to be caused by the 
host’s inflammatory response41. For example, brandykinins are implicated in the induction 
of rhinorrhea, sore throat and nasal obstruction pathogenesis whilst prostaglandins D2 and 
F2α can induce coughing and sneezing42. Mild fever may also present as a result of the 
release of pyrogens, including IL-1 and TNF. Symptom scores have most commonly been 
demonstrated to correlate with viral titre and neutrophil infiltration in the upper 
airways36,43. Indications of disease can be exhibited as early as 10-12h p.i. but on average 
develop 1-2 days p.i. and peak around 2-3 days p.i. usually resolving in 7-10 days after 
inoculation32,44.  
 
1.1.5 Therapies 
Due to the limited cross-reactivity of neutralizing antibodies to the ~101 RV serotypes 
generated in traditional vaccine strategies, RV-specific therapies have shifted to 
development of antiviral agents45. Examples include compounds synthesized to prevent 
uncoating by stabilisation of the viral capsid, the most promising of which is the drug, 
pleconaril. Reported findings from phase II clinical trials demonstrated that pleconaril 
treatment reduced symptom duration by 3 days compared with placebo treatment. 
Although the drug was generally well tolerated, the authors highlighted the need for further 
characterisation of its potential for drug interactions46. Another compound, ruprintrivir, 
which is still in the preclinical stage, acts as an irreversible inhibitor of RV 3C protease and 
has been demonstrated to reduce cold symptoms, nasal shedding and viral titre compared 
with placebo47. Two pharmaceutical companies have also generated truncated, soluble 
forms of ICAM-1 which effectively neutralizes the virus to prevent cell surface attachment. 
Although treatment significantly reduced disease symptoms, maintenance of drug 
concentration in the nasopharynx proved to be difficult due to mucociliary clearance, 
sneezing and nose-blowing48,49.  
Despite a number of promising results using antiviral compounds, RV-specific prophylactic 
or therapeutic treatments remain unlicensed. As a result, treatment of symptoms by non-
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prescriptive medicines including nasal decongestants, analgesics and antitussives remains 
the most common approach48.  
 
1.2 Asthma  
1.2.1 Epidemiology 
Asthma is a disease of global importance as demonstrated by statistics relating to morbidity, 
mortality and associated healthcare expenditures50.  Approximately 300 million people 
worldwide suffer from asthma, with prevalence among people in most European countries 
increasing. This trend is also evident in less developed countries and has been attributed to 
urbanisation and implementation of Westernised lifestyles.  Estimations predict that if this 
rising trend persists, an additional 100 million people will be afflicted with asthma by 
202551.  In the UK, approximately 5.4 million people are currently receiving treatment for 
asthma, representing one of the highest prevalence in the world. Incidence is higher in 
children affecting approximately 1 in 10, making it the most common chronic childhood 
disease in the UK, while mortality statistics indicated ~1100 deaths attributed directly to 
asthma in 200952. In addition to the UK, prevalence of clinically diagnosed asthma is high in 
Australia, New Zealand, and developed countries within North, Central, and South 
America51.   
Economic costs including hospital admissions, physician visits and pharmacological 
expenditures associated with this condition rank as one of the highest among chronic 
diseases 53. The cost to the NHS for treatment and care of asthma sufferers is estimated at 
£1 billion a year.  When this amount is extrapolated to include missed work/school days and 
lost productivity, an approximate £2.5 billion is spent on asthma-related expenditures per 
year in the UK 53.  
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1.2.2 Definition and diagnosis  
Asthma is a heterogeneous syndrome that can broadly be defined as a disorder of the 
conducting airways resulting in variable degrees of airflow obstruction that is reversible or 
partly reversible54. Airway inflammation is central in disease pathology and, together with 
alterations in airway smooth muscle growth and structural changes throughout the 
conducting airways, contribute to airway hyperresponsiveness (AHR), mucosal inflammation 
and airway remodelling55. Pathology is aggravated by repeated episodes of airway 
inflammation and altered tissue repair and regeneration which can occur spontaneously or 
in response to environmental stimuli54.  
 
Diagnostic features of disease include recurrent wheezing, cough, shortness of breath 
(dyspnea) and chest tightness or any combination thereof and are reported in 90% of 
patients with asthma56.  However, these symptoms alone cannot confirm diagnosis and 
additional information about the subject’s personal history such as cough or shortness of 
breath after exercise, worsened chest symptoms in the early morning or night waking as a 
result of aggravated symptoms can assist diagnosis. A family history of asthma and/or other 
allergic disease is also a useful diagnostic marker as asthma clusters in families, as well as 
worsening of symptoms in response to known triggers such as pets, house-dust mites, 
tobacco smoke or cold/humid air57,58. Although these respiratory symptoms are indicative of 
disease, lung function tests are a main criterion for an objective diagnosis of asthma. Airflow 
limitation is indicated by the spirometric measurements, forced expiratory volume in one 
second (FEV1) and slow or forced vital capacity (FVC). In milder asthmatics where there is an 
absence of fixed airway obstruction, airway flow limitation is usually reversible, either 
spontaneously or in response to treatment, as indicated by an increased FEV1/FVC ratio. In 
addition, peak expiratory flow (PEF), which is associated with FEV1 in most asthmatics, is 
useful for detection of variability in airway function. Bronchial provocation tests which 
indicate the concentration of histamine/methacholine required to produce a 20% fall (PC20) 
in FEV1 are also a useful measure of AHR
57.  
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1.2.3 Classification  
Due to its heterogeneous nature, asthma has been  grouped under various  phenotypes;  
however classification on a clinical basis is broadly divided into two forms, namely allergic 
and non-allergic asthma59. Allergic or atopic asthma is the most common form of disease 
and is predominantly characterised by the presence of allergen-specific IgE usually indicated 
by a positive skin-prick test (SPT) to a panel of common environmental allergens60,61. By 
contrast, non-allergic asthma is not driven by allergen although sufferers can present with 
symptoms of allergic disease such as eosinophilic infiltration in the lung. Alternatively, a 
number of asthmatic sufferers present with a robust neutrophilic response in the airways 
which is indicative of a more severe, steroid-resistant asthma phenotype or viral-induced 
asthma exacerbation62. In accordance with these subsets, Woodruff et al. classified two 
unique molecular phenotypes based on the extent of Th2 inflammation; groups were 
defined as ‘Th2-high’ and ‘Th2-low’ with the latter subset characterised as poor responders 
to current asthma therapies63.  
 
The Global Initiative for Asthma (GINA) guidelines previously classified asthma based on 
disease severity including intermittent, mild persistent, moderate persistent and severe 
persistent subdivisions. This classification is based on lung function variability and airflow 
limitation as well as level of symptoms and frequency of disease58. More recently, statistical 
cluster analyses of cross-sectional data have identified phenotypic subsets of asthmatic 
patients that differ based on age of disease onset, gender, atopic status, disease duration, 
medication use and lung function tests64. A key purpose of these groupings is to tailor 
asthma management to specific phenotypes with the hope of creating more targeted and 
therefore more effective therapies62.   
 
1.2.4  Disease models of allergen-driven asthma 
Asthma pathophysiology is associated with airway inflammation, however multiple immune 
pathways are implicated in the activation of inflammatory components that bring about 
disease symptoms65. The majority of research into the cellular components and mechanisms 
of asthma has been centred on allergic asthma induced by environmental allergens. These 
findings are largely derived from studies of allergen-challenged atopic patients and analyses 
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of biopsies, bronchial alveolar lavage (BAL), sputum and serum and ex vivo studies of clinical 
samples66-68.  
 
In addition, mouse models of allergic airways inflammation have proven invaluable in 
investigating the role of cellular and molecular components in vivo using genetically 
modified mouse strains, monoclonal antibodies that block a singular component of the 
immune system or local gene overexpression. The most commonly employed mouse model 
of acute allergic airways inflammation entails systemic sensitisation with allergen combined 
with an adjuvant such as aluminium hydroxide (alum). This is followed by multiple allergen 
challenges to the airways over 1-2 weeks, although variations on this basic model have been 
described including the route of delivery of the sensitising allergen and the number of 
challenges administered69. The most frequently used experimental allergen is the hen egg 
ovalbumin (OVA), which is utilised in this study. Other allergens that are commonly 
described include complex aeroallergens including house dust mite (HDM), cockroach 
extract, ragweed and Aspergillus species69-72. To model more chronic aspects of asthmatic 
disease such as remodelling in the airways, prolonged exposure to low allergen levels in the 
airways for periods of up to 12 weeks in mice have also been employed72.   Findings from 
these models and data from human studies have enabled characterisation of the early and 
late response to allergen challenge in the allergic asthmatic phenotype, which is briefly 
outlined below.  
 
1.2.5 Allergen-driven asthma 
In the asthmatic lung, inhaled allergen that is not removed by mucociliary clearance is taken 
up by antigen presenting cells (APC) that are distributed throughout the respiratory tract59. 
Allergen is presented to naive T and B cells and, in the presence of high levels of IL-4 (the 
source of which is still unclear) and low levels of IL-12, T cells differentiate towards the Th2 
phenotype54. Isotype switching of B cells to IgE synthesis requires IL-4 and IL-13 provided by 
Th2 cells resulting in allergen-specific IgE synthesis and secretion which is followed by 
maturation into high-secreting IgE plasma cells. Binding of IgE to the α-chain of high-affinity 
FcεRI on mast cells and basophils represents the process of sensitisation73. Subsequent 
allergen re-exposure results in cross-linking of the receptor-bound IgE and triggers 
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degranulation of cells and the release of preformed mediators (including histamine), newly 
generated mediators (including leukotrienes and prostaglandins) and an array of 
chemokines and cytokines54. These mediators are responsible for the induction of the early-
phase asthmatic response characterised by constriction of airway smooth muscle cells, 
increased AHR, vascular leakage, mucus secretion and recruitment of additional 
inflammatory cells. Via the release of factors including IL-5, CCL5/RANTES and 
CCL11/Eotaxin-1, eosinophils infiltrate the asthmatic lung and are one of the principal 
cellular features of the late-phase asthmatic reaction. Furthermore, mast cells contribute to 
inflammatory damage on airway endothelial cells, extracellular matrix and neurons through 
the release of granule proteins including eosinophil cationic protein (ECP), major basic 
protein (MBP) and eosinophil peroxidase (EPO)73,74. Th2 cells, in addition to playing a role in 
allergen sensitisation, are central in the late-phase asthmatic response due to their ability to 
augment inflammation through the release of various chemokines and cytokines. The most 
commonly characterised Th2 cytokines in the allergic response include IL-4, IL-5, IL-9 and IL-
13. In addition to the functions described for IL-4 and IL-5, IL-13 plays an integral role in 
regulating mucus hypersecretion and bronchioconstriction by acting on smooth muscle cells 
while IL-9 has been demonstrated to promote differentiation and recruitment of mast cells 
to the airways (Figure 1.1)62. 
 
More recently, attention has shifted to the asthmatic airway epithelium and secreted 
factors have been demonstrated to play a role in the initiation and amplification of Th2 
inflammation75. Specifically, there has been considerable interest in the epithelial-derived 
cytokines, thymic stromal lymphopoietin (TSLP) and IL-33 as well as IL-25, which forms the 
focus of this research. Importantly, IL-25 and/or IL-33 have been demonstrated to promote 
Th2 inflammation by activating a subset of newly identified type 2 innate cells that secrete 
Th2 cytokines upon binding71,76-78. In doing so, these innate cell populations create an 
environment at mucosal sites that is permissive for the development and activation of CD4+ 
Th2 cells and augmented Th2 inflammation79.  These cell populations have been reported to 
be recruited in response to IL-25 and/or IL-33, helminth infection and most recently, 
allergen76-78,80. Of relevance is the presence of a member of the newly grouped innate 
lymphoid cells (ILC) 2 termed nuocytes in the lungs of allergen-sensitised and challenged 
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mice, suggesting a potential role in the asthmatic lung76,81. This novel subset as well as 
additional IL-25-responsive innate populations are described in section 1.5.4.1 and 
summarised in table 1.3. 
 
 
Figure 1.1 Representation of the Th2 immune response in the allergic pulmonary environment. Inhaled 
allergen is taken up by DCs, which then recruit and activate Th2 cells via binding of CCL17/TARC and 
CCL22/MDC to CCR4 expressed on Th2 cells. Binding of IgE to FcεRI on mast cells and basophils 
represents the process of sensitisation. Subsequent allergen re-exposure results in degranulation of cells 
and the release of histamine, leukotrienes and prostaglandins and an array of chemokines and cytokines 
(Diagram taken from Kraft, M. et al.82).  
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1.2.6   Asthma therapies 
There is currently no cure for asthma and therapeutic approaches are based on reducing the 
day-to-day variability of symptoms to improve quality of life. These therapies vary according 
to disease severity and symptoms58. For example, mild, infrequent asthma is most widely 
treated by administration of a quick-acting bronchodilator such as a short-acting beta 
agonist (SABA) (e.g. salbutamol) which reverses smooth muscle constriction. For more 
persistent asthma, treatment is aimed at symptom prevention and better control by 
suppression of airway inflammation using an inhaled corticosteroid 1-2 times daily. 
Alternatively, a leukotriene-receptor antagonist can be used instead of corticosteroids to 
control mild asthma which works by blocking the effects of leukotrienes. For severe, 
persistent asthma, a combinative therapy of long-acting beta agonist and inhaled 
corticosteroids is effective due to their ability to reduce both bronchoconstriction and 
airway inflammation. Furthermore, an anti-IgE blocking monoclonal antibody (omalizumab) 
has been demonstrated to block circulating IgE and may be an attractive option for 
treatment of refractory allergic asthma56.  
The therapeutic approaches listed above are largely based on treating allergen-induced 
airway responses. Although these therapies have been demonstrated to increase stability of 
disease and improve the quality of life of patients, acute exacerbations of asthma still 
occur83, which are discussed in detail below.  
 
1.3 Asthma Exacerbations 
1.3.1 Epidemiology  
Loss of control of symptoms can result in an exaggerated lower airway response to 
environmental triggers termed an acute exacerbation84. Allergens, environmental 
pollutants, medication, cold/humid air, exercise and occupational irritants have been 
identified as triggers, however virus infections account for the large majority of severe 
episodes55. RVs are the most frequently detected viruses during exacerbations however 
other respiratory viruses such as   respiratory syncytial virus (RSV), coronavirus, adenovirus, 
bocavirus, influenza and parainfluenza have also been observed8,9. Severe exacerbations 
have been broadly classified as those that require an emergency department visit, hospital 
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admission or unscheduled visits to the doctor, and account for the majority of asthma-
related expenses as well as the greatest morbidity and mortality in sufferers 65,85. 
Johnston et al. demonstrated prevalence of respiratory viruses in asthma exacerbations in a 
seminal longitudinal study of 108 asthmatic children between 9 and 11 years of age. For 13 
months nasal aspirate samples were collected and tested using RT-PCR as a viral diagnostic 
at the onset of infection or when asthma symptoms worsened. Viruses were detected in 
80% of children with a reduced PEF and episodes of wheeze and in 85% of those with a 
combination of URT infections, wheeze, cough and a fall in PEF.  Nearly two-thirds of 
detected infections were due to RV while coronavirus (15%), influenza and parainfluenza 
(both 8%) and RSV (5%) accounted for the remaining cases 8. Similar associations have been 
recorded in asthmatic adults where cold symptoms were associated with the majority of 
asthma exacerbations with RVs accounting for 61% of the viruses detected9. A more recent 
study examined a mixed population of children and adolescents (aged 7-16 years old) 
admitted to hospital for acute exacerbations and reported that respiratory viruses were 
detected in 78% of subjects. Similar to previous findings, RV infections comprised 83% of the 
viruses found while influenza (15%), enterovirus (4%), and respiratory syncytial virus (2%) 
were also identified86. A causal relationship for RV-induced exacerbations was also 
implicated by the fact that hospitalisations due to acute exacerbations corresponded closely 
with patterns of increased infectious rates of RV in the early fall in the northern hemisphere.  
This phenomenon was reported in asthmatic children aged 5-15 years who presented to the 
emergency department during 3 weeks in September with acute exacerbations. Respiratory 
viruses were detected in 62% of afflicted children, of which 52% were caused by human 
picornaviruses 87.  
 
1.3.2 Pathogenesis and treatment 
The variations in airway inflammation between chronic asthma and acute exacerbations 
have been demonstrated by studies of induced sputum samples. These cellular profiles 
indicate a heterogeneous mixture of eosinophils and neutrophils which was associated with 
a significant increase in IL-8, IL-5 and ECP in acute asthma88. Increased T cell activation has 
also been reported in severe cases with an increased population of both Th1 and Th2 cells in 
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the peripheral blood and in induced sputum89. In addition, increased activated CD8+ cells 
have been measured in tissue from fatal asthma exacerbations. Mucus plugging of the 
airways, which results in hyperinflation due to air trapping, has also been recorded in fatal 
cases. These reports are associated with increased neutrophilia in the submucosal gland and 
augmented degranulation of mast cells65,83.  Although multifactorial, acute asthma is 
predominantly characterised by increased airway inflammation and an augmented number 
of granulocytes particularly in the lower airways. Inflammatory profiles can vary depending 
on the stimulus, with virus-induced exacerbations associated with greater neutrophilia while 
allergen-induced episodes may present with more eosinophilic inflammation (Figure 1.2)83.   
The limited therapies available during an acute exacerbation indicate the diverse 
immunopathogenesis of exacerbations and highlight a need to investigate mechanisms of 
disease to improve treatment65. Although conventional asthma therapy can reduce the 
frequency of exacerbation, the characteristic neutrophilic inflammatory response in a virus-
induced attack has been demonstrated to be more resistant to corticosteroid treatment83,90. 
In fact, based on findings that patients experimentally infected with RV and treated with 
oral corticosteroids had an increased nasal RV titre, therapy in some instances may be more 
detrimental91.     
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Figure 1.2   Variations in cellular profiles between chronic asthma and an acute exacerbation. The 
latter is characterised by a heterogeneous mixture of granulocytes (eosinophils and neutrophils), 
CD4+ T cells (Th1 and Th2 cells) and a greater influx of inflammatory cells (macrophages and 
dendritic cells).  Mucus plugging of the airways and increased smooth muscle constriction have also 
been reported in severe exacerbations.  
 
1.3.3 Interaction between infection and allergic asthma  
A fundamental question to address is why RV infections that usually manifest as a self-
limiting mild disease of upper airways in healthy individuals (cold) cause severe lower 
respiratory tract infections and precipitate asthma exacerbations in asthmatic individuals92-
94. Studies have highlighted a strong association between atopy, allergen exposure and 
respiratory viral infections with an increased risk of exacerbations of asthma in children and 
adults92,95. In addition, research indicates that atopic sensitisation and respiratory viral 
infections in early life may interact to increase the risk of asthma inception and/or 
development15,16. Notably, Kusel et al. evaluated a community-based cohort of 198 children 
with a familial history of asthma and compared acute respiratory illnesses in the first year of 
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birth to respiratory outcomes at age 5. The presence of asthma at age 5 was significantly 
associated with children who were sensitised early (by 2 years of age) to common 
aeroallergens and those with virus-induced LRT infections in the first year of life 15.  In a 
mixed population of children aged 2 months to 16 years,  the strongest likelihood for 
wheezing in children older than 2 years old were those who tested positive for RV (via RT-
PCR) in combination with either increased allergen-specific IgE, nasal eosinophilia or ECP96.   
Heymann et al. also demonstrated that RV was the predominant respiratory virus detected 
in children aged 3-18 years admitted to hospital with wheezing. In accordance with previous 
findings, serum IgE values were higher in wheezing children while 84% of those with wheeze 
were sensitised to at least one aeroallergen97.  
In adults, RV infection of atopic (as indicated by allergen-specific IgE) asthmatics  resulted in 
increased duration of disease as well as increased severity of lower respiratory symptoms 
compared with infected cohabitating partners who were non-atopic non-asthmatics98. This 
study indicated that intrinsic differences may exist that potentially affect the way viral 
infections interact with the asthmatic pulmonary environment.  
Two seminal studies assessed whether allergen exposure increased the risk of acute asthma 
in conjunction with viral infection in sensitised asthmatics. Green et al. investigated 60 
patients aged 17-50 admitted with acute exacerbations who were assessed for the presence 
of respiratory infection as well as total and allergen-specific IgE. The combination of 
sensitisation, exposure to high levels of common household and environmental allergens 
and viral infection was strongly associated with the risk of hospital admittance with acute 
asthma92. Similar findings in children (aged 3-17 years) were also reported by Murray et al. 
indicating a synergism between sensitisation, allergen exposure and viral infections in 
inducing asthma exacerbations95.                 
 
1.3.4 Mechanisms of RV-induced asthma exacerbations 
Experimental RV infection of volunteers in the presence or absence of allergic inflammation 
(most commonly in the form of atopic asthma and/or allergic rhinitis) has proven invaluable 
in investigating the interaction between virus and allergy.  Clinical samples including induced 
sputum, BAL, tissue biopsies, serum as well as ex vivo studies of human bronchial epithelial 
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cells (HBEC) and peripheral blood mononuclear cells (PBMCs) from patients have been used 
to investigate mechanisms of RV-induced exacerbation92.  These results are discussed 
below. 
1.3.4.1  RV-modulated ICAM-1 expression  
The major RV serotype has been demonstrated to upregulate expression of its own 
receptor, ICAM-1, in a Th2 environment. In vitro studies demonstrated that RV infection 
enhanced receptor expression on nasal epithelial cells from atopic asthmatics compared 
with non-atopic healthy controls99. Grunberg et al. similarly reported ICAM-1 was 
upregulated in bronchial biopsies in asthmatic subjects experimentally infected with RV-
16100. Furthermore, Th2 cytokine pre-treatment of a nasal epithelial cell line resulted in 
enhanced ICAM-1 expression which was also associated with increased viral titre101. Based 
on these findings, it was theorised that elevation of ICAM-1 by Th2-associated factors and 
RV infection may contribute to increased symptom severity due to increased viral load. In 
addition, due to its role in the recruitment of inflammatory cells, it has been hypothesised 
that ICAM-1 may exacerbate disease by augmenting inflammation83. 
1.3.4.2  Deficient type I and type III IFNs 
An abnormal innate antiviral response has also been implicated as a potential mechanism in 
HBECs from atopic asthmatics. Specifically, cultured primary HBECs obtained from atopic 
asthmatics and non-atopic, healthy controls   were infected with RV-16 in vitro. Asthmatic 
HBECs produced less type I IFN-β, exhibited enhanced viral replication and decreased cell 
apoptosis compared with HBECs from healthy controls. Exogenous treatment of HBECs with 
IFN-β reversed pathogenic effects by reducing viral release indicating that 1.) the IFN-β 
pathway was intact and the lack of response in asthmatics cells was due to deficient 
production and 2.) IFN-β may prove a useful therapeutic by restoring the deficient antiviral 
response in asthma102.  
Further evidence of the importance of an effective antiviral response was demonstrated in 
BAL cells from asthmatic subjects that were found to have reduced levels of type III IFN-λ. 
RV-infected HBECs and macrophages from asthmatics were also deficient in IFN-λ which 
inversely correlated with asthma symptom scores, BAL viral load and markers of 
inflammation in the BAL and sputum of RV-infected asthmatics103. These findings indicate 
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that increased RV-induced cytotoxicity and reduced apoptosis due to decreased primary IFN 
production may result in enhanced release of inflammatory products and viral shedding 
resulting in exacerbation of disease.  
1.3.4.3   Imbalanced Th1/Th2 responses 
In addition to deficient innate immune responses, an imbalanced adaptive response has also 
been reported in RV-infected asthmatics.  While a robust Th1 response is associated with an 
effective antiviral response, RV-infected asthmatics have been reported to have a defective 
type I response and/or a heightened Th2 response. PBMCs from atopic asthmatics infected 
with RV produced significantly less IFN-γ and IL-12 compared with cells from healthy 
controls. In addition, IL-4 expression was induced exclusively in asthmatic cells while the 
IFN-γ/IL-4 ratio was approximately 3 times lower compared with controls104.   
A lower IFN-γ/IL-5 mRNA ratio was also detected in sputum from RV-infected atopic patients 
which was inversely related to peak cold symptoms and the length it took to clear the 
virus39. Message et al. also measured blood and BAL IFN-γ and IL-10 in RV-infected atopic 
asthmatics and healthy controls and demonstrated that higher levels were associated with 
less severe drops in lung function, lower RV load and diminished symptoms. Conversely, Th2 
cytokines including IL-4, IL-5, and IL-13 were related to increased pathogenesis of virus-
induced asthma symptoms93. 
1.3.4.4   Innate FcεRI-expressing cells 
Studies have demonstrated that allergic rhinitis patients infected with RV and treated with 
segmental allergen challenge one month before, during and after infection, had significantly 
greater BAL histamine levels compared with non-allergic controls. These increases, which 
were observed during acute infection and one month after infection, were absent in non-
allergic and individuals challenged with allergen alone. Proposed mechanisms for this 
enhancement included RV-induced enhanced mediator release from pulmonary mast cells 
or circulating basophils105. Although yet to be investigated in asthmatics, in vitro studies 
have reported that RV-infected cell lines from human mast cells and basophils  can enhance 
IgE/anti-IgE-induced histamine release in both cell lines as well as IL-4 and IL-6 protein in 
basophil supernatant106. Furthermore, RV infection increased total serum IgE in asthmatic 
patients which correlated with reduced lung function while RV-infected allergic rhinitis 
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patients displayed elevated total serum IgE and histamine compared with infected non-
allergic controls107,108.  
1.3.4.5  Aberrant epithelial cell structure 
The asthmatic epithelium has been reported to have a deficient physical barrier function 
with patchy disruption of tight junctions75. Newly identified asthma susceptibility genes 
identified in genome-wide association studies indicated that the majority were 
predominantly expressed in the epithelium109,110. These polymorphisms may contribute to 
enhanced susceptibility to environmental stimuli as indicated by weakened barrier function 
of asthmatic epithelium to oxidant-induced apoptosis and protease allergens111,112. 
Furthermore, undifferentiated primary HBECs were reported to be more susceptible to RV 
infection with approximately 30 to 130 times more viral RNA measured compared with 
differentiated epithelium 113; similarly, RV replication was also demonstrated to be greater 
in damaged epithelium than intact epithelium114.   Due to the fact the major precipitants of 
asthma exacerbations, namely viruses and allergens, both modulate the epithelium, it may 
be that both factors work synergistically to further weaken barrier function in the 
intrinsically impaired asthmatic epithelium; allergens, particularly of a proteolytic nature, 
may damage the airway epithelium promoting greater RV replication while the damage 
caused by RV may enhance absorption of allergen. Both outcomes have the potential to 
enhance airway inflammation as a result of an increased release of proinflammatory 
mediators115.  Furthermore, by weakening the barrier function via proteolytic activity or by 
increasing epithelium permeability, some allergens have the potential to facilitate access to 
DCs and may promote Th2 sensitisation and enhance activation of allergen-specific Th2 
cells59. 
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1.3.4.6  Induction of epithelial-derived mediators  
The airway epithelium has been reported to express a wide array of inflammatory mediators 
in response to RV infection which play an important role in the recruitment of innate and 
adaptive effector cells. Namely, RV-infected HBECs have been shown to secrete IL-1α and β, 
IL-6, CXCL8/IL-8, CCL5/RANTES, CCL11/Eotaxin-1, CCL24/Eotaxin-2, TNF-α and 
CXCL10/interferon-inducible protein 10 (IP-10) in HBECs in vitro12,116,117.  Analyses of human 
clinical samples have reported an increase in CXCL8/IL-8 in the nasal lavage of RV-infected 
asthmatic children which correlated with increased neutrophilia and symptom severity118. 
Similarly, eosinophil granule proteins have been detected in RV-infected asthmatic children, 
which were associated with significantly increased levels of the eosinophilic 
chemoattractant, CCL5/RANTES119. The T cell chemoattractant, CXCL10/IP-10, has also been 
demonstrated to be increased in the serum of patients with acute asthma which was also 
predictive of virus-induced asthma exacerbations and increased disease severity120.  
 The possibility exists that RV-induced epithelial-derived cytokines are capable of directly 
initiating and amplifying Th2 immunity. For example, RV infection has been reported to 
stimulate TLR-3-dependant secretion of the Th2 cytokine, TSLP, which has been 
demonstrated to induce Th2 cell differentiation. Furthermore, the finding that IL-4, together 
with RV infection, synergistically enhanced TSLP provides a mechanism whereby RV could 
exacerbate pre-existing allergic inflammation in the asthmatic lung121.   Of interest, IL-33, 
also epithelial-derived, has been demonstrated to be induced by Influenza A virus in the 
human epithelial cell line, A549, as well as in mouse respiratory epithelial cells (MLE-15)122.  
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Figure 1.3 Potential mechanisms of RV-induced asthma exacerbations including RV-modulated 
ICAM-1 expression (1.3.4.1), deficient type I and type III IFNs (1.3.4.2), imbalanced Th1/Th2 
responses (1.3.4.3), increased innate FcεRI-expressing cells and IgE (1.3.4.4), aberrant epithelial cell 
structure (1.3.4.5) and increased induction of epithelial-derived mediators (1.3.4.6) 
 
1.4 TSLP and IL-33 
Both TSLP and IL-33 have primarily been identified to play a role in Th2 immunity in clinical 
and experimental findings. Epithelial cells from asthmatic subjects have been shown to 
express more TSLP compared with healthy controls while enhanced levels of IL-33 have 
been reported in epithelial cells from bronchial biopsies and in the BAL fluid from moderate 
and severe asthmatics compared with healthy controls123-125. In mice, transgenic 
overexpression of TSLP in the airways was reported to induce Th2 inflammation while naive 
mice administered IL-33 displayed eosinophilia in the airways, splenomegaly, enhanced 
serum IgE and increased IL-5 and IL-13 levels, clearly indicating a role for both cytokines in 
type 2 immunity126.  
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TSLP signals through a heterodimeric receptor complex composed of the IL-7Rα (CD127) 
chain and a γc-like chain specific for TSLP (TSLPR) which is located on a number of cell types 
(Table 1.1).  Studies indicate that TSLP binding promotes Th2 skewing; Wang et al. reported 
that TSLP-treated DCs upregulated the OX40L cell surface expression priming naive T cells to 
become Th2 cells. This OX40L-OX40 interaction and the suppression of IL-12 production by 
DCs (induced by TSLP) was theorised to contribute to Th2 cell differentiation127.  
As a member of the IL-1 family, IL-33 signals through an IL-1R like (IL-1RL1) subunit, also 
known as ST2 or type 1 ST2 (T1/ST2), and associates with the IL-1R accessory protein (IL-
1RAcP)128-130. Together with IL-3, IL-33 has been demonstrated to act directly on human 
basophils to induce IL-4 production131,132. In addition to the induction of T1/ST2-expressing 
innate lymphoid cells reported in helminth infected and allergen-challenged mice, infection 
with influenza induced an innate T1/ST2+ population termed natural helper (NH) cells which 
responded to IL-33 by producing IL-13 and were required for virus-induced AHR (Table 
1.1)133.   These findings indicate that, like TSLP, type 2-inducing agents as well as virus are 
capable of inducing IL-33. 
 
 Cell sources Inducing stimuli Cell targets 
TSLP Epithelial cells, basophils, mast 
cells and keratinocytes 121,134-136 
Allergen, helminth infection, RV 
and/orIL-4, IL-13, RSV 134 137  121 
DCs, mast cells, monocytes, 
macrophages, B cells, T cells, 
basophils, eosinophils and 
epithelial cells130,138-141 
IL-33 Epithelial cells, endothelial cells, 
bronchial smooth muscle cells, 
keratinocytes, fibroblasts and 
adipocytes 122,126,142,143 
Allergen, helminth infection, 
Influenza A virus67,122,144 
Endothelial cells, eosinophils, 
basophils, mast cells, NK cells, 
natural killer T (NKT) cells, B 
cells, differentiated Th2 cells, 
NH cells,  78,133,145-151 
Table 1.1 Cellular sources, targets and inducing stimuli for TSLP and IL-33. Abbreviations: 
DC=dendritic cell; NK=natural killer; NKT=natural killer T; NH=natural helper  
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1.5 IL-25  
1.5.1 Structure and regulation  
IL-25, originally designated IL-17E, was first identified in 2000 by homology based cloning of 
the IL-17 family members152. In contrast to other members of the IL-17 family members, 
which exhibit roles in autoimmune disease and pathogen defence, IL-25 has been shown to 
play a role in the Th2 immune response153.   
Encoded by the il25 gene located at locus 14q11.2 on chromosome 14, pre-mRNA splicing 
events produce two IL-25 isoforms. One isoform forms the canonical sequence while the 
second differs by the exclusion of 16 amino acids (a.a.) in the signal peptide as a result of 
removal of one intron, making it 161 a.a. long. The precursor protein undergoes proteolytic 
processing, and in the case of the canonical sequence, forms a 32 residue signal peptide 
attached to a 145 amino acid chain (177 a.a. in total). The amino acid chain is glycosylated at 
the 136th amino acid and contains 2 disulphide bonds which facilitate folding and processing 
into its mature form which is then secreted154. The calculated mature molecular weight is 
~16.7kDa although recent studies suggest that this form is cleaved further by matrix 
metalloproteinase (MMP)7  to form a more active form with an enhanced binding  affinity 
to its receptor155. The encoded human protein possesses approximately 16-20% sequence 
homology to the IL-17 family members, IL-17A, IL-17B and IL-17C. The greatest sequence 
homology lies within the C-terminal where 4 conserved cysteine residues, which form the 
disulphide bonds, are located while the greatest sequence divergence is observed at the N-
terminal152. Comparison of the human canonical sequence with the singular encoded mouse 
sequence (~169 a.a.) reveals approximately 80% homology153.  
Although regulatory gene expression has been characterised for the majority of the IL-17 
family, very little is known about regulation of IL-25 gene expression. Analysis of the gene 
sequence upstream of the IL-25 encoding region indicates potential binding sites for signal 
tranducer and activator transcription 6 (STAT6), GATA-3 and NF-κB156. However, whether 
these transcription factors are functionally required for IL-25 induction is currently 
unknown.   
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1.5.2 Cellular expression  
Original RT-PCR analysis of IL-25 expression indicated the presence of low levels of mRNA in 
several tissues, including brain, kidney, lung, prostate, testis, spinal cord, adrenal glands and 
trachea152. Further analysis by Fort et al. on the cellular level demonstrated enhanced mRNA 
expression in highly polarized Th2 cells from mice cultured in vitro153. Since then, a 
multitude of cell types have been reported as IL-25 producers, predominantly in response to 
classical Th2 inducing stimuli including allergen, pollutants and/or IgE cross-linking. These 
findings are summarised in table 1.2. Importantly, IL-25 has been reported to be produced 
by lung epithelial cells in vitro and in vivo and has therefore been theorised to play a role in 
the initiation of Th2 inflammation70,157. For example, Angkasekwinai et al. reported direct 
induction of IL-25 gene expression from the human alveolar cell line, A549, and primary 
mouse lung epithelial cells in response to the allergens, Aspergillus oryzae and ragweed70.  
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Human 
samples 
    
Cell type  Sample source  Inducing stimuli IL-25 product Ref. 
Eosinophils  
 
 
 
Cultured from PBMCs from 
normal and atopics 
Biopsy of bronchial mucosa 
and skin sections from 
asthmatics/atopics 
Serum and whole blood  
IL-5 and GM-CSF or  IL-3 and 
GM-CSF added to media 
SPT-positive allergen  
 
Churg-Strauss Syndrome 
mRNA (RT-PCR) and 
protein (ELISA) 
Protein (IHC) 
 
Protein (ELISA and 
FC) 
127 
 
158 
 
159 
Basophils Cultured from PBMCs from 
normal and allergic subjects 
IgE cross-linking  mRNA (RT-PCR) and 
protein (ELISA)  
127 
Mast cells Cultured from PBMCs from 
normal and allergic subjects 
Biopsy of bronchial mucosa 
and skin sections from 
asthmatics/atopics 
PMA/Ionomycin 
 
SPT-positive allergen   
mRNA (RT-PCR) 
 
Protein (IHC) 
 
127 
 
158 
 
Keratinocytes Cultured from normal 
subjects 
Biopsies from patients with 
atopic dermatitis and 
normal subjects 
Ragweed extract 
 
Atopic dermatitis 
mRNA (RT-PCR) 
 
mRNA (RT-PCR) and 
protein (IHC) 
127 
Epithelial cells Primary nasal epithelial cells 
cultured from normal 
subjects 
Polyriboinosinic: 
polyribocytidtlic acid (poly I:C) 
mRNA (RT-PCR) and 
protein (ELISA) 
160 
Epithelial cell 
line 
Human alveolar 
adenocarcinoma cell line 
(A549) 
Aspergillus oryzae and ragweed mRNA (RT-PCR) 70 
Dendritic cells Biopsies from patients with 
atopic dermatitis and 
normal subjects 
Atopic dermatitis 
LPS 
Protein (confocal 
microscopy)     
Protein (FC)                                    
161 
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Murine 
samples 
    
Cell type  Sample source  Inducing stimuli IL-25 product Ref. 
Mast cells Cultured bone marrow-
derived mast cell cultures  
IgE cross-linking mRNA (RT-PCR) and 
protein 
(immunoblotting) 
162 
Th2-polarised T 
cells 
Naive CD4+ T cells isolated 
from  BALB/c, B6 and 129 
SvEv mice  
Polarisation with IL-4/anti-IL-
12/anti IFN-γ mAb 
mRNA (RT-PCR) 153 
CD4+ and CD8+ 
T cells 
Cecal patch of naive BALB/c 
mice 
 mRNA (RT-PCR) 163 
Airway 
epithelial cells 
Lung sections from NK-cell 
depleted mice 
Primary type II alveolar 
epithelial cells cultured from 
BL6 mice 
Depletion of NK cell/IFN-γ                           
                                       
Aspergillus oryzae and ragweed 
 
Protein (IHC) 
 
mRNA (RT-PCR) 
157 
 
70 
Airway 
epithelial cell 
line  
Cultured mouse lung 
epithelial (MLE) cell line  
Aspergillus oryzae and ragweed mRNA (RT-PCR) 70 
Intestinal 
epithelial cells 
Isolation of intestinal 
epithelial cells  
Commensal bacteria in large 
intestine 
mRNA (RT-PCR) 164 
Alveolar 
macrophages 
 
 
Lung sections and tissue 
samples from a rat model of 
titanium dioxide-induced 
inflammation   
 Cultured alveolar 
macrophages from the BAL 
cells of rats stimulated with 
titanium dioxide                            
Titanium dioxide  mRNA (RT-PCR) and 
protein (IHC) 
 
mRNA (RT-PCR) and 
protein 
(immunoblotting) 
165 
Microglia Digested brain and spinal 
cord homogenate from a 
mouse model of EAE and 
WT controls 
EAE mRNA (RT-PCR) 166 
Table 1.2   Summary of cellular producers of IL-25 in human and murine studies.  Abbreviations: 
FC=flow cytometry; B6=Black6; LPS=Lipopolysaccharide; mAb=monoclonal antibody; 
IHC=immunohistochemistry; NK=natural killer; EAE=experimental autoimmune encephalomyelitis; 
WT=wild type 
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1.5.3 Role of IL-25 in the immune system 
1.5.3.1 Type 2 immunity 
Shortly after its initial discovery, Fort et al. carried out preliminary characterisation of IL-25 
by injecting mice intraperitoneally with IL-25 and observed a Th2-like response. This was 
marked by production of IL-4, IL-5 and IL-13, blood eosinophilia, increased serum IgE, IgG1 
and IgA as well as increased mucus production, eosinophilia and epithelial cell hyperplasia in 
the lungs and digestive tract. Interestingly, IL-25 induction of eosinophilia and 
histopathological changes were also present in recombination-activating gene (Rag)-
knockout mice indicating a T cell-independent source of Th2 inflammation153. In accordance 
with this data, it was demonstrated that transgenic overexpression of IL-25 in mice resulted 
in increased circulating eosinophils, IL-4, IL-5, CCL11/Eotaxin-1, and IgE levels167,168. By 
overexpressing IL-25 in the lung epithelium, transgenic mice also displayed increased 
CCL11/eotaxin-1, CCL24/eotaxin-2, CCL22/MDC and MUC5ac gene expression in lung tissue 
as well as increased epithelial hyperplasia and eosinophils in the lung parenchyma70. Clinical 
studies have since shown increased gene expression in IL-25 and its receptor, IL-17RB, in 
tissue from patients with asthma and atopic dermatitis as well as increased IL-25 protein 
from the nasal lavage of allergic rhinitis patients127,160,161.  
 
Tamachi et al. further demonstrated induction of IL-25 by allergen in a mouse model of 
allergic airways inflammation showing that gene expression was upregulated in response to 
OVA inhalation. However, in contrast with previous studies, they reported that 
overexpression of IL-25 alone was not sufficient to initiate allergic inflammation but instead 
enhanced OVA-induced eosinophil and CD4 T cell recruitment169. In addition, IL-25 mRNA 
was induced in response to intranasal and intratracheal challenge with cockroach allergen in 
a mouse model of chronic allergic asthma71.  
 
A functional role for IL-25 in allergic inflammation was confirmed by inhibiting IL-25 in a 
mouse model of allergic airways disease. By blocking IL-25, using a neutralising antibody 
before OVA sensitisation and 4 hours prior to OVA challenge, AHR was prevented and 
airway eosinophila, goblet cell hyperplasia, serum IgE as well as BAL IL-5 and IL-13 protein 
were decreased. Strikingly, administration of blocking antibody before OVA challenge in 
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sensitised mice prevented AHR and reduced IL-5 and IL-13 expression in the airways. IL-25 
also caused airway changes independently of Th2 cytokines; mice lacking IL-4, IL-5, IL-9 and 
IL-13 exhibited increased AHR following IL-25 treatment170. Using a different  IL-25 blocking 
antibody clone, similar findings were demonstrated in a model of allergic airways 
inflammation using a combination of Aspergillus oryzae and OVA; inhibiting IL-25 before 
each allergen challenge resulted in decreased airway eosinophilia and reduced BAL IL-4, IL-5 
and IL-13 production70. Using a soluble form of the IL-25 receptor to neutralise endogenous 
IL-25, OVA-sensitised and challenged mice displayed decreased OVA-induced eosinophilia 
and CD4+ T cell recruitment in the lung169.     
     
A role for IL-25 in driving airway remodelling has also been reported in mice overexpressing 
the TGF-β family signalling molecule, Smad2, in the airway epithelium. In addition to 
promoting an airway remodelling phenotype, these mice were also demonstrated to 
produce elevated IL-25. By administering an IL-25 blocking antibody in mice exposed to 
HDM extract, airway smooth muscle hyperplasia, collagen deposition, and AHR were 
attenuated. IL-25 neutralisation also blocked recruitment of endothelial progenitor cells to 
the lung as well as completely inhibiting IL-33 and TSLP expression. Gregory et al. theorised 
that IL-25 may drive the production of IL-33 and TSLP in vivo and thus play a key role in 
orchestrating airway remodelling201.         
   
IL-25 deficient mice have also been employed to demonstrate the ability of IL-25 to induce a 
protective type 2 protective immune response to parasitic infections80,163. Specifically,         
Il-25-/-  mice displayed inefficient expulsion of the nematode, Nippostrongylus brasiliensis, 
which correlated with delayed cytokine production by Th2 cells and a reduction in an IL-4, 
IL-5 and IL-13-producing non-B non-T (NBNT) cell population80.  Conversely, IL-25 treatment 
resulted in rapid worm expulsion which was proposed to be driven by IL-25-induced 
expansion of this newly identified cell population. Similarly, knock-out mice failed to clear a 
Trichuris infection which was associated with reduced IL-4 and IL-13 levels and reciprocally 
increased amounts of IFN-γ and IL-17A. Treatment of these knock-out mice with exogenous 
IL-25 promoted immunity and Th2 cytokine responses in the form of antigen-specific IL-4 
and lymphocyte-dependant goblet cell hyperplasia163. Using oxazolone to induce a type 2 
 43 
 
model of colitis, IL-25 was also demonstrated to have a proinflammatory role in the mucosa 
by inducing IL-13-producing NKT cells and nuocytes which enhanced intestinal 
inflammation. By blocking the IL-25 receptor using the antibody clone D9.2, symptoms of 
disease were lessened and mucosal infiltration of NKT cells and nuocytes was reduced. This 
was associated with decreased IL-13 levels, blood eosinophilia and IgE and correlated with 
reduced IL-4, IL-5 and IL-13 production by cultured mesenteric lymph node (MLN) cells171.  
 
1.5.3.2   Autoimmunity and anti-inflammatory effects 
In contrast with its abilities to augment Th2 inflammation, IL-25 has been demonstrated to 
limit Th17-driven autoimmune inflammation.  For example, IL-25 deficient mice have been 
reported to be highly susceptible to experimental autoimmune encephalomyelitis (EAE), a 
Th17-driven autoimmune inflammatory disease of the central nervous system (CNS) that 
serves as a model of human multiple sclerosis (MS). This increased susceptibility was 
associated with enhanced levels of IL-17A, IFN-γ and TNF-α-producing T cells in the CNS. The 
cause of disease was demonstrated to be directly linked to a resultant lack of IL-13 as IL-13-/- 
mice failed to protect against EAE. Due to inhibition of IL-23, IL-1 and IL-6 expression, which 
are required for Th17 differentiation and function, it was suggested that IL-25 may play a 
role in the regulation of Th17 development166.  This study was corroborated by recent 
findings that IL-25 acts as a critical regulator of the IL-13/IL17A axis during AHR in a model of 
allergic airways disease. By inhibiting IL-25 during allergen challenge, IL-13 levels were 
decreased significantly with a reciprocal increase in IL-17A that was shown to be integral for 
protection against AHR. This regulation of IL-17A was once again demonstrated to be 
directly associated with IL-13172.    
Unlike findings that demonstrated a proinflammatory effect in a type 2 model of colitis, IL-
25 has been reported to have protective, anti-inflammatory properties in a Th1-mediated 
colitis model of gut inflammation in mice.  Reports indicated that these effects may be 
mediated by downregulated IL-12 and IL-23 level173,174 or via IL-25-induced alternatively 
activated macrophages175.  IL-25 was also shown to downregulate lipopolysaccharide (LPS)-
induced IL-6, TNF-α and IL-1β expression by human CD14+ cells. Further studies in mice 
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showed that IL-25 was also protective against LPS-induced lethal endotoxemia by inhibiting 
monocyte-derived proinflammatory cytokines176.   
 
1.5.3.3  Viral infection and IL-25  
Whilst numerous studies have demonstrated the importance of IL-25 in allergy and parasite 
expulsion, comparatively little is known about IL-25 during viral infection. Siegle et al. 
demonstrated increased IL-25 gene expression in response to pneumonia virus of mice 
(PVM). Neonatal mice were infected with virus to provide a species-specific model of RSV 
disease and then sensitised and challenged with low amounts of OVA to mimic chronic 
asthma. A moderate dose of allergen was then administered to induce exacerbation of 
disease in an attempt to investigate pathogenic mechanisms of childhood asthma. Induction 
of IL-25 by virus was theorised as a possible driver of Th2 inflammation that was noted to be 
upregulated by PVM infection 14 days p.i177. However, an additional study by the same 
group demonstrated that blocking IL-25 had limited effects on preventing induction of Th2 
inflammation but did suppress subepithelial fibrosis and epithelial cell hypertrophy, again 
highlighting a role in airway remodelling. By blocking IL-4 and IL-25, Th2 inflammation was 
abrogated178.  
One other study involving RSV-infected NK/IFN-γ-depleted mice demonstrated development 
of viral-specific Th2 effector cells and the induction of Th2 inflammation in the airways. In 
the absence of IFN-γ, lung epithelial-derived IL-25, as measured by IHC, was upregulated in 
response to RSV infection. By administering an IL-25 blocking antibody, IL-25 was shown to 
play an integral part in the differentiation of Th2 cells. This was demonstrated to be partly 
due to upregulation on DCs of Jagged1 expression, a costimulatory molecule that has been 
reported to polarise naive CD4+ T cells toward a Th2 phenotype157. 
 
1.5.4 Signalling and the IL-25 receptor 
Bioactivity of IL-25 is dependent on non-covalent binding to its principal receptor, IL-17RB, 
which forms a heterodimer with IL-17RA152,179. IL-17RB, also designated IL-17Rh1, Evi27 and 
IL7BR, is a 506 amino-acid single transmembrane protein that also acts as a receptor to IL-
17B but binds with much lower affinity compared with IL-25152,180. Notably, polymorphisms 
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in the IL-17RB gene in humans have also been linked with asthma181. Although IL-17RA does 
not bind directly to IL-25 and instead interacts with the IL-17RB-IL-25 complex, it is integral 
for IL-25 signal transduction179,180. This has been demonstrated in Il-17rb-/- and Il-17ra-/- mice 
that failed to respond to intranasal administration of IL-25 indicated by an absence of Th2 
inflammation. Furthermore, in vitro studies have shown that blocking IL-17RA resulted in a 
decrease in IL-5 by IL-25-stimulated human PBMCs179. Like the rest of the IL-17 family, IL-
17RB contains a SEF/IL-17R (SEFIR) subdomain in its cytoplasmic tail which has been 
demonstrated to bind Act1 in a SEFIR-dependant manner following IL-25 binding182.   
Accordingly, mice deficient in Act1 and administered IL-25 displayed decreased allergen-
induced airway eosinophilia while Act1 deficiencies in epithelial cells resulted in reduced 
Th2 lung inflammation182. Similarly, an Act1 deficiency in T cells resulted in decreased 
eosinophilia and abrogated AHR in a model of allergic airways inflammation183. The 
cytoplasmic domain of IL-17RB also contains a TNFR-associated factor (TRAF)6-binding motif 
which directly associates with TRAF6 upon receptor ligation. TRAF6 then activates NF-κB 
which has been demonstrated by blocking this pathway using a double-negative form of 
TRAF6184.  
Other studies of IL-25-IL-17RB signal transduction have investigated T cell signalling 
reporting activation of GATA-3, Nuclear factor of activated T-cells cytoplasmic (NFATc) 1, 
JunB, c-Jun N-terminal kinase (JNK), mitogen-activated protein kinase (MAPK) and STAT6 
pathways70,127,169. IL-25-induced activation of these pathways mediates a range of effects 
including induction of Th2 cytokines, cell differentiation and IL-17RB receptor upregulation 
which will be discussed in greater detail in the next section.   
 
1.5.5  IL-25 regulation and IL-25-responsive cells 
IL-17RB gene expression has been detected in the kidney, liver, lung and gastrointestinal 
tract amongst others. While IL-25 has been shown to act on peripheral blood and intestinal 
CD14+ cells to reduce inflammatory cytokine responses176 , the majority of IL-17RB-
expressing cells induce a Th2 response upon IL-25 binding.  These populations include 
invariant NKT (iNKT) cell185,186, Th2 cells70,127, Th9 cells187, eosinophils188, epithelial cells182, 
airway smooth muscle cells189, lung fibroblasts190, endothelial cells191 and several newly 
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identified innate immune cells including multi-potent progenitor type 2 cells (MPPtype2) 
cells77, innate type2 helper (Ih2) cells 192, NH cells 193,  human innate lymphoid cells (ILC)68, 
nuocytes78 and type 2 myeloid (T2M) cells71.  
 
1.5.5.1 IL-25-mediated immunity 
i.  Innate immune cells 
Recently, several different groups have identified populations of innate cell populations that 
express Th2 cytokines in response to allergen challenge or helminth infections68,71,78,193. 
Aside from the shared ability to express Th2 cytokines, these populations vary with regard 
to surface marker expression, anatomical location and expression of transcription factors 
(Table 1.3)194. Recently, type 2 innate cells formed from lymphoid precursors have been 
grouped together under the heading innate lymphoid cells (ILC) 2 which include NH cells, Ih2 
cells and nuocytes. Nuocytes represents one of the most well characterised ILC2 subsets.  
First identified as an IL-25-induced lineage negative (lin-) (i.e. absence of T cell, B cell, 
macrophage, DC, neutrophil, eosinophil, mast cell, basophil, NKT cell or NK cell markers) 
NBNT cell population, these cell were demonstrated to be required for eradication of N. 
brasiliensis infection80. Neill et al. further characterised these cells as major producers of IL-
13 and therefore designated them nuocytes after the 13th letter of the greek alphabet, nu. 
These cells have since been defined as lin-ICOS+CD44+CD45+Sca1+CD90.2+CD117+(IL-
7Rα/CD127)+MHCclass II+T1/ST2+IL-17RB+ and were shown to expand in the MLN and 
spleen in response to intraperitoneal injection of IL-25 and IL-33. In addition to producing IL-
5, nuocytes represented the major IL-13-producing cell population in mice infected with N. 
brasiliensis at day 5 after infection and were demonstrated to be crucial for efficient worm 
expulsion78. Importantly, nuocytes have recently been reported to infiltrate the lung in 
response to OVA challenge representing the dominant innate source of IL-13 in a mouse 
model of allergic airways disease. Using a 12 day and 25 day OVA-induced lung allergy 
model, nuocytes were not only detected at the start of the allergic response but also 
persisted through the adaptive response with greater numbers detected at day 25 post-
sensitisation. Notably, intranasal administration of IL-25 or IL-33 induced nuocytes in the 
airways while adoptive transfer was able to restore AHR and eosinophilia in IL-25-dosed Il13-
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/- deficient mice. These results highlight a role for IL-25-induced nuocytes in the initiation of 
Th2 cytokine production in the lung that is independant of CD4+ Th2 cells76.    
An additional group of innate myeloid IL-25-responsive cells that have been reported to 
accumulate in the lung following allergen exposure are the recently termed T2M cells71. This 
population was first identified as a CD11b+GR1+Ly6C+/−CD117−CD4−CD11c−MHC class IIlow 
cell population that produced IL-4 in the lung after chronic allergen challenge195.  Petersen 
et al. demonstrated that an IL-17RB+CD11b+Gr-1mid population represented the major 
source of IL-4 and IL-13 in a model of chronic allergic asthma and, in contrast with Neill et 
al., reported a small number of lin-cKit+Sca-1+IL-17RB+ NBNT cells after allergen challenge. 
Using Il-17rb-/- mice, lung inflammation, airway eosinophilia and mucus production was 
demonstrated to decrease after chronic allergen exposure which was associated with 
reduced Th2 cytokine production by T2M and CD4+ T cells. Similarly, airway administration 
of IL-25 significantly increased IL-4 and IL-13-producing IL-25-responsive CD11b+Gr-1mid 
infiltrates in the lung while adoptive transfer of T2M cells together with IL-25 in Il-17rb-/- 
mice induced mucus production and inflammation marked by an increase in IL-13 and 
Muc5ac mRNA.  
Of clinical importance is an innate lymphoid population described as lin-(IL-7Rα/CD127)+ 
which express the Th2 marker chemoattractant receptor homologous molecule expressed 
on Th2 lymphocytes (CRTh2) and have been identified in the human lung, gut and nasal 
tissue and peripheral blood. These cells responded to IL-25 and IL-33 by producing IL-5 and 
IL-13 and were found in higher proportions in nasal polyps of patients with rhinosinusitis. 
Findings suggest that these cells may represent the human equivalent of ILC2s previously 
identified in mouse studies68,81.        
  
Additional IL-25-responsive ILC2s that have been identified in other anatomical locations 
aside from the lung include NH and Ih2 cells.  NH cells were identified in fat associated 
lymphoid clusters (FALC) in mice, which are located along the gut mesentery surrounded by 
adipose tissue. Characterised as a lin-CD117+Sca-1+CD25+(IL-7Rα/CD127)+T1/ST2+ 
population, these cells were reported to express IL-4, IL-5, IL-6, and IL-13 mRNA 
constitutively, which when stimulated with IL-25 and IL-2 or IL-33 produced large amounts 
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of IL-5 and IL-13. Importantly, the existence of these cells in human FALC was demonstrated.  
Ih2 cells have been reported to be a major source of IL-13 in the MLN, spleen, liver and bone 
marrow in mice following infection with N. brasiliensis. These lin-ICOS+CD117+Sca-1-
CD90.1+CD44+CD45+ cells expand robustly in response to intraperitoneal treatment with IL-
25 or IL-33 and adoptive cell transfer, together with IL-25, is sufficient for clearance of 
nematode infections. 
Lastly, MPPtype2 cells have been identified in the gut associated lymphoid tissue (GALT) of 
mice administered IL-25. Uniquely, this population has the ability to differentiate into 
multiple cell lineages in culture, including macrophages, basophils and mast cells. Defined as 
lin-Sca-1+CD117int, MMPtype2 cells were reported to confer immunity to T. muris infection 
when adoptively transferred to Il-25-/- mice and were associated with the production of IL-4, 
IL-5 and IL-13.  
                                                           Mouse                                                                                             Human 
 T2M cells MMPtype2 Nuocytes  
(ILC2) 
Ih2 cells 
(ILC2) 
NH cells 
(ILC2) 
CRTh2+ type 2  
Anatomical 
location 
Lung, BM, 
PB 
MLN, GALT MLN,  spleen,  
peritoneum, lung  
MLN,  spleen,  
liver, BM  
FALC Gut, lung, PB 
Lin-                    
CD117+ 
Sca1+ 
No 
(CD11b+ 
Gr-1mid)  
Yes Yes Lin- 
CD117+Sca1-  
Yes Lin-CD117+ 
T1/ST2+ No No Yes Unknown  Yes IL1R1 
expression 
(IL-7Ra+/ 
CD127) 
No No Yes Unknown Yes Yes 
CD44+ No No Yes Yes Yes Unknown 
CD90.1+ No No Yes Yes Yes Unknown 
Transcription 
factor 
expression 
Unknown   RORA Gata-3,  
Stat6 
Maf, Gata-3,  
JunB,  Stat6, 
Id2,  Tbx21 
Id2 
Cytokine 
responsiveness 
IL-25 IL-25 IL-25, IL-33  IL-25,  IL-33 IL-25,  IL-33 IL-25,  IL-33 
Physiological 
significance  
Secrete IL-4 
and IL-13; 
increased 
mucus  
Upregulate 
IL-4, IL-5 
and IL-13 
mRNA; 
increased 
mucus  
Secrete IL-5 and 
IL-13; increased 
mucus  
Secrete IL-5 
and IL-13; 
increased 
eosinophilia  
Secrete IL-5 
and IL-13; 
increased 
mucus  
Secrete IL-5 
and IL-13 
Table 1.3 A summary of characterised innate cell populations. Abbreviations: MLN=mesenteric 
lymph nodes; FALC=fat associated lymphoid clusters; BM=bone marrow; GALT=gut associated 
lymphoid tissue; PB=peripheral blood. Table was adapted from Hams et al.194 
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ii. iNKT cells 
A population of iNKT cells, defined as an innate T cell subset that recognise glycolipid ligands 
on target cell instead of peptides, have also been demonstrated to express IL-17RB together 
with CD4185,186,196. By stimulating with IL-25, this population produced IL-13 and IL-4 in 
vitro196.  In addition, intranasal administration of IL-25 induced AHR in wild-type mice which 
was absent in iNKT cell-deficient mice. Furthermore, adoptive transfer of IL-17RB+CD4+iNKT 
cells reconstituted AHR in iNKT-deficient mice, strongly indicating a role for this cell 
population in asthma pathogenesis185.  Recently, this IL-17RB+ iNKT cell subset has been 
further characterised into CD4+ and CD4- expressing populations; IL-17RB+CD4- cells secrete 
Th17 cytokines in response to IL-23 while IL-17RB+CD4+ cells secrete Th2, Th9 and Th17 
cytokines in response to IL-25. The latter subset has been demonstrated to produce IL-9, -
10, -17A and -22 in addition to IL-4 and IL-13 in response to IL-25 which is dependent on the 
transcription factor, E4BP4 (E4 promoter–binding protein 4). Notably, IL-17RB+ iNKT cells 
were demonstrated to play a role in the pathogenesis of virus-induced AHR. Specifically, 
mice were infected intranasally with RSV four times at 10 day intervals and were treated 
with the immunogen, recombinant G of RSV (rec Gs) 4 days after the first infection. After 
the last dosing with RSV, mice were exposed to rec Gs and AHR measured 24 hours later. 
AHR was observed only in wild-type mice but was absent in iNKT cell-deficient and Il-17rb-/- 
mice. Accordingly, adoptive transfer of IL-17RB+ iNKT cells but not an IL-17RB-iNKT subset 
induced AHR in iNKT cell-deficient mice186.  
iii. Th2 cells 
Th2 cells represent key mediators of IL-25-driven allergic inflammation in the adaptive 
response. Subsequent to early studies that reported enhanced expression of IL-17RB on 
human Th2 memory cells, Angkasekwinai et al. demonstrated a role for IL-25 in promoting 
Th2 cell differentiation in an IL-4 and STAT6-dependant manner. Specifically, IL-25 was 
shown to induce early IL-4 expression in naive CD4+ T cells from mice via upregulation of 
NFATc1 and JunB which resulted in increased GATA3 expression and Th2 cell differentiation 
in vitro. Furthermore, IL-25 treatment of cultured naive T cells induced IL-4, IL-5 and IL-13 
levels which was inhibited by anti-IL-25 antibody treatment70.  
In contrast with these findings, Wang et al. reported that IL-25 promoted proliferation in 
activated human Th2 memory cells while resting Th2 memory cells were unable to respond 
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to IL-25 due to low surface IL-17RB expression. However, activation of DCs via stimulation 
with TSLP induced robust enhancement of IL-17RB expression on cultured human Th2 
memory cells.  Stimulation with IL-25 enhanced proliferation and induced activated Th2 
memory cells to acquire an effector-memory phenotype by CCR7 and CD27 downregulation 
while maintaining CRTh2 and CD62L/L-selectin surface expression. Further findings 
suggested that these effects may be due to sustained GATA3 expression by IL-25 which 
further promotes c-MAF and JunB expression in an IL-4-independant manner127.    
IL-25 has also been demonstrated to act indirectly to induce Th2 polarisation. Kaiko et al.  
reported that IL-25 initiated RSV-induced Th2 cell responses in an NK-depleted mouse 
model via upregulation of Jagged1. This was demonstrated by culturing lymph node cells 
from mice with anti-Jagged1 antibody which reduced levels of IL-13 by approximately 3-fold 
indicating a role for Jagged1 in Th2 induction. Similarly, by inhibiting IL-25 in cultured DCs, 
Jagged1 expression was significantly reduced supporting the hypothesis that IL-25- and 
Jagged1-mediated Th2 responses may be linked157.  
In a mouse model of allergic airways disease, IL-25 was demonstrated to enhance Th2 
inflammation via an OVA-activated CD4+ Th2 cell-dependant pathway. Transgenic 
expression of IL-25 in the lung enhanced OVA-induced CD4+ T cell and eosinophil airway 
recruitment. In this model, IL-25-driven eosinophilia was dependent on CD4+ T cells. 
Furthermore, Stat6-/- mice displayed an absence of IL-25-induced enhancement in 
eosinophil and CD4+T cell recruitment into the airways suggesting that this process is STAT6 
dependant169.      
iv. Th9 cells 
Recent findings suggest that IL-9-producing T cells are divergent from the conventional Th2 
lineage. The presence of IL-4 alone cannot induce IL-9 production during naive T cell 
differentiation and requires TGF-β which greatly enhances IL-9 expression and inhibits IL-4, 
IL-5 and IL-13 production197,198. As a result, these cells have been defined as Th9 cells and 
were reported by Angkasekwinai et al. to express IL-17RB. It was also reported that naive T 
cells from mice were polarised to Th9 cells by stimulating with IL-4 and TGF-β. Subsequent 
treatment of differentiated cells with IL-25 induced significantly enhanced IL-9 and IL-10 
production which was dependant on IL-17RA and IL-17RB signalling. However IL-25 alone 
was not sufficient to initiate Th9 polarisation.    These results were substantiated in a mouse 
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model of allergic disease using Aspergillus oryzae and OVA which demonstrated that mice 
overexpressing IL-17RB on CD4+ T cells displayed increased IL-9 production 187.  
v. Eosinophils 
Stimulation of human eosinophils with IL-25 showed increased expression of IL-6, CXCL8/IL-
8, CCL2/MCP-1 and CCL3/MIP-1α in vitro188. IL-25 was also shown to increase eosinophil 
viability as determined by flow cytometry analysis as well as upregulate surface expression 
of ICAM-1 while suppressing ICAM-3 and CD62L/L-selectin expression. This IL-25-dependent 
production of mediators as well as upregulated eosinophil surface markers was mediated 
via JNK, p38 MAPK, and NF-κB pathways188,199. 
vi. Structural cells 
In addition to the lung epithelium acting as a source of IL-25, treatment of the mouse lung 
epithelial cell line (MLE12) with IL-25 strongly induced expression of CCL11/Eotaxin-1, 
CCL5/RANTES, CCL22/macrophage-derived chemokine (MDC), TSLP and MUC5ac gene 
expression70. Additional structural cells in the lung that have been reported to be responsive 
to IL-25 stimulation include airway smooth muscle cells189, lung fibroblasts190 and human 
vascular endothelial cells (HUVEC)191. Specifically, IL-25-treated HUVECs displayed 
angiogenesis which was associated with induced expression of vascular endothelial growth 
factor (VEGF) expression and upregulation of its receptors191. These cells were also recently 
reported to produce basic fibroblast growth factor (BFGF) in response to IL-25 
stimulation200.  
 
1.5.6 IL-25-mediated positive feedback loop and a potential role in asthma 
exacerbations 
Numerous IL-25-responsive Th2 cytokine-producing T and non-T cell populations have been 
identified70,78,187,199. The finding that IL-25 is produced by the respiratory epithelium directly 
in response to allergen suggests that it acts upstream of Th2 inflammation, possibly acting 
as an initiating factor70.  Based on recent findings, it is possible this early source of IL-25 acts 
on IL-25-responsive innate cell populations such as lineage negative cells, releasing Th2 
cytokines in a T cell independent manner76,78. Further to this, bioactive IL-25 produced by 
eosinophils has been reported to act directly on activated Th2 memory cells stimulating IL-5 
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production127. Based on the findings that IL-25 increases eosinophil viability and Th2 cell-
derived IL-5 promotes longevity as well as activation of eosinophils, a positive IL-25-
mediated feedback loop between innate (non-T) Th2-cytokine producing cells and  effector 
memory CD4+ Th2 cells has been theorised127,199.  
Furthermore, preliminary data demonstrate that, in addition to allergen, virus may play a 
role in the induction of IL-25157,177. The findings that the associated epithelial-derived 
cytokines, IL-33 and TSLP, have been reported to be induced by influenza A and RV 
respectively is suggestive that IL-25 may also be upregulated in response to virus122.  Given 
that bronchial epithelial cells are the primary site of RV infection, it may be hypothesised 
that RV infection of the airway epithelium induces the pro-Th2 cytokine, IL-25. The 
implications of RV-induced IL-25 by the airway epithelium suggest that in a Th2 pulmonary 
environment, formed by exposure to environmental allergens, IL-25 has the potential to 
activate innate and adaptive Th2 effector cells enhancing allergic inflammation76,127.  
 
 
 
 
 
  
 53 
 
Figure 1.4   Cellular producers of IL-25 and IL-25-responsive cells that form a potential IL-25-mediated 
positive feedback loop between innate and adaptive immunity 
 
1.5.7 Investigation of IL-25 using mouse models of RV infection and RV-induced allergic 
airways disease 
The induction of IL-25 by RV, with or without exposure to allergen, has not been 
investigated. Therefore, in this study we assessed RV-induced IL-25 expression in human 
airway epithelial cells lines as well as HBECs from atopic asthmatics and healthy controls in 
vitro. We then investigated IL-25 induction in a mouse model of RV infection which was 
developed by Bartlett et al. within our laboratory202. This mouse model can be employed for 
investigating minor group RV infections in BALB/c mice as well as major group RV infections 
in transgenic BALB/c mice expressing a mouse-human ICAM-1 chimera. Characteristic 
features of human RV infection have been demonstrated as displayed by airway 
neutrophilia, expression of proinflammatory cytokines and chemokines and mucus 
production in both major and minor group infected mice. Furthermore, in situ hybridisation 
detection of negative-strand replicative viral RNA in lung tissue confirmed RV replication in 
mice202. 
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In addition to examining RV-induced IL-25 in vitro and in vivo, the primary aim of this study 
was to elucidate interplay between allergen exposure and RV infection by investigating the 
role of IL-25 in RV-induced asthma exacerbations. To achieve these aims, we employed a 
mouse model of RV-induced allergic airways disease which was also developed within our 
laboratory. This model incorporates the extensively characterised OVA-induced allergic 
airways disease model, together with concomitant exposure to minor group RV infection 
administered with the final airways allergen challenge, thus modelling exacerbation of 
ongoing atopic airways inflammation by RV infection202. Using this model, we investigated 
the effects of infection and allergen on IL-25 and Th2-associated mediators as well as IL-
17RB-expressing cell populations. Finally, to define a mechanistic role for RV-induced IL-25, 
we blocked IL-25-mediated signalling in our model of RV-induced allergic airways disease by 
neutralising IL-17RB and assessed effects on Th2 responses associated with disease 
pathogenesis to define a role for IL-25 in RV-induced asthma exacerbations.   
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Chapter 2: Methods and Materials 
2.1 Virological techniques 
2.1.1 Rhinovirus propagation: preparation of inoculum  
RV-1B stocks were obtained from the American Type Culture Collection (ATCC) and 
propagated in H1 HeLa cells (human epithelial carcinoma cell line) (ATCC). To generate 
laboratory working stocks, monolayer cultures of HeLa cells were infected for 24 hours (h) 
to attain 100% cytopathic effect (CPE). The cell/virus suspension was harvested and cells 
were lysed by freezing and thawing twice before pelleting the debris by centrifugation. The 
supernatant was collected and aliquots of inoculums were stored at -80oC and subsequently 
used for viral propagation for in vivo studies and infection of bronchial epithelial cells for in 
vitro studies. Serotype specificity was confirmed by neutralisation with specific antiserum 
(ATCC).   
 
2.1.2 Rhinovirus propagation for in vivo work  
H1 HeLa cells were grown to 90% confluency in 25 T175 flasks (Nunc) in HeLa growth media 
(Table 2.7) at 37oC with 5% CO2. A 30ml working stock of RV-1B (procedure described above) 
was added to 500ml of HeLa infection media (Table 2.7) and a volume of 20ml was 
aliquoted per flask and incubated at room temperature (RT) for 1h with constant shaking. 
To attain approximately 90% cytopathic effect (CPE), cells were incubated at 37oC for 20h.  
Cells containing virus were pelleted by centrifugation and resuspended in 15ml phosphate 
buffered saline (PBS) (Table 2.6). Centrifugation and resuspension was repeated to remove 
residual media before resuspending cells in 36ml of PBS and freeze thawing twice to lyse 
cells to mediate viral release. Cell debris was removed by centrifugation and supernatant 
was filtered through a 0.2μm syringe filter. Virus was precipitated by adding polyethylene 
glycol and 0.5M sodium chloride (Table 2.6) and the solution was placed on ice for 1h. 
The precipitate was collected by centrifugation and the resultant pellet resuspended in PBS 
and concentrated to a volume of ~2.5ml using an Amicon Ultra-15 centrifugal filtration tube 
(Millipore). Concentrated virus stock was aliquoted and stored at -80 oC until use.  
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2.1.3 Rhinovirus inactivation  
RV-1B stock was exposed to 1200 µJ/cm2 UV light for 30 minutes (min) under sterile 
conditions and used as a negative control for in vivo and in vitro experiments. 
 
2.1.4 Rhinovirus titration 
Ohio HeLa cells (ATCC) were seeded in 96-well cell culture plates (Costar Corning) at 1x105 
cells/ml in HeLa infection media (Table 2.7) and exposed to serial 10-fold dilutions of viral 
stocks. Specifically, 50μl of concentrated virus was added to 150μl of cells and diluted 1:10 
in quadruplicate wells.  Cells were incubated at 37oC for 96h and CPE was assessed and 
scored by observation using a light microscope. As a comparative measure, a stock of RV-1B 
of a known titre was tested alongside virus samples. The Spearman-Karber formula was 
used to calculate the tissue culture infectious dose (TCID50)
203.  
 
2.2 Mouse models 
2.2.1 Mice 
6-8 week old, female BALB/c mice were obtained from Charles River UK and maintained 
within the CBS facility at St Mary’s Campus, Imperial College London, under specific 
pathogen free (SPF) conditions.  
 
2.2.2 General Anaesthesia  
Mice were administered the inhalant anaesthetic, isoflurane (Table 2.6), prior to intranasal 
(i.n.) challenges. For terminal anaesthesia, mice were injected intraperitoneally (i.p.) with 
200μl of pentobarbitone solution (Table 2.6). 
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2.2.3 RV-1B infection model 
BALB/c mice (n=4 or n=5) were infected i.n. with 50µl of RV-1B or UV-inactivated RV-1B (UV-
RV-1B) at a TCID50 of approximately 5x10
6. In addition to treating with inactivated virus as a 
negative control, one group of mice were mock infected i.n. with PBS of the same volume. 
Terminal anaesthesia was carried out at 10h, day (d) 1, d2, d4 and d7 post-infection (p.i.). 
(Figure 2.1).   
 
Figure 2.1   Mouse model of RV infection 
 
2.2.4 RV-induced allergic airways disease model 
Mice were sensitised i.p. with 50µg hen egg ovalbumin (OVA) (Table 2.6) and 2mg of 
Aluminium Hydroxide (Alum) (Table 2.6) in 200µl of PBS on d-13. Mice were challenged i.n. 
with 30µg OVA in 30µl of PBS, or PBS alone, on d-2, d-1 and d0. Mice were then infected i.n. 
with 50µl 2 x 106 TCID50 RV-1B or UV-RV-1B immediately after the third OVA challenge on d0 
(Table 2.1). Animals were culled at various times p.i. (Figure 2.2).   
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           Figure 2.2   Model of RV-induced allergic airways disease. 
 
Experimental 
groups 
Sensitisation 
(OVA/Alum i.p.) 
Challenge 
(3x OVA i.n) 
RV-1B infection 
(RV-1B i.n./UV-RV-1B control) 
RV OVA Yes Yes Yes 
UV OVA Yes Yes No (UV-RV-1B control) 
RV PBS Yes No (PBS control) Yes 
UV PBS Yes No (PBS control) No (UV-RV-1B control) 
Table  2.1   Summarised nomenclature of treatment groups in model of RV-induced allergic    
airways   disease. Abbreviations: OVA=ovalbumin; Alum=aluminium hydroxide 
 
2.2.5 Blocking of IL-25 signalling in a model of RV-induced allergic airways disease  
Mice were sensitised, challenged and infected as described above in section 2.2.4 with the 
exclusion of the RV PBS control group. To block RV-induced IL-25 signalling, 0.5mg of anti-IL-
17RB antibody (clone D9.2) (provided by Prof. Andrew McKenzie, MRC Laboratory of 
Molecular Biology, Cambridge) was administered i.p. in 200μl sterile PBS to all treatment 
groups 4h before infection as well as on d3 and d5 p.i. In addition, identically treated groups 
were administered 0.5 mg of anti-c-myc mouse IgG1 isotype control antibody (Clone 9e10.2) 
(also provided by Prof. Andrew McKenzie, MRC Laboratory of Molecular Biology, 
Cambridge) under the same treatment regime. Animals were culled at the time-points 
represented in figure 2.3 while nomenclatures of all treated groups are summarized in table 
2.2 below for clarification.  
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Figure 2.3   Blocking of IL-25 signalling in a model of RV-induced allergic airways disease. 
Abbreviations: OVA=ovalbumin; Alum=aluminium hydroxide. 
 
Experimental groups Sensitisation 
(OVA/Alum 
i.p.) 
Challenge 
(OVA i.n) 
RV-1B infection 
(RV-1B i.n./UV-RV-1B) 
Antibody 
treatment 
 
RV OVA (anti -IL-17RB) Yes Yes Yes Anti-IL-17RB 
UV OVA (anti-IL-17RB) Yes Yes No (UV-RV-1B control) Anti-IL-17RB 
UV PBS  (anti-IL-17RB) Yes No (PBS control) No (UV-RV-1B control) Anti-IL-17RB 
RV OVA (Isotype) Yes Yes Yes Isotype control  
UV OVA (Isotype) Yes Yes No (UV-RV-1B control) Isotype control 
UV PBS  (Isotype) Yes No (PBS control) No (UV-RV-1B control) Isotype control 
Table 2.2   Summarised nomenclature of treatment groups of mice administered anti-IL-17RB and 
isotype control antibody in a model of RV-induced allergic airways disease 
 
2.3 Sample recovery and processing from in vivo studies 
2.3.1 Bronchoalveolar lavage (BAL) 
Mice were intubated and lungs were lavaged by syringing 1.5ml of BAL fluid (Table 2.6) in 
and out approximately 5 times. BAL fluid cells were pelleted by centrifugation to separate 
cells and supernatant. Supernatant was collected, snap-frozen and stored at -80oC for 
cytokine and chemokine analysis by ELISA while cells were re-suspended in 100μl ACK (Table 
2.6) for 1min. The solution was neutralised with 1ml of RPMI media containing 10% foetal 
bovine serum (FBS) (Table 2.6) and cells were centrifuged, resuspended in 1ml of the same 
media and counted before processing the BAL cytospins. After completion of cytospins, the 
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remaining BAL cell suspension was centrifuged and the pellet resuspended in 350µl of 
Buffer RLT containing 1% β-mercaptoethanol (Table 2.6) for RNA purification.  
 
2.3.2 BAL cytospins and differential counts  
Using the Cytospin3 system (Shandon), BAL cells resuspended in media were centrifuged 
onto cytoslides (Tharmac). Slides were air-dried and fixed and stained using the REASTAIN 
Quick-Diff Kit (Table 2.8). Groups were blinded and differential cell counts were carried out 
on a total of 200 cells per slide.      
 
2.3.3 Processing of lungs for RNA extraction 
The right apical lung lobe was excised and transferred immediately into 600µl of ‘RNA Later’ 
buffer (Table 2.6). Samples were stored at -80oC until use. Lung tissue was homogenised 
mechanically in 600µl Buffer RLT containing 1% β-mercaptoethanol and centrifuged to 
attain the supernatant which was then processed as described in section 2.9.1. 
 
2.3.4 Processing of lung homogenate for ELISA 
The remaining lobes of the right lung (excluding the apical lobe) were harvested and rinsed 
with PBS, snap-frozen and stored at -80oC. Lobes were homogenised in 600μl of PBS 
containing dissolved Protease Inhibitor Cocktail (Table 2.6) and lung homogenate was 
centrifuged to attain the supernatant which was snap-frozen and stored at -80oC until use. 
 
2.3.5 Processing of lungs for flow cytometry 
The harvested left lung lobe was crudely chopped in gentleMACSTM C Tubes (Militenyi 
Biotech) containing 5ml of lung digestion buffer (Table 2.6) using a gentleMACSTM 
Dissociator (Militenyi Biotech). After incubating samples for 45min at 37oC, a second round 
of mechanical dissociation was performed on lung samples and cells were pelleted by 
centrifugation. Red blood cells were lysed in 5ml of ACK (Table 2.6) before neutralising the 
solution with RPMI media containing 10% FBS and attaining a single cell suspension via 
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filtration through a 100μm cell strainer (BD Biosciences). Cells were pelleted and 
resuspended in 2ml of RPMI media containing 10% FBS for the purpose of calculating total 
live cell counts using trypan blue exclusion as determined by light microscopy.   
 
2.3.6 Processing of lungs for histology 
Mice were subjected to cardiac perfusion with PBS prior to inflating whole mouse lungs with 
4% paraformaldehyde fixative (Table 2.6). Inflated lungs were arranged on labelled cassettes 
and placed in 4% paraformaldehyde fixative for staining with anti-mouse/human IL-25 
antibody (Table 2.9).   
 
2.3.7 Processing of serum  
Blood was collected from the carotid artery and processed in microtainer serum separation 
tubes (BD Biosciences). Blood was left to coagulate at RT for 1h and serum was separated by 
centrifugation prior to storing samples at -80oC.  
 
2.4 Enzyme-Linked Immunosorbent Assay (ELISA)  
2.4.1 Cytokines and chemokines in lung homogenate and BAL  
Chemokine and cytokines were measured using Mouse DuoSet ELISA Development kits. In 
accordance with the protocol supplied with kits, 96 well plates (Nunc Maxisorp, Thermo 
Scientific) were coated with 100μl of capture antibody diluted in PBS and left at RT 
overnight. Plates were washed 3X with ELISA wash buffer (Table 2.6) and blocked with 200μl 
of ELISA blocking solution (Table 2.6) for 2h at RT.  After a repeated wash step, 100μl of 
samples and recombinant protein standards were added and incubated for 2h at RT. For 
analysis of IL-4, IL-5, IL-13 and IL-33 from lung homogenate, samples were diluted 1:10 in 
ELISA reagent diluent (Table 2.6) or used 1:2 for IL-25 and TSLP analysis. BAL samples were 
diluted 1:2 for chemokine and IL-4, IL-5 and IL-13 analyses and undiluted for remaining 
analytes. Standard curves were prepared using 2-fold dilutions of recombinant protein in 
ELISA reagent diluent with the recommended high standard. Plates were washed and 100μl 
secondary biotinylated antibodies diluted in ELISA reagent diluent were incubated for 1h. 
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After a repeated wash step, streptavidin-HRP (Table 2.6), diluted 1:200 in ELISA reagent 
diluent, was added to plates and incubated for 20min at RT in the dark.  Subsequent to 
washing, 100μl TMB substrate (Table 2.6) was added to plates and the colour reaction was 
stopped after approximately 15min with 50μl ELISA stop solution (Table 2.6). The optical 
density of each well was measured using a microplate reader (Spectramax plus384) set to 
450nm and quantified by comparison to an 8 point standard curve. Analyses of results were 
carried out using Softmax Pro 3.1.2 software (Molecular Devices). 
 
2.4.2 IL-25 from cell supernatant  
IL-25 in cell supernatant from cultured human airway epithelial cell lines and HBECs from 
patients was measured using an ultrasensitive human IL-25 in-house ELISA developed by 
Novartis. Assays were performed by Matt Edwards and Betty Shamji from Novartis, 
Horsham Research Centre, UK.      
 
2.4.3 MUC5ac and MUC5b  
BAL samples were diluted 1:10 in PBS and serial dilutions of supernatant from PMA and 
ionomycin stimulated-NCI-H292 cells (for MUC5ac) and BAL supernatants from OVA-
sensitised and challenge mice (for MUC5b) were used to generate an 8 point standard 
curve. Samples and standards were added to 96 well plates and incubated at 37oC 
overnight. For detection of MUC5ac, plates were washed and blocked with PBS/2% BSA 
before adding an anti-MUC5ac biotinylated antibody (Table 2.9) diluted to a final 
concentration of 400ng/ml and incubated for 2h at RT. For detection of MUC5b, a mouse 
anti-MUC5b (clone EU-MUC5b) antibody (attained from Prof. Dallas M. Swallow) was used 
as a secondary antibody and bound antibody was detected with peroxidase conjugated goat 
anti-mouse IgG (Table 2.9)  Plates were washed and streptavidin-HRP was added and 
incubated for 20min at RT in the dark. ELISAs were developed and read as described above.  
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2.4.4 IgE  
2.4.4.1 OVA-specific IgE  
96 well plates were coated with 2.5μg/ml OVA in PBS and incubated overnight at 4oC. Plates 
were washed and blocked with ELISA blocking solution and left for 2h at RT. After a 
repeated wash step, 100μl of mouse serum diluted 1:80 in ELISA reagent diluent was added 
to plates. Standards were prepared using two-fold dilutions of a mouse anti-OVA IgE 
antibody (Table 2.9) in ELISA reagent diluent with a high standard of 0.075μg/ml. After 2h 
incubation at RT, plates were washed and a rat anti-mouse IgE detection antibody (Table 
2.9), diluted 1:1000 in ELISA reagent diluents, was added and incubated for 2h at RT. Plates 
were processed as described above and samples compared to an 8 point standard curve.  
 
2.4.4.2  Total IgE 
Total IgE was measured using BD OptEIATM Mouse IgE Set (See Table 2.9). In accordance with 
the supplied protocol, 96 well plates were coated with 100μl of capture antibody (anti-
mouse IgE) diluted 1:250 in PBS and left at RT overnight. Plates were washed 3X with ELISA 
wash buffer and blocked with 200μl of PBS with 10% FBS for 2h at RT.  After a repeated 
wash step, 100μl of mouse serum diluted 1:100 in PBS with 10% FBS and purified mouse IgE 
standard were added and incubated for 2h at RT. Plates were washed and 100μl secondary 
biotinylated antibody (anti-mouse IgE) diluted 1:500 in PBS with 10% FBS were incubated for 
1h. After a total of 5 washes, plates were processed as described above and samples 
compared to an 8 point standard curve.  
 
2.5 Flow cytometry analysis 
2.5.1 Surface staining of lung and BAL leukocytes  
Approximately 1-10 x 105 BAL cells and 3 x 106 lung cells were incubated in 100μl FACS 
buffer (Table 2.6) containing 5μg/ml Fc Block (Table 2.10) for 20min at 4oC. Fluorochrome-
conjugated antibodies specific for cell surface markers (Table 2.10) were added in a volume 
of 100μl of FACS buffer to cells and incubated for 30min at 4oC in the dark. Cells were 
washed with PBS and stained with a viability marker (LIVE⁄DEAD® Fixable Aqua Dead Cell 
Stain Kit, Invitrogen) for 20min at 4oC in the dark. After washing again with PBS, cells were 
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fixed using BD Cytofix buffer (Table 2.6) and, if intracellular staining was performed, samples 
were permeabilised by washing cells with BD Cytoperm buffer (Table 2.6). Cells were 
resuspended in FACS buffer and analysed within 24h. 
 
2.5.2 Intracellular staining of lung and BAL leukocytes 
To detect IL-4 production, 1 x 106 cells/ml of stimulation media (Table 2.7) was incubated at 
37oC for 4h. Cells were then stained for surface markers and fixed and permeabilised as 
described above. Fluorochrome-conjugated IL-4 antibody (Table 2.10) was added to cells in 
a volume of 200μl of BD Cytoperm buffer and incubated for 30min at 4oC in the dark. After 
washing with BD Cytoperm buffer, cells were resuspended in FACS buffer and analysed 
within 24h. 
 
2.5.3 Acquisition and analysis of flow cytometry data 
Flow cytometry was performed using a LSRII Fortessa flow cytometer (BD Biosciences) and 
BD FACS Diva software was used to acquire data. Data analysis was performed using FlowJo 
analysis software (Version 7.6.1)(Tree Star Inc). Representative flow plots illustrating gating 
strategies implemented as well as Fluorescence Minus One (FMO) controls which were used 
to set the gates are represented in Figures 2.4. 
 
2.6 Airway hyperreactivity measurements 
Airway hyperreactivity was measured by inhalation of methacholine aerosol (Table 2.6) in 
unanaesthetised, spontaneously breathing mice. Specific airway resistance (sRaw) was 
measured in a double chamber plethysmograph (Electomedsystems) while enhanced pause 
(Penh) was quantified using an unrestrained whole body plethysmography system 
(Electomedsystems).  Both techniques were performed by Dr Ross Walton, Imperial College 
London. sRaw was measured over 5min by exposing mice to increasing aerosolised 
concentrations of 5mg/ml, 10 mg/ml, 15 mg/ml, 20 mg/ml and 30 mg/ml and each dose was 
administered for 1min. Quantification of Penh was assessed over 5min periods after 1min 
aerosolisation challenge after exposure to 3 mg/ml, 10 mg/ml, 15 mg/ml, 30 mg/ml and 100 
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mg/ml of methacholine. For both plethysmograph experiments, aerosolised water was used 
as a control and used as baseline values. Data was analysed using eDacq v1.8 software 
(Electomedsystems) and the following equations applied to calculate Penh and sRaw 
respectively.  
Penh = [(TE/RT)-1] X (PEF/PIF)  
TE = Duration of expiration 
RT = Relaxation Time (Time needed to exhale the first 64% of the tidal volume) 
PEF = Peak Expiratory Flow (ml/s) 
PIF = Peak Inspiratory Flow (ml/s) 
 
sRaw = [(TI+TE)/(2 x π) X (Patm-47) X 1.36 X 2 X π X dT/(TI+TE)] 
TI = Duration of inspiration  
TE = Duration of expiration 
Patm = atmospheric pressure 
dT = delay between nasal and thoracoabdominal flow 
 
2.7 Immunohistochemistry 
Formalin-fixed, paraffin-embedded lung tissues were deparaffinised and antigen unmasking 
was carried out by immersing sections in citrate buffer (10mM at pH6.0). Sections were then 
covered with 3% hydrogen peroxidase to inhibit endogenous peroxidase activity and left for 
5min before washing with PBS. Cell membranes were permeabilised adding 0.1% saponin in 
PBS and non-specific staining was blocked by incubating with 5% rabbit serum for 20min at 
RT. Sections were incubated with 60μg/ml rat anti-mouse IL-25 antibody or a rat IgG isotype 
control (Table 2.9) at 4oC overnight. Sections were then washed and incubated with 1:100 
dilution of HRP labelled rabbit anti-rat secondary antibody for 1h. After a further wash with 
PBS, sections were incubated with ABC reagent (Vector ABC Kit) and the reaction visualised 
with chromogen-fast diaminobenzidine5 (DAB) as a chromogenic substrate. Slides were 
counterstained with haematoxylin to provide nuclear and morphological detail, and 
mounted in DPX Mountant (Sigma-Aldrich).  
For quantification of IL-25+ epithelial cells, immunostaining intensity for IL-25 protein was 
scored semi-quantitatively between 0 to 1.5 (0 = negative; 0.5 =weak staining, 1 = moderate 
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staining, and 1.5 =strong staining). Infiltrating IL-25+ inflammatory cells in the airway lamina 
propria were quantified and expressed as the number of positive inflammatory cells per 
millimetre length of the reticular basement membrane. All counting of histology slides were 
performed by one investigator and slides were blinded to experimental treatments. Staining 
and scoring was carried out by Dr Jie Zhu (Royal Brompton Hospital, Imperial College 
London).   
 
2.8 In vitro work 
2.8.1  Cell maintenance   
The human bronchial epithelial cell line (BEAS-2B) (ATCC) were cultured in BEAS-2B growth 
media (Table 2.7) in T175 flasks while commercially purchased primary HBECS (Lonza) and 
primary HBECS from patients were cultured in HBEC BEGM complete media (Table 2.7) in 
T75 flasks (Nunc) at 37oC with 5% CO2. For maintenance of HeLa cell lines (including Ohio 
and H1 sublines), cells were cultured in HeLa growth media (Table 2.7) in T175 flasks under 
identical conditions. Respective media was changed every 2-3 days and cells passaged when 
80-90% confluent.  
 
2.8.2  Subculture procedure 
2.8.2.1  BEAS-2B and HeLa cell lines 
BEAS-2B or HeLa cells were washed twice with PBS and 2.5ml of trypsin-EDTA (TE) (10X) 
(Table 2.7) diluted to 1X in PBS was added to cells and incubated for 2-3min at 37oC. Trypsin 
was neutralised by adding 7.5ml of respective growth media to BEAS-2B or HeLa cells and 
2.5ml of the cell suspension was added to T175 flasks containing 28ml of growth media for 
propagation.  
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2.8.2.2  Commercially purchased primary HBECS (Lonza)  
Primary HBECS obtained from Lonza were sourced from 4 individuals that were non-
asthmatic, non-smoking and non-alcoholic (Table 2.3). For subculturing, primary cells were 
washed with 4ml of HEPES Buffered saline solution (Table 2.7) and 2ml trypsin-EDTA (1X) 
(Table 2.7) was added to cells for ~2min at 37oC with intermittent banging of the flask to 
ensure detachment of cells. The cells were centrifuged after adding 4ml of trypsin 
neutralizing solution (TNS) (Table 2.7). Pelleted cells were resuspended in 10ml HBEC BEGM 
complete media and a third of the total volume was propagated into a new T75 flask 
containing 12ml of complete media.  
HBECS source number Age (years) Sex Race Smoking and alcohol consumption 
4F0174 18 Female C No 
4F0872 34 Male AA No 
4F1604 27 Male AA No 
6F4181 19 Male C No 
Table 2.3 Primary HBECS (Lonza). Abbreviations: C=Caucasian; AA=African American 
 
2.8.3 Cell quantification 
Cells to be quantified were added to 0.1% trypan blue (Table 2.6) at a 1:1 ratio. A Neubauer 
haemocytometer was used to count cells in a volume of 10μl and observed using a light 
microscope. Viable cells were counted in three squares (each square measuring 1mmx1mm 
in dimension and composed of 9 sub-squares) bordered by double lines and the average 
taken and multiplied by the dilution factor to give cell number X104/ml.   
 
2.8.4  Ex vivo human bronchial epithelial cells from bronchial brushings 
2.8.4.1 Bronchoscopy  
Bronchoscopies were carried out in the Endoscopy Unit at St. Marys Hospital, Paddington, in 
accordance with British Thoracic Society guidelines. Lung function (FEV1) was recorded 
before and after bronchoscopy and all participants received nebulised 0.5mg Salbutamol 
and 0.5mg Ipratropium bromide prior to the procedure.  
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2.8.4.2 Processing of human bronchial epithelial cells from bronchial brushings 
Bronchial epithelial cells were obtained by scraping a subsection of the patient’s bronchial 
wall 5-10 times with a sterile 5mm sheathed endobronchial brush (Olympus BC-202D-5010). 
Sheathed brushes were stirred vigorously in a sterile tube containing 10ml of prewarmed   
HBEC BEGM complete media. Both brushes and sheaths were detached into the media and 
immediately transported to the laboratory for processing while maintaining samples at 
37oC.  
Media containing sheathed brushes were gently vortexed and brushes and sheaths were 
flushed with fresh media to facilitate detachment of cells into solution.  In addition, brushes 
were passed through a pipette tip into a small amount of media to ensure complete 
removal of adherent cells.  All media containing detached cells was pooled and centrifuged 
at 10000g for 6min. Supernatant was discarded and the cell pellet was resuspended in 10ml 
complete media and cell counted as described in section 2.8.3. The cell suspension was 
seeded into T25 (Nunc) flasks pre-coated with collagen coating solution (Table 2.7)  that had 
been incubated at 37oC /5% CO2 overnight. Cells were then left undisturbed for 48h to allow 
maximum adherence to the flask, after which the media was discarded and replaced with 
10ml fresh complete media containing 100μl of Ultroser G (Table 2.7). Complete media 
supplemented with Ultroser G was replaced every two days for a week, after which only 
complete media was used. Cells were cultured until 70–80% confluent and subcultured into 
larger flasks as described above for HBECS (Lonza). At passage 2-3, cells were seeded into 12 
well plates.   
 
2.8.5 RV infection of human bronchial epithelial cells  
BEAS-2B cell lines and all primary HBECs were grown to 80% confluency in 12 well plates.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
Approximately 16h before infection, cells were serum starved by adding BEGM serum free 
media (Table 2.7) to primary HBECs or BEAS-2B serum free media (Table 2.7) to BEAS-2B cell 
lines. After removal of media, cells were incubated with 200μl RV-1B working stock diluted 
in PBS for 1h at RT with constant shaking.  A dose-dependent response to a range of RV 
titres was carried out prior to experiments to attain a desirable MOI. A titre of ~5x106 was 
used for infection of BEAS-2B cells while HBECs were infected with a titre of ~2.5x106. Cells 
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were exposed to virus in parallel with UV-inactivated RV-1B and/or PBS as negative controls. 
After infection, inoculum was replaced with BEAS-2B infection media (Table 2.7) and BEGM 
serum free media for BEAS-2B and HBECs respectively. Supernatant was collected and cells 
lysed by adding Buffer RLT and 1% β-mercaptoethanol to attain RNA at various hours after 
infection.    
 
2.9 Molecular Biology Techniques 
2.9.1 RNA extraction and cDNA synthesis 
Cells were lysed with Buffer RLT and 1% β-mercaptoethanol prior to RNA extraction. Total 
extractions were carried out using the Qiagen Rneasy Mini Kit (Table 2.8) according to 
manufacturers’ instruction which included the optional on-column DNase I digestion step 
(Table 2.8). Resultant RNA was resuspended in 30µl of Rnase/Dnase-free water. The 
quantity (in ng/µl) of the RNA was analysed using a ND-1000 Spectrophotometer system 
(Thermo Scientific). Approximately 15μg of RNA/sample of mouse lung tissue and ~5μg of 
RNA/sample from cell culture experiments was used to prepare cDNA. Synthesis of cDNA 
was carried out using random hexamer primers (Table 2.6) and reagents from the 
Omniscript Reverse Transcription Kit (Table 2.8). The volumes of reagents added per 
reaction are listed in table 2.4 and cDNA reactions were performed at 37oC for 1h.  
 
Reagent Volume/reaction 
10x Buffer RT 4µl 
dNTP mix (each dNTP 5mM)  4µl 
Random primers (Promega) 2µl 
Omniscript RT 2µl 
Rnase/Dnase free water 8µl 
RNA Template 20µl 
Table 2.4   Composition of cDNA reactions 
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2.9.2 Primer/probe design 
Primers and probes for mouse and human IL-25 were designed for this study while 
additional genes, listed in table 2.5, were previously established within the laboratory. 
Genomic and mRNA sequences of genes of interest were obtained using NCBI PubMed and 
compared to create primers/probes that crossed exon junctions and had a low penalty score 
using Clone Manager (Sci-Ed) and Primer Express v3.0 Software (Applied Biosystems). 
Forward/reverse primers were optimised for use by testing concentrations of 50nM, 300nM 
and 900nM while probes were used at a fixed concentration of 175nM per reaction.  
 
PRIMER NAME Sequence (5’-3’) Concentration (nM) 
Murine specific    
IL-25 forward CACACCCACCACGCAGAAT 300 
IL-25 reverse CAACTCATAGCTCCAAGGAGAGATG 300 
IL-25 probe FAM-CCAGCAAGGATGGCCCCCTCA-TAMRA 100 
Human specific   
IL-25 forward GAGATATGAGTTGGACAGAGACTTGAA 300 
IL-25 reverse CCATGTGGGAGCCTGTCTGTA 300 
IL-25 probe  FAM-CTCCCCCAGGACCTGTACCACGC-TAMRA 100 
RV forward   GTGAAGAGCCSCRTGTGCT 50 
RV reverse GCTSCAGGGTTAAGGTTAGCC 300 
RV probe  FAM-TGAGTCCTCCGGCCCCTGAATG-TAMRA 100 
Murine and human    
18S forward CGCCGCTAGAGGTGAAATTCT 300 
18S reverse CATTCTTGGCAAATGCTTTCG 300 
18S probe FAM-ACCGGCGCAAGACGGACCAGA-TAMRA 100 
Table  2.5   Sequences and concentrations for primer and probes used in q-PCR 
 
2.9.3 Taqman q-PCR 
Quantitative (q) PCR was carried out on 1µl of cDNA by adding Quantitect Probe PCR 
Mastermix (Table 2.4), Rnase/Dnase free water and gene specific primers and probes (Table 
2.5). Reactions were run on an ABI 7500 Real-Time PCR System (Applied Biosystems) under 
the following cycling conditions: 50oC for 2min; 95oC for 1min; 45 cycles at 95oC for 15sec 
and 60oC for 1min. Using cDNA diluted 1:100, 18S ribosomal RNA (rRNA) quantification was 
carried out using specific primers and probes (Table 2.5) for normalising qPCR expression 
analysis. All samples were analysed in duplicates. Data was analysed using ABI Prism 7500 
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SDS Software Version 4.0 (Applied Biosystems). Messenger RNA copy number was 
quantified by comparison to a 10-fold dilution series of plasmid containing PCR product and 
normalised for 18S rRNA.     
 
2.9.4 Cloning of standards 
Products from qPCR were analysed on a 1% (w/v) agarose tris-acetate-EDTA (TAE) gel (Table 
2.6) together with a DNA ladder (Table 2.6) to indicate product size. PCR products were 
excised from the gel, purified using a QIAquick PCR purification kit (Table 2.8) and inserted 
into a pCR2.1 TOPO TA vector (Table 2.8).  Vector and insert were transformed into 
chemically competent TOP10 E.coli cells (Table 2.8) by heat shock treatment at 42oC for 
30sec. Cells were plated onto lysogeny broth (LB) agar plates (Table 2.7) containing 
100µg/ml of ampicillin (Table 2.6) and incubated at 37oC overnight. Correct insert ligation 
was assessed by restriction enzyme digest with EcoRI endonuclease and analysed on a gel 
and by amplification of insert b qPCR. Positive clones were grown up in LB broth (Table 2.7) 
containing 100 µg/ml of ampicillin and purification of plasmid DNA was carried out using 
Qiagen Plasmid Midi and Maxi Kits (Table 2.8).  
 
2.10 Statistical analysis 
All graphical data is expressed as mean ±SEM (standard error of the mean). A minimum of 4 
animals per group were used for all in vivo experiments. In addition, a representative of at 
least 2 independent experiments or combined experiments is depicted. For in vitro 
experiments, at least 4 independent experiments were performed in duplicate or triplicate 
wells for studies in BEAS-2B and HBECs (Lonza). Experiments performed on HBECs from 
patients’ bronchial brushings were performed in duplicate wells but only carried out once 
due to limitation of cells.  
 
Where groups were greater than 2 and/or multiple comparisons were analysed, results 
were analyzed by ANOVA and differences between groups identified using Bonferroni’s 
post-test with 95% confidence using GraphPad Prism4 software. When only two groups 
were analysed and one condition was variable a 2 tailed unpaired t test was used to 
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compare groups. Clinical data was analysed by one-way ANOVA using the Kruskal-Wallis test 
with a 95% confidence interval with Dunn’s multiple comparison test. Correlations were 
assessed with linear regression and Spearman’s coefficient (r) value. P values are 
represented throughout as follows:* P<0.05, ** P<0.01, ***P<0.001.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 73 
 
 
 
Live/dead marker
FS
C
-A
FS
C
-H
FSC-A
SSC-A
SS
C
-H
SSC-A
FS
C
-A
Fi
gu
re
2.
4.
1
R
e
p
re
se
n
ta
ti
ve
fl
o
w
cy
to
m
e
tr
y
ga
ti
n
g
fo
r
liv
e
,
si
n
gl
e
ce
ll
s
Lu
ng
ce
lls
in
a
m
o
de
lo
f
R
V
-i
n
du
ce
d
al
le
rg
ic
ai
rw
ay
s
d
is
e
as
e
w
e
re
ga
te
d
to
in
cl
u
d
e
liv
e
,
si
n
gl
e
ly
m
p
h
o
cy
te
s.
N
u
m
b
e
rs
in
d
ic
at
e
d
o
n
th
e
p
lo
ts
re
fl
e
ct
th
e
p
e
rc
e
n
ta
ge
o
f
ce
lls
th
at
ar
e
p
re
se
n
t
w
it
h
in
th
e
ga
te
d
ar
e
as
.A
b
b
re
vi
at
io
n
s:
FS
C
-A
=f
o
rw
ar
d
sc
at
te
r-
ar
ea
;F
SC
-H
=
fo
rw
ar
d
sc
at
te
r-
h
ei
gh
t;
SS
C
-A
=s
id
e
sc
at
te
r-
ar
ea
;S
SC
-H
=
si
d
e
sc
at
te
r-
he
ig
ht
T1/ST2
Fc
εR
I
CD49b
IL
-4
Fc
εR
I
CD49b
IL
-4
CD4
C
D
3
T1/ST2
Fi
gu
re
2.
4.
2
R
e
p
re
se
n
ta
ti
ve
fl
o
w
cy
to
m
e
tr
y
ga
ti
n
g
fo
r
b
as
o
p
h
il
s
B
as
o
p
h
ils
in
a
m
o
d
e
lo
f
R
V
-i
n
d
u
ce
d
al
le
rg
ic
ai
rw
ay
s
d
is
e
as
e
w
e
re
id
e
n
ti
fie
d
b
y
ga
ti
n
g
C
D
3-
/C
D
4-
ce
lls
w
h
ile
lu
n
g
ce
lls
st
ai
n
ed
w
it
h
al
lm
ar
ke
rs
w
it
h
th
e
e
xc
lu
si
o
n
o
f
T1
/S
T2
an
d
Fc
εR
Iw
e
re
u
se
d
as
a
co
n
tr
o
lt
o
se
t
ga
te
s
to
id
e
n
ti
fy
C
D
49
b
+
/F
cε
RI
+
ce
lls
.
Si
m
ila
rl
y,
lu
n
g
ce
lls
st
ai
n
ed
w
it
h
al
lm
ar
ke
rs
w
ith
th
e
e
xc
lu
si
o
n
of
C
D
49
b
an
d
IL
-4
w
e
re
u
se
d
as
a
co
n
tr
o
lt
o
se
t
ga
te
s
fo
rm
e
as
u
re
m
e
n
to
fC
D
49
b
+
/I
L-
4+
ce
lls
.
 74 
 
 
 
 
 
C
D
3
CD4
IL-4
IL-4
Fi
gu
re
2.
4.
4
R
e
p
re
se
n
ta
ti
ve
fl
o
w
cy
to
m
e
tr
y
ga
ti
n
g
fo
r
IL
-1
7R
B
+
IL
-4
+
C
D
4+
T
ce
ll
s
an
d
IL
-4
+
C
D
4+
T
ce
ll
s
C
D
4+
/C
D
3+
ce
lls
w
e
re
st
ai
n
ed
w
it
h
al
l
m
ar
ke
rs
w
it
h
th
e
e
xc
lu
si
o
n
o
f
IL
-4
an
d
IL
-1
7R
B
(1
A
)
as
w
e
ll
as
IL
-4
(2
A
)
w
h
ic
h
w
e
re
u
se
d
as
co
n
tr
o
ls
to
se
t
ga
te
s
an
d
d
e
fi
ne
IL
-4
+/
IL
-1
7R
B
+
(1
B
)
an
d
IL
-4
+
C
D
4+
T
ce
lls
(2
B
).
1
A
1
B
2
B
2
A
IL-4
IL-4
FS
C
-A
FS
C
-A
2
B
CD4
C
D
3
T1/ST2
FS
C
-A
T1/ST2
FS
C
-A
IL-17RB
IC
O
S
IL
-1
7
R
B
IL
-1
7
R
B
Fi
gu
re
2.
4.
3
R
e
p
re
se
n
ta
ti
ve
fl
o
w
cy
to
m
e
tr
y
ga
ti
n
g
fo
r
in
n
at
e
ly
m
p
h
o
id
ce
ll
s
(I
LC
)
2.
C
e
lls
th
at
w
e
re
n
e
ga
ti
ve
fo
r
Fc
εR
I,
IL
-4
an
d
C
D
49
b
w
e
re
so
rt
ed
fu
rt
h
e
r
to
e
xc
lu
d
e
C
D
3
an
d
C
D
4
e
xp
re
ss
in
g
ce
lls
.
To
de
fi
n
e
T1
/S
T2
+
ce
lls
,
sa
m
p
le
s
w
e
re
st
ai
ne
d
w
ith
al
l
m
ar
ke
rs
w
it
h
th
e
ex
cl
u
si
on
o
f
T1
/S
T2
w
h
ic
h
w
e
re
th
e
n
ga
te
d
to
id
e
n
ti
fy
IL
-1
7R
B
+
/I
C
O
S+
ce
lls
.
 75 
 
Table 2.6 Reagents and buffers  
Name Composition Application Supplier 
ACK lysis buffer  0.15M Ammonium Chloride,  1mM 
Potassium Hydrogen Carbonate, 
0.1mM Disodium EDTA in 500ml 
dH2O. Sterile filtered 
Depletion of red blood cells  All reagents from 
Sigma-Aldrich 
Agarose Agarose molecular grade powder Agarose gel electrophoresis Sigma-Aldrich 
Aluminium Hydroxide 
(Alum)  
Aluminium Hydroxide (Al)OH3 
Hydrate 
Sensitisation of mice Sigma-Aldrich 
Ampicillin (100mg/ml) Supplied in 70%(v/v) ethanol E. coli culture for plasmid 
cloning  
Sigma-Aldrich 
β-mercaptoethanol (β-
ME) 
14.3M C2H6O5 Isolation of RNA Sigma-Aldrich 
BAL fluid  Earle’s Balanced Salt Solution 
55mM  Disodium EDTA   
12mM lidocaine hydrochloride 
monohydrate 
Lavage of mouse lung Gibco 
Gibco 
Sigma-Aldrich 
Buffer RLT  Lysis of mouse tissue/cells 
and human cells 
Qiagen 
Cytofix/Cytoperm™ 
solution 
1% Paraformaldehyde  
Saponin 
Simultaneous fixation and 
permeabilization of cells for 
flow cytometry  
BD biosciences 
DNA ladder 1kB Plus DNA ladder 100bp-12kB 
DNA standard (1μg/μl) 
Agarose gel electrophoresis Invitrogen 
EcoRI restriction enzyme  Buffer H 10X Buffer, BSA, 5,000u 
EcoRI 
Cloning for TaqMan Promega 
ELISA reagent 
diluent/blocking solution 
1% BSA in  
Dulbecco's Phosphate-Buffered 
Saline (DPBS) 
Sample and standard dilution 
buffer and blocking solution 
Sigma-Aldrich 
Gibco 
ELISA wash buffer PBS  and 0.05% tween20 ELISA plate washing Sigma-Aldrich  
ELISA stop solution 2M H2SO4  Stopping of ELISA reaction Sigma-Aldrich 
FACS buffer  1% (w/v) BSA and 0.01% (w/v) 
Sodium Azide in DPBS. Sterile 
filtered  
Processing of cells for 
staining in flow cytometry 
Sigma-Aldrich 
Isoflurane  ‘Isoflurane-Vet’ 100% w/w Anaesthesia in mice  Merial 
Lung digestion buffer 10% (v/v) FCS, 2% (v/v) HEPES, 1% 
(v/v) sodium bicarbonate in RPMI,  
1mg/ml collegenase Type XI and 
80units/ml Bovine Pancreatic 
Dnase Type IV   
 Sigma-Aldrich 
 
 
Sigma-Aldrich 
Methacholine  Acetyl-β-methl-choline chloride, 
dessicate  
Assessment of airway 
hyperreactivity (AHR) in mice 
Sigma-Aldrich 
Ovalbumin  Chicken egg ovalbumin, 5X 
crystalline 
Mouse sensitisation and 
challenge  
Calbiochem 
Paraformaldehyde 
fixative (4%) 
4% paraformaldehyde (w/v) heated 
to 60oC in PBS, pH increased by 1 N 
NaOH to increase solubility and 
adjusted to pH 7.4 
Fixative of mouse lung cells Sigma 
Pentobarbitone 
 
Pentoject Pentobarbitone Sodium, 
20% w/v 
Terminal anaesthesia in mice AnimalCare Ltd. 
Phosphate buffer saline 
(PBS) (1X)  
Dulbecco's PBS (1x) without 
calcium and magnesium 
General use A&E Scientific (PAA) 
PBS (1X) 0.014M KH2PO4, 0.008M Na2HPO4-
7H20, 0.0026M KCl, 0.137M NaCl 
Cell culture  Invitrogen 
Polyethylene glycol 
(PEG)  
Polyethylene glycol 6000,  
7% w/v 
Precipitation of virus for 
RV1B propagation 
Fluka 
Protease Inhibitor 
Cocktail Tablets 
Composed of several protease 
inhibitors for the inhibition of 
serine and cysteine proteases (one 
tablet dissolved in 50ml PBS) 
Prevent break down of 
proteins in solution for lung 
homogenate ELISAs 
Roche 
Quantitect Probe PCR HotStarTaq DNA Polymerase, Taqman RT PCR (Qiagen, USA) 
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Mastermix  QuantiTect Probe RT-PCR Buffer, 
dNTP mix, ROX dye 
Quantitative PCR probes  Random hexadeoxynucleotides 
(0.5μg/ml) 
cDNA synthesis Eurofins 
Random primers Random hexadeoxynucleotides 
(0.5μg/ml) 
cDNA synthesis Invitrogen 
RNA Later buffer RNA stabilisation buffer Stabilisation of RNA from 
mouse tissue and human 
cells  
Qiagen 
Strepavidin-HRP (Horse 
Radish Peroxidase) 
ELISA grade Strepavidin-HRP 
conjugate  
ELISA  R and D Systems 
T4 DNA ligase 100 units T4 DNA ligase in storage 
buffer 
Ligation Promega 
T4 DNA ligase (10X) 
reaction buffer 
300mM Tris-HCl, 100mM MgCl2, 
100mM DTT, 10mM ATP 
Ligation Promega 
TE buffer (1X), Molecular 
grade 
10mM Tris-HCl containing 1mM 
EDTA. Na2 
Plasmid, primer/probe 
resuspension 
Promega 
Tetramethyl benzidine 
(TMB) substrate  
3,3′,5,5′- Tetramethyl benzidine  
liquid substrate 
Substrate for horseradish 
peroxidase in ELISA  
Invitrogen 
Tris-acetate-EDTA buffer 
(TAE)  
2M tris-acetate solution containing 
50mM EDTA  
Agarose gel electrophoresis Invitrogen 
Trypan blue  0.4% trypan blue in 0.85% saline 
solution 
Assessment of cell viability Invitrogen  
 
Table 2.7 Media and media supplements  
Name Composition Application Supplier 
Bronchial epithelium basal 
medium (BEBM) 
Refer to manufacturer’s information on 
media composition 
HBEC culture Lonza 
BEGM single quot additives Refer to manufacturer’s composition HBEC culture Lonza 
HBEC BEGM serum free 
media 
HBEC BEGM complete growth media 
without 13g/L bovine pituitary extract 
Serum starving for 
HBEC infection 
Lonza 
Collagen coating solution 10% BSA (sterile filtered),  
1% Recombinant human like collagen 
1% fibronectin in BEGM  
Seeding of HBECs 
from bronchial 
brushings 
Sigma-Aldrich 
Biovision  
Invitrogen  
HBEC BEGM complete 
growth media 
BEBM with BEGM single quot additives HBEC culture As stated above 
Dulbeccos modified eagles 
medium (DMEM) 
Refer to manufacturer’s media composition HeLa culture PAA Laboratories 
RPMI 1640 media Refer to manufacturer’s media composition BEAS-2B culture PAA Laboratories 
Foetal Bovine Serum  Heat inactivated foetal bovine serum HeLa and BEAS-2B 
culture 
Invitrogen 
HEPES buffered saline 
solution 
30mM HEPES HBEC culture  Lonza 
HEPES buffered solution  238.3 g/L prepared in distilled water. pH: 
7.2 to 7.5 
HeLa and BEAS-2B 
culture 
Invitrogen 
Sodium Bicarbonate  7.5% sodium bicarbonate in solution HeLa and BEAS-2B 
culture 
Invitrogen 
Penicillin-Streptomycin  10,000U/ml penicillin G sodium and 
10,000μg/ml Streptomycin sulphate in 
0.85% saline 
HBEC culture Invitrogen 
HeLa growth media 10% (v/v) FCS, 2% (v/v) HEPES, 1% (v/v) 
sodium bicarbonate in DMEM 
HeLa culture Invitrogen 
HeLa serum free media 2% (v/v) HEPES, 1% (v/v) sodium 
bicarbonate in DMEM 
HeLa culture Invitrogen 
HeLa infection media 
 
2% (v/v) FCS, 2% (v/v) HEPES, 1% (v/v) 
sodium bicarbonate in DMEM 
HeLa culture Invitrogen 
BEAS-2B growth media 10% (v/v) FCS, 2% (v/v) HEPES, 1% (v/v) 
sodium bicarbonate in RPMI 
BEAS-2B culture Invitrogen 
BEAS-2B serum free media 2% (v/v) HEPES, 1% (v/v) sodium BEAS-2B culture Invitrogen 
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bicarbonate in RPMI 
BEAS-2B infection media 2% (v/v) FCS, 2% (v/v) HEPES, 1% (v/v) 
sodium bicarbonate in RPMI 
BEAS-2B culture Invitrogen 
Trypsin-EDTA (1X) 0.025% trypsin, 0.01% EDTA  HBEC sub-culture Lonza 
Trypsin-EDTA (10X) 0.5% trypsin, 5.3mM EDTA HeLa and BEAS-2B 
sub-culture 
Invitrogen  
Trypsin Neutralising solution 
(TNS) 
Refer to manufacturer’s media composition HBEC sub-culture Lonza 
Luria-Bertani (LB) media 10g tryptone, 5g yeast extract, 5g NaCl, in 
1L distilled water 
E. coli culture for 
plasmid cloning  
Sigma-Aldrich 
Stimulation media  10% (v/v) FCS, 2% (v/v) HEPES, 1% (v/v) 
sodium bicarbonate in RPMI 
50ng/ml phorbol myristate acetate (PMA)  
500ng/ml ionomycin  
1μl/ml GolgiStop containing monensin 
 Sigma-Aldrich 
 
Sigma-Aldrich 
BD Biosciences 
LB agar  14g of agarose in 1L LB media E. coli culture for 
plasmid cloning 
Sigma-Aldrich 
Ultroser-G 
BioSpera  
  
   
 
Serum substitute lyophilized Ultroser G Supplement medium 
for HBECs from 
bronchial brushings 
Pall Life Sciences, 
UK 
 
Table 2.8 Commercially available kits  
Name Components Application  Supplier 
Mouse DuoSet ELISA 
Development kit  (IL-4, -5,, -
25, 33, CCL11, CCL24, CCL5, 
CCL17  
Capture Antibody, Detection 
Antibody, Standard, Streptavidin-HRP 
Measurement of cytokines 
and chemokines  in mice 
R and D Systems 
Mouse IL-13 Quantikine 
Immunoassay 
2x Mouse IL-13 Microplates, IL-13 
Conjugate, IL-13 Standard, IL-13 
Control, Assay Diluent RD1-14, 
Calibrator Diluent RD5T, Wash Buffer 
Concentrate, Colour Reagent A and B, 
Stop Solution 
Measurement of IL-13 in mice R and D Systems 
Mouse Serum Total IgE 
ELISA Set  
Anti-mouse IgE monoclonal antibody 
capture antibody,  Biotinylated anti-
mouse IgE monoclonal antibody 
detection antibody, Streptavidin-
horseradish peroxidase conjugate 
(SAv-HRP), Purified mouse IgE 
standard 
Measurement of total IgE in 
mice 
BD OptEIA 
Omniscript RT (Reverse 
Transcription) Kit 
dATP, dCTP, dGTP, dTTP (10mM) in 
water, 10X Buffer RT, Omniscript 
reverses transcriptase, RNase-free 
water 
cDNA synthesis Promega 
One Shot® TOP10 
Competent Cells 
Components used in study: One Shot® 
TOP10 Chemically Competent E. Coli, 
S.O.C Medium 
Cloning of products for 
TaqMan 
Invitrogen 
Plasmid Midiprep Kit Buffer P1, Buffer P2, Buffer P3, Buffer 
QBT, Buffer QC, Buffer QF, Qiagen-tip 
100 
Medium-scale plasmid 
isolation 
Qiagen 
Plasmid Maxiprep kit  Buffer P1, Buffer P2, Buffer P3, Buffer 
QBT, Buffer QC, Buffer QF, Qiagen-tip 
500 
Large-scale plasmid isolation Qiagen  
QIAquick PCR Purification 
Kit  
QIAquick Spin Columns, Buffers, 
Collection Tubes 
PCR purification for cloning Qiagen 
Quantitect Probe PCR 
Mastermix  
HotStarTaq DNA Polymerase, 
QuantiTect Probe RT-PCR Buffer, 
dNTP mix, ROX dye 
Taqman RT PCR (Qiagen, USA) 
REASTAIN Quick-Diff Kit Reastain Quick-Diff Blue containing, Differential staining of REAGENA Ltd 
 78 
 
Azur II 0,09 % 
Glycerol 5 %, Sodiumazide <0,1 % 
Reastain Quick-Diff Fix containing 
Methanol 100 %, Methyleneblue 
<0,01 % Reastain Quick-Diff Red 
containing Eosin Y 0,12 %, 
Sodiumazide <0,1 % 
cytospins 
RNase-free DNase set 1500 units RNase-free DNase I, RNase-
free buffer RDD 
DNase digestion in total RNA 
isolation 
Qiagen 
RNeasy Mini Kit  Buffer RLT, Buffer RW1, Buffer RPE, 
RNase-free water, RNeasy mini spin 
columns, collection tubes 
Total RNA isolation Qiagen  
TOPO TA cloning kit (with 
pCR 2.1-TOPO vector) 
Components used in study: pCR 2.1-
TOPO (10ng/μl), salt solution  (1.2M 
NaCl, 0.06M MgCl2 
Cloning of products for 
TaqMan 
Invitrogen 
 
Table 2.9 Antibodies used in IHC and ELISA 
 
Name 
 
Clone 
 
Application  Working conc.   
 
Supplier 
Mouse anti-MUC5AC 
(biotinylated) 
45-M1 ELISA 0.4µg/ml ThermoScientific 
Peroxidase-conjugated goat 
anti-mouse IgG (Fc specific)  
 ELISA 5µg/ml Sigma-Aldrich 
Mouse anti-OVA IgE 2C6 ELISA 1µg/ml Genetex 
Rat Anti-Mouse IgE (ε chain 
specific) (biotinylated) 
23G3 ELISA 0.5µg/ml Southern Biotech 
Purified anti-mouse/human 
IL-25 (IL-17E)  
35B IHC 60µg/ml Biolegend  
Rat IgG control antibody  IHC 60µg/ml Sigma-Aldrich 
Peroxidase-conjugated 
rabbit  anti-rat IgG-biotin y 
 IHC 1:100 Dako 
 
Table 2.10 Antibodies used in flow cytometry 
 
Name 
 
Clone 
 
Conjugate Working conc.   
 
Supplier 
     
Hamster anti-mouse CD3e 500A2 Alexa Fluor 700 
 
2.5µg/ml eBiosciences 
Rat anti-mouse  CD4 RM4-5 Brilliant  Violet 605 2.5 µg/ml Biolegend 
Rat anti-mouse CD49b DX5 PerCP-Cy5.5 2.5 µg/ml Biolegend 
Hamster anti-mouse ICOS 
(CD278)  
C398.4A 
 
Pe-Cy7 2.5 µg/ml Biolegend 
Hamster anti-Mouse FcεR1 MAR-1 PE 2.5 µg/ml eBiosciences 
T1/ST2 DJ8 FITC 5 µg/ml MD Biosciences 
Anti-mouse IL-17RB  D9.2 Alexa Fluor  647 5 µg/ml Obtained  from Dr David 
Cousins (Kings College, London) 
Rat anti-mouse IL-4 11B11 Brilliant violet 421 2.5 µg/ml Biolegend 
Fc Block (anti-mouse 
CD16/CD32) 
2.4G2  5µg/ml BD Biosciences 
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Chapter 3: Results 
Characterisation of IL-25 induction in response to RV infection in vitro and in vivo 
3.1 Introduction  
The airway epithelium is the first point of contact for all inhaled stimuli in the asthmatic lung 
and plays a pivotal role in shaping subsequent immune responses via the release of 
mediators75. Importantly, the major triggers of asthma exacerbations, namely RV and 
allergen, are both capable of modulating the lung epithelium and induce epithelial-derived 
chemokines and cytokines that initiate recruitment and activation of immune cells26,67. 
Notably, IL-25 is released by adenocarcinomic human alveolar basal epithelial cells (A549) 
and the mouse lung epithelial cell line, MLE12, when stimulated with the allergens, 
Aspergillus oryzae and ragweed70. Furthermore, stimulation of human nasal epithelial cells 
(HNEC) with poly I:C, a synthetic analog of dsRNA used to mimic viral infection, induced IL-
25160. Given that bronchial epithelial cells are the primary site of RV infection we 
hypothesized that RV infection of the airway epithelium induces the cytokine, IL-25. 
Therefore, we initially investigated in vitro expression of IL-25 in response to the human RV-
1B (serotype 1B) in human airway epithelial cell lines and bronchial epithelial cells obtained 
from bronchoscopic brushings from atopic asthmatics and healthy patients.  
Based on these findings, we then sought to characterise IL-25 induction in a mouse model of 
RV infection. The majority of studies in mice have reported IL-25 induction in response to 
established Th2 inducers including allergen and models of nematode infections70,80,170. 
Though two recent studies have demonstrated enhanced IL-25 expression in response to 
RSV infection in NK cell depleted mice and to PVM infection in unmodified BALB/c 
mice157,177, the induction of IL-25 by RV, with or without concomitant exposure to allergen, 
has not been investigated. The finding that the pro-Th2 cytokine, IL-25, is induced by RV 
could provide an association between the antiviral response and Th2 driven inflammation 
and implicate IL-25 as a potential initiator of RV-induced exacerbations. In addition, 
confirmation of IL-25 induction in response to RV in the airways of BALB/c mice would verify 
suitability of this model to investigate our primary aim, namely to investigate the role of IL-
25 in exacerbation of Th2 inflammation in a model of RV-induced allergic airway disease. 
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3.2 Hypotheses and aims  
3.2.1 Hypotheses   
i.) RV-1B infection induces IL-25 expression in human bronchial epithelial cells (HBECs) 
in vitro 
ii.) RV-1B infection induces IL-25 expression in the airways of mice in vivo 
 
3.2.2 Aims 
 To characterise RV-1B-induced IL-25 expression in vitro (Part 1) and in vivo (Part 2) 
Part 1: To investigate IL-25 expression in RV-1B-infected human airway epithelial cell 
lines and HBECs from atopic asthmatics (AAs) and non-atopic non-asthmatic (NANAs) 
patients 
i.) To use quantitative (q) PCR to determine the magnitude and kinetics of IL-25 
gene expression in RV-infected BEAS-2Bs, A549s, H292s and commercially 
purchased primary HBECs 
ii.) To measure IL-25 gene expression by qPCR and IL-25 protein by ELISA in RV-
infected cultured HBECs from AA and NANA subjects and assess if increased 
RV-induced IL-25 correlates with asthma relevant clinical parameters in 
patients 
Part 2: To investigate IL-25 expression in the lungs of RV-1B-infected BALB/c mice. 
i.) To confirm successful RV-1B infection by measuring: 
 RV-1B RNA copies in the lung using qPCR 
 Inflammatory airway leukocyte infiltration in the bronchial alveolar 
lavage (BAL)  via differential cell counts 
 Viral-associated proinflammatory cytokines and chemokines in the BAL 
by ELISA. 
ii.) To determine the magnitude, kinetics and cellular source/s of IL-25 in the 
airway and lung tissue by qPCR, ELISA and immunohistochemistry (IHC). 
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3.1    Results: Part 1 
3.3.1 RV-induced IL-25 in human airway epithelial cell lines 
3.3.1.1  BEAS-2B cells 
The human bronchial epithelial cell line, BEAS-2B, was infected with RV-1B and IL-25 
expression was measured at the indicated time-points post-infection (p.i.). Gene expression 
was quantified by qPCR while protein in cell supernatants was measured using an in-house 
ELISA developed by Novartis.  
Using a multiplicity of infection (MOI) of 2 (TCID50 of 5x10
6), RV-1B induced IL-25 mRNA 
which was significantly upregulated compared with media (P<0.05) and UV-RV-1B-treated 
controls (P<0.05) at 24h p.i. (Figure 3.1 A). This titre was selected based on previous dose-
dependent assays that demonstrated using a MOI of 2 induced the highest amounts of IL-25 
at 24h p.i. (Figure 3.1 B).  
Previous reports have demonstrated that the proinflammatory cytokine, IL-6, is induced by 
RV infection and replication in BEAS-2B cells therefore levels were measured in cell 
supernatants by ELISA to confirm that cells were successfully infected 116,204.  RV-1B 
infection induced significantly higher levels of IL-6 protein compared with UV-inactivated 
virus (P<0.05) at 24h p.i. (Figure 3.1 C) indicating that IL-25 gene expression was RV 
replication-dependant.   
IL-25 protein was not detectable in cell supernatant from RV-1B-infected or control-treated 
cell cultures (data not shown).  
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Figure 3.1 Measurement of IL-25 and IL-6 expression in RV-infected BEAS-2B cell lines BEAS-2B cells 
were exposed to RV-1B in parallel with UV-inactivated RV-1B (UV-RV-1B) and PBS (media) as 
negative controls. Cells were harvested at the indicated time-points p.i. and IL-25 mRNA (A) was 
measured after optimising the RV-1B viral titre for infection (B). IL-6 protein expression (C) was 
measured to confirm RV infection and replication. For detection of IL-25 gene, cellular RNA was 
extracted and cDNA synthesized by qPCR. Data is expressed as the number of mRNA copies per μl of 
cDNA added per qPCR reaction. IL-6 protein was detected in cell supernatant by ELISA. Data is 
represented as the mean (+/-SEM) of triplicate wells per treatment condition and is representative 
of at least 4 independent experiments.* RV-1B vs UV-RV-1B; # RV-1B vs media (*/# P<0.05) 
(**P<0.01) 
 
3.3.1.2 Commercially purchased primary HBECs (Lonza) and additional human airway 
epithelial cell lines  
IL-25 gene expression was also measured in the human alveolar adenocarcinoma cell line, 
A549, the mucoepidermoid carcinoma cell line, NCl-H292, as well as commercially available 
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primary HBECs (Lonza).  All cells were infected with RV-1B and IL-25 mRNA was measured by 
qPCR at 6h, 8h, 24h, 48h and 72h p.i.  
IL-25 mRNA and protein was undetectable in all cell lines and primary HBECs. RV-1B 
replication was confirmed by significantly higher levels of IL-6 protein in cell supernatants as 
measured by ELISA in RV-1B-infected cells and control-treated cells (data not shown).    
 
3.3.2 Analysis of RV-induced IL-25 in HBECs from atopic asthmatics (AA) and non-atopic 
non-asthmatic (NANA) patients 
IL-25 gene and protein expression was measured in cDNA samples and in supernatants from 
RV-1B-infected and media-treated cells from 10 atopic asthmatics (AAs) and 10 non-atopic 
non-asthmatics (NANAs). These samples were obtained as part of a human clinical study 
carried out by Dr Jonathan Macintyre.  
 
3.3.2.1 Clinical characteristics of subjects  
HBECs were obtained from bronchoscopic brushings from moderate AAs (according to the 
BTS and GINA guidelines50,58) with cells from NANAs as controls. Inclusion criteria for 
asthmatic patients was an age range of 18-65 years old, a clinical diagnosis of asthma, 
symptom questionnaires positive for asthma, a skin prick test (SPT) positive for at least one 
allergen, a histamine provocation concentration of <8mg/ml producing a 20% fall (PC20) in 
FEV1, an absence of other chronic respiratory or systemic disease and a status of either non-
smoker or ex-smoker (with a history of <5 packs/year) (Table 3.1). 
Healthy control subjects were aged between 18-65 years, were negative for asthma in 
symptom questionnaires, negative for allergen-specific SPT, had a PC20 of >16mg/ml, 
possessed <80IU/ml of IgE, had an absence of chronic respiratory or systemic disease and 
were non-smokers or ex-smokers (with a history of <5 packs/year). Subjects were excluded 
if they had contracted a respiratory tract infection within the last 6 weeks before the study 
or possessed any other abnormalities in lung function (Table 3.1).  
All subjects gave written informed consent and the study was approved by the St. Mary’s 
Hospital Ethics Committee. 
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3.3.2.2 Statistical summary of clinical characteristics of subjects 
All characteristics relating to clinical diagnosis of asthma, indications of lung function and 
atopic read-outs were significantly different in AAs compared with NANAs as indicated by 
represented P values in Table 3.1.  
 
Clinical characteristics Atopic Asthmatics Non-atopic non-asthmatics P value 
Sex 70% M 30% F 30% M 70% F   
Age 34.5 (±2.252) 28 (±2.408) 0.1011 
ACQ 1.054 (±0.259) 0 0.0002 
ICS 80% (±0.133) 0 0.0021 
ICS and LABA (Salbutemol) 80% (±0.133) 0 0.0021 
Exacerbations/year 1.4 (±0.306) 0 0.025 
PEF % predicted 93.3 (±2.103) 106.286 (±1.748) 0.002 
FEV1 % predicted 89.667 (±2.739) 106.857 (±1.575) 0.0001 
FEV1/FVC ratio 78.788 (±2.107) 88.333 (±2.092) 0.0046 
P20 (mg/ml) 3.096 (±0.764) 16 or >16 0.0001 
IgE (units/ml) 218.87 (±63.024) 9.286 (±2.119) 0.0001 
SPT (number)  3.4 (±0.400) 0 0.0001 
Table 3.1 Clinical characteristics of subjects from whom HBECs were attained. Values are 
presented as the mean for each group, namely atopic asthmatics (n=10) and non-atopic non-
asthmatics (n=10), with the standard error of the mean (SEM) represented in brackets. Gender and 
asthmatic subjects on medication (inhaled corticosteroids and/or long acting beta agonists), are 
represented as percentages. Abbreviations: ACQ=asthma control questionnaire; ICS=inhaled 
corticosteroids; LABA=long acting beta agonist; PEF=peak expiratory flow rate; FEV1=forced 
expiratory volume in 1 second; PC20= provocative concentration of histamine causing a 20% drop in 
FEV1; FVC=forced expiratory vital capacity, SPT= skin prick test 
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3.3.2.3  Quantification of IL-25 gene expression in HBECs 
IL-25 mRNA was quantified in RV-1B-infected and media-treated cells from AAs and NANAs 
by qPCR. RV-1B infection induced significantly greater levels of IL-25 gene expression in cells 
from AAs at 8h p.i. compared with media-treated cells from AAs (P<0.05) and NANAs 
(P<0.01) harvested at the same time-point (Figure 3.2 A). No significant differences or 
trends in IL-25 expression were observed in any treatment groups at 24h p.i. (Figure 3.2 B). 
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Figure 3.2 Measurement of IL-25 gene expression in RV-infected cells from AAs and NANAs Cells 
from 10 AAs and 10 NANAs were exposed to RV-1B (RV) in parallel with PBS (media [M]) as a negative 
control and were harvested to measure IL-25 gene expression at 8h (A) and 24h (B) p.i. For IL-25 gene 
quantification, cellular RNA was extracted and cDNA synthesized by qPCR. Data is expressed as the 
number of mRNA copies per μl of cDNA added per qPCR reaction. Data is represented as the mean 
(+/-SEM) of triplicate wells per treatment condition and is representative of 1 independent 
experiment (* P<0.05; **P<0.01). 
 
3.3.2.4 Quantification of IL-25 protein in HBECs 
IL-25 protein was detected in cell supernatants from RV-1B-infected and media-treated cells 
from AAs and NANAs using an in-house ELISA developed by Novartis. Though no significant 
differences were observed between treated cells at 8h p.i. (Figure 3.3 A), IL-25 levels were 
significantly elevated in supernatants from RV-1B-infected cells from AAs compared with 
supernatants from media-treated cells from NANAs (P<0.01) at 24h p.i (Figure 3.3 B).  
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Figure 3.3  Measurement of IL-25 protein expression in RV-infected cells from AAs and NANAs Cells 
from 10 AAs and 10 NANAs were exposed to RV-1B (RV) in parallel with PBS (media [M]) as a 
negative control and were harvested to measure IL-25 protein expression at 8h (A) and 24h (B) p.i. 
IL-25 protein was measured in cell supernatants from cultured cells using an in-house ELISA 
developed at Novartis Horsham Research Centre, West Sussex. Data is represented as the mean (+/-
SEM) of triplicate wells per treatment condition and is representative of 1 independent experiment 
(**P<0.01). 
 
3.3.2.5 Correlations between IL-25 protein expression levels and clinical characteristics    
To assess if increased IL-25 was related to clinical parameters, protein levels were correlated 
with clinical measurements in AAs and NANAs. IL-25 measurements at 8h and 24h p.i. in RV-
1B-infected and media-treated controls were compared against clinical read-outs of atopy 
(IgE levels and SPT), indications of lung function (FEV1/FVC ratio), AHR (PC20 measurement) 
as well as the number of recorded AE/year and ACQ results. Correlations were assessed with 
linear regression and Spearman’s coefficient (r) value which, together with summarised P 
values, are represented for IL-25 levels in cells from AAs at 24h p.i. vs clinical parameters in 
Table 3.2.  No significant correlations between IL-25 levels and clinical parameters were 
observed in cells from NANAs at any time-point p.i. or in cells from AAs at 8h p.i. and media-
treated cells at 24h p.i. However, increased IL-25 in RV-1B-infected cells from AAs at 24h p.i. 
was significantly associated with increased positive SPT scores (r=0.8245; p=0.0047) (Figure 
3.4 A). A trend for increased IL-25 and an increased number of recorded AE/year was also 
evident at 24h p.i. (r=0.6097; p=0.0667) though this correlation was not significant (Figure 
3.4 B).  
A B 
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Spearman r 0.6055 -0.2557 -0.0121 0.03892 -0.2727 0.2203 
p value 0.0667 0.4697 0.9730 0.9184 0.4483 0.5367 
p value summary ns ns ns ns ns Ns 
Table 3.2 Summary of correlations between IL-25 protein levels in RV-1B-infected/media-treated 
controls from AAs (n=10) and clinical parameters. Spearman’s coefficient (r) value and summarised p 
values are represented. 
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Figure 3.4  Correlations between IL-25 protein expression levels in RV-infected cells from AAs at 
24h p.i. and clinical characteristics RV-1B-induced IL-25 protein levels in cells from AAs (n=10) were 
correlated with positive number of skin-prick tests (SPT) (A) and recorded asthma 
exacerbations/year (B).  Spearman’s coefficient (r) value and summarised p values are represented 
on both graphs. 
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3.4 Results: Part 2 
3.4.1 Characterisation of RV-1B infection in BALB/c mice 
3.4.1.1 RV-1B viral load  
BALB/c mice were infected i.n. with RV-1B or UV-inactivated RV1B (UV-RV-1B) at a TCID50 of 
5x106 per mouse. Viral RNA was detected via qPCR in processed lung tissue that was 
harvested from mice at various time-points p.i.  
In RV-1B-infected mice, viral load was significantly increased at 10h p.i. compared to levels 
in mice treated with UV-RV-1B (P<0.05) (Figure 3.5). This increase persisted until day (d) 1 in 
infected mice (RV-1B vs UV-RV-1B P<0.05), after which viral load decreased in both treated 
groups and was comparable at d7 p.i.  
 
 
 
 
 
 
 
Figure 3.5  Quantification of RV-1B viral load in the mouse lung BALB/c mice were infected i.n with 
RV-1B or dosed with UV-inactivated virus (UV-RV-1B) as a negative control. Lungs were harvested at 
10h and at days 1, 2, 4 and 7 p.i. and processed by extracting RNA and synthesizing cDNA to quantify 
viral RNA copies via qPCR.  Data is expressed as the number of RNA copies per μl of cDNA added per 
qPCR reaction. Data is representative of at least 2 experiments. Each group of mice (n=4-6) is 
represented as the mean (+/-SEM) while statistical significance is denoted for comparison between 
RV-1B and UV-RV-1B treatment at the indicated time-points p.i. (*P < 0.05) 
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3.4.1.2  Airway leukocyte infiltration  
To confirm successful RV-1B infection of mice (as previously characterised by early 
neutrophila and delayed lymphocytosis202), differential cell counts were carried out on BAL 
cells from RV-1B-infected and UV-RV-1B-treated mice. The airways leukocyte profile was 
characterised by differential staining and cellular morphology in BAL cells fixed to cytospin 
slides.  
RV-1B induced rapid neutrophilia as early as 10h p.i. (RV-1B vs UV-RV-1B P<0.01) and 
peaked at d1 p.i. (RV-1B vs UV-RV-1B P<0.001) (Figure 3.6 A). This influx of neutrophils 
accounted for approximately 80% of total BAL cells at 10h and d1 p.i (Figure 3.6 B). 
Neutrophilic inflammation in infected mice had decreased by d2 and was resolved by d4 and 
d7 p.i. RV-1B also induced a significant infiltration of BAL lymphocytes at d2 (RV-1B vs UV-
RV-1B P<0.05), d4 (RV-1B vs UV-RV-1B P<0.05) and d7 p.i. (RV-1B vs UV-RV-1B P<0.01) 
(Figure 3.6 C). The peak of lymphocytosis was observed at d7 p.i. and accounted for 
approximately 10% of total BAL cells (Figure 3.6 D). Both neutrophilic and lymphocytic 
responses observed in RV-1B-infected mice were consistent with previously published 
results of this model202. UV-inactivated virus failed to induce an inflammatory cellular 
response, suggesting that the observed increase in neutrophils and lymphocytes in infected 
mice was dependant on RV-1B replication.   
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Figure 3.6  Kinetic airway leukocyte infiltration in response to RV-1B infection BALB/c mice 
were infected i.n with RV-1B or dosed with UV-inactivated virus (UV-RV-1B) as a negative control. 
BAL cells from mice were fixed to cytospin slides and stained to quantify total numbers and 
percentages of neutrophils (A and B respectively) and lymphocytes (C and D respectively). All slides 
were blinded to experimental treatments. Data is represented as the mean (+/-SEM) of 4-6 mice per 
group and is representative of at least 2 experiments. Statistical significance is denoted for RV-1B vs 
UV-RV-1B-treated mice at the indicated time-points p.i. (*P <0.05) (**P<0.01) (***P<0.001). 
 
3.4.1.3 Proinflammatory mediators in the BAL 
The induction of proinflammatory chemokines and cytokines in response to RV-1B infection 
in mice and humans has previously been demonstrated202 39. To confirm an effective RV-1B 
infection, proinflammatory mediators in the BAL fluid of mice were quantified by ELISA. A 
significant early increase in the proinflammatory cytokine, IL-6, was observed at 10h p.i. in 
RV-1B-infected mice (RV-1B vs UV-RV-1B P<0.001) (Figure 3.7 A). This induction was still 
significant at d1 p.i. (RV-1B vs UV-RV-1B P<0.001), after which levels decreased to baseline 
after d2 p.i. A similar trend in induction in response to RV-1B was observed with the antiviral 
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type III interferon, IFN-λ (Figure 3.7 B). Levels in infected mice were significantly higher at 
10h (RV-1B vs UV-RV-1B P<0.05) and d1 p.i. (RV-1B vs UV-RV-1B P<0.05) and progressively 
decreased after d2 p.i. The neutrophil chemoattractant, CXCL1/KC, was induced 
concurrently with the onset of neutrophilia at 10h p.i. (RV-1B vs UV-RV-1B P<0.001) and 
remained significantly higher at d2 p.i. (RV-1B vs UV-RV-1B P<0.001) in RV-1B-infected mice 
compared with treated controls (Figure 3.7 C). A comparatively later peak in the T cell 
chemokine, CCL5/RANTES, was observed at d1 (RV-1B vs UV-RV-1B P<0.001) and d2 p.i (RV-
1B vs UV-RV-1B P<0.001) in RV-1B-infected mice (Figure 3.7 D) which preceded the 
significant infiltration of lymphocytes observed at d4 and d7 p.i.  
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Figure 3.7  Quantification of proinflammatory mediators in response to RV-1B infection BAL from 
RV-1B-infected and UV-RV-1B-treated controls was collected at the indicated time-points and BAL 
supernatant was used to measure IL-6 (A), IFN-λ (B), CXCL1/KC (C) and CCL5/RANTES (D) by ELISA. 
Data is represented as the mean (+/-SEM) of 4-6 mice per group and is representative of at least 2 
experiments. Statistical significance is denoted for RV-1B vs UV-RV-1B-treated mice at the indicated 
time-points p.i. (*P < 0.05) (**P<0.01) (***P<0.001).  
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3.4.2 IL-25 expression in response to RV-1B infection 
3.4.2.1 IL-25 gene expression in the BAL cells and lung tissue 
Studies in mouse models have demonstrated induction of IL-25 during Th2-mediated 
immune responses; however the induction of IL-25 by RV infection in vivo has not previously 
been reported. Based on results from part 1 of this chapter which indicated that RV alone 
upregulated IL-25 in vitro, we sought to investigate IL-25 expression in mice infected with 
RV-1B. 
IL-25 gene expression was quantified by qPCR in lung tissue and BAL cells from RV-1B-
infected mice and UV-RV-1B-treated controls. RV-1B induced a significant early increase of 
IL-25 mRNA in lung tissue (RV-1B vs UV-RV-1B P<0.01) (Figure 3.8 A) and BAL cells (RV-1B vs 
UV-RV-1B P<0.05) (Figure 3.8 B) which was significantly greater than treated controls at 10h 
p.i. After d1 p.i., IL-25 gene expression levels decreased steadily in infected mice and by d7 
p.i. quantities were comparable to mRNA levels in treated control.  
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Figure 3.8  Measurement of IL-25 mRNA in the BAL cells and lung tissue from RV-1B-infected mice 
BALB/c mice were infected i.n with RV-1B or dosed with UV-inactivated virus (UV-RV-1B) as a 
negative control.  BAL cells were harvested by flushing lungs before excising the lung tissue at the 
time-points indicated p.i. Lung tissue (A) and BAL cells (B) were processed by extracting RNA and 
synthesizing cDNA to measure IL-25 gene expression by qPCR. Data is expressed as the number of 
mRNA copies per μl of cDNA added per qPCR reaction. Data is representative of at least 3 
experiments. Each group of mice (n=4-6) is represented as the mean (+/-SEM) while statistical 
significance is denoted for comparison between RV-1B and UV-RV-1B treatment at the indicated 
time-points p.i. (*P<0.05) (**P<0.01).   
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3.4.2.2 IL-25 protein expression  
As IL-25 protein was undetectable in the BAL, processed lung homogenate from RV-1B-
infected mice and UV-RV-1B-treated controls was used to quantify protein levels by ELISA 
while a PBS-treated control group was also included (baseline). RV-1B induced an initial 
sharp increase in IL-25 protein expression at d1 p.i. and from d2-d7 p.i. levels remained 
significantly elevated compared with UV-RV-1B-treated controls (d2 P<0.05; d4 P<0.01; d7 
P<0.01) (Figure 3.9). Inactivated virus triggered IL-25 expression that was comparable to 
levels measured in mice at 10h and emulated expression patterns observed in infected 
mice. However, these amounts were on average ~2-fold lower in UV-RV-1B-treated groups 
compared with infected groups from d2-d7 p.i.   
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Figure 3.9  Measurement of IL-25 protein in lung tissue from RV-1B-infected mice BALB/c mice 
were infected i.n. with RV-1B or UV-activated virus (UV-RV-1B) or PBS (baseline) as a control. Lung 
tissue from mice was collected at the indicated time-points and used to measure IL-25 protein 
expression in processed lung homogenate by ELISA. Each group of mice (n=4-6) is represented as the 
mean (+/-SEM) while statistical significance is denoted for comparison between RV-1B and UV-RV-1B 
at the indicated time-points p.i. (*P < 0.05) (**P<0.01). Data is representative of at least 3 
experiments.  
 
3.4.2.3 Immunostaining for IL-25 protein expression  
To further analyse IL-25 protein expression and identify cellular sources of IL-25 in vivo, 
immunostaining was carried out on paraffin-embedded lung tissue from RV-1B-infected 
mice and UV-RV-1B-treated controls at 10h, d1, d2 and d4 p.i. while a PBS-treated control 
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group was also included (baseline). IL-25 immunoreactivity was observed in the bronchial 
epithelium and in infiltrating inflammatory cells in the airway lamina propria of RV-1B-
infected mice.  
i.) Airway epithelial cells 
Airway epithelium was semi-quantitatively scored by Dr Jie Zhu (Royal Brompton Hospital, 
Imperial College London) and IL-25 immunoreactivity was detected by brown staining 
(Figure 3.12 A-K).  IL-25 protein expression in the bronchial epithelium of RV-1B-infected 
mice was significantly greater at 10h (RV-1B vs UV-RV-1B P<0.05) and d1 p.i. (RV-1B vs UV-
RV-1B P<0.01) compared with treated controls (Figure 3.10). At d2 p.i., IL-25 
immunoreactivity was reduced in RV-1B-infected mice and by d4 p.i., levels were similar to 
UV-RV-1B-treated controls. Epithelial IL-25 immunostaining was also observed in UV-RV-1B-
treated controls; however significantly greater levels observed in RV-1B-infected mice early 
after infection indicated that IL-25 protein expression was predominantly virus replication 
dependant. 
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Figure 3.10  Measurement of IL-25+ epithelial cells in lung tissue from RV-1B-infected mice 
BALB/c mice were infected i.n. with RV-1B or UV-activated virus (UV-RV-1B) or PBS (baseline) as a 
control. Lungs were harvested at the indicated time-points and immunostained to quantify IL-25+ 
epithelial cells. Immunostaining intensity for IL-25 protein was scored semi-quantitatively between 0 
to 1.5 (0 = negative; 0.5 =weak staining, 1 = moderate staining, and 1.5 =strong staining). All counts 
were performed by one investigator and slides were blinded to experimental treatments. Each group 
of mice (n=5) is represented as the mean (+/-SEM) while statistical significance is denoted for 
comparison between RV-1B and UV-RV-1B at the indicated time-points p.i. (*P <0.05) (**P<0.01) 
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ii.) Inflammatory cells 
Infiltrating IL-25+ inflammatory cells were also quantified and expressed as the number of 
positive inflammatory cells per millimeter length of the reticular basement membrane 
(Figure 3.13 A-E). Significantly increased numbers of IL-25 immunoreactive cells were 
quantified in the airway lamina propria at d1 (RV-1B vs UV-RV-1B P<0.01; RV-1B) and d2 p.i. 
(RV-1B vs UV-RV-1B P<0.001) compared with treated controls (Figure 3.11). By d4 p.i., these 
levels were greatly reduced but still remained higher than levels in UV-RV-1B-treated mice. 
Although double staining IHC would be required to verify results, the majority of IL-25+ cells 
at d1 p.i. appeared to be macrophages and neutrophils while some IL-25+ lymphocytes were 
observed at d2 p.i. based on morphological identification.  
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Figure 3.11  Measurement of IL-25+ inflammatory cells in lung tissue from RV-1B-infected mice 
BALB/c mice were infected i.n. with RV-1B or UV-activated virus (UV-RV-1B) or PBS (baseline) as a 
control. Lungs were harvested from mice at the indicated time-points and immunostained to 
quantify infiltrating IL-25+ inflammatory cells in the airway lamina propria. Data is expressed as the 
number of positive inflammatory cells per millimetre length of the reticular basement membrane. All 
counts on histology slides were performed by one investigator and slides were blinded to 
experimental treatments. Each group of mice (n=5) is represented as the mean (+/-SEM) while 
statistical significance is denoted for comparison between RV-1B and UV-RV-1B treatment at the 
indicated time-points p.i. (**P<0.01) (***<0.001) 
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(A ) 10hRV - 1B  p.i . (X40)  (B ) 10h RV - 1B  p.i . (X20)  
( C )  10h UV - RV - 1B  p.i . (X40)  ( D )  10h UV - RV - 1B  p.i . (X20)  
( E ) d1  RV - 1B  p.i . (X40)  ( F ) d1  RV - 1B  p.i . (X20)  
( G ) d1  UV - RV - 1B  p.i . (X40)  ( H ) d1  UV - RV - 1B  p.i . (X20)  
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Figure 3.12  Representative immunohistochemistry staining for IL-25 in the lung epithelium in 
tissue from RV-1B-infected, UV-RV-1B and PBS-treated mice BALB/c mice were infected i.n. with 
RV-1B or UV-activated virus (UV-RV-1B) and PBS (baseline) as negative controls. IL-25 
immunoreactivity is represented by brown staining in RV-1B-infected mice at 10h (A-B) and d1 p.i. 
(E-F) and in UV-RV-1B-treated (C-D; G-H) and PBS-treated controls (I-J) at a magnification of X20 
(scale bar=150μm) and X40 (scale bar=75μm). An isotype control (K) at a magnification of X20 is also 
represented.  
 
 
 
 
  
( I ) d1   PBS - mock (X40) (J) d1    PBS - mock (X20) 
(K)  Isotype control (X20) 
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Figure 3.13  Representative immunohistochemistry staining for IL-25+ inflammatory cells Black 
arrows point to IL-25+ macrophages (A and B) and neutrophils (C) in RV-1B-infected mice at d1 p.i. as 
well as IL-25+ lymphocytes (D) at d2 p.i. which were identified based on morphology. PBS-mock 
controls (E) are also represented. All slides are represented at a magnification of X40 (scale bar=75µm). 
 
3.4.3 Quantification of Th2 cytokines 
Due to fact that RV induced IL-25, the classical Th2-associated cytokines, IL-4, IL-5 and IL-13 
were also measured in BAL cells and lung tissue from RV-1B-infected mice and UV-RV-1B-
treated controls. All measured cytokines were undetectable in all treated groups (results not 
shown). 
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3.5 Summary 
In part one of this chapter, we reported that RV-1B infection of the human bronchial 
epithelial cell line, BEAS-2B, induced IL-25 gene expression; however, gene induction was 
not detected in other investigated cell lines or commercially purchased primary HBECs.  
Furthermore, IL-25 protein in cell supernatants from RV-1B-infected BEAS-2B cells was 
undetectable as measured by ELISA. In contrast, IL-25 mRNA and protein was detected in 
the majority of RV-1B-infected and media-treated HBECs from AAs and NANAs. Moreover, 
RV-1B induced significantly higher IL-25 gene expression at 8h p.i. and protein at 24h p.i. in 
cells from AA patients compared with media-treated HBECs from healthy controls. These 
findings are novel and indicate intrinsic differences in the bronchial epithelium of asthmatics 
compared with healthy subjects. Furthermore, enhanced IL-25 protein expression was 
associated with asthma-associated outcomes; enhanced protein levels at 24h p.i. 
significantly correlated with sensitisation to a greater number of common environmental 
allergens as indicated by a positive wheal and flare responses in AA patients. Furthermore, 
an association between cells from AA patients producing more RV-induced IL-25 protein and 
increased numbers of recorded asthma exacerbations per year in subjects was also evident.  
In part two of this chapter, we demonstrated IL-25 induction in response to RV infection in 
vivo and confirmed that the release of mediators in BALB/c mice were characteristic of 
experimental RV infections in patients and in vitro studies of HBECs40,205. These read-outs 
included an early robust neutrophilic response followed by lymphocytic inflammation as 
well as strong induction of the mouse CXCR2-specific chemokine, CXCL1/KC, the 
proinflammatory cytokine, IL-6 and CCL5/RANTES in the airways of RV-infected mice. IL-25 
induction was initially confirmed by a significant early increase in IL-25 gene expression in 
the lung and airways of RV-infected mice. Although IL-25 protein was undetectable in the 
BAL, increased protein expression in the lung tissue of infected mice was confirmed by ELISA 
and IHC results. Immunostaining confirmed findings from part 1 demonstrating that the 
bronchial epithelium is a major source of early RV-induced IL-25 expression. Macrophages, 
neutrophils and lymphocytes were also identified as potential IL-25 producers in the airway 
lamina propria.  
In summary, in vitro results indicated that HBECs from asthmatics possess a greater 
propensity to produce IL-25 than cells from non-atopic non-asthmatic individuals. Based on 
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the ability of IL-25 to augment an allergic response, this induction may represent a 
mechanism of exacerbated RV-induced allergic inflammation in the asthmatic lung. In vivo 
results demonstrated that IL-25 was upregulated in RV-1B-infected mice; however it was 
apparent from the absence of Th2 inflammation (as demonstrated by undetectable IL-4, IL-5 
and IL-13 and the absence of airway eosinophilia) that enhanced IL-25 alone was not 
sufficient to initiate an allergic phenotype. In the next chapter we sought to investigate the 
effects of RV infection and allergen on IL-25 production in a mouse model of RV-induced 
allergic airways disease with the ultimate aim of assessing if IL-25 plays a role in 
exacerbation of Th2 allergic disease. 
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Chapter 4: Results 
IL-25 induction in response to allergic and viral interactions in a model of RV-induced 
allergic airways disease 
4.1 Introduction 
Epidemiological and experimental studies have demonstrated an interaction between 
allergen exposure, RV infection and the risk of exacerbations of asthma92,95. Notably, two 
seminal clinical studies showed that the combination of allergic sensitisation, exposure to 
high levels of allergen and viral infection, including RV, was strongly associated with the risk 
of hospital admittance with acute asthma in both children and adults92,95. While Th2-
mediated inflammation is clearly implicated in the asthmatic response, it is unknown how 
the immune response to RV infection interacts with Th2 immunity to cause an asthma 
exacerbation.  
To elucidate potential mechanisms of interplay between allergen exposure and RV infection 
in a sensitised system, a mouse model of RV-induced allergic airways disease was developed 
in our laboratory202. Using this model, we aimed to test the hypothesis that a Th2 
pulmonary environment in conjunction with virus synergistically enhances IL-25. 
The upregulation of IL-25 in response to allergen alone has been reported in several in vivo 
and in vitro studies while clinical findings have shown an increase in IL-25 mRNA and its 
receptor in tissue from chronic asthmatics70,127,169,170. However, the induction of IL-25 by RV, 
with or without concomitant exposure to allergen, has not been investigated. 
Studies in mouse models of allergic airways inflammation have demonstrated that IL-25 has 
the potential to act directly on both innate and adaptive Th2 cytokine-producing cells in the 
lung76,169,187. Therefore, based on this evidence we postulated that RV-induced IL-25 
augments allergic inflammation via activation of Th2-associated cells which are recruited to 
the mouse lung by allergen sensitisation and challenge, thus representing a link between 
antiviral responses and Th2 driven inflammation. For these reasons, IL-25 and Th2-related 
innate and adaptive responses were investigated in our model of RV-induced allergic 
airways disease by assessing various time-points after infection including early (10h p.i.) and 
later (d7 p.i.) events. 
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4.2 Hypotheses and Aims 
4.2.1  Hypotheses 
i.) RV infection in an allergen sensitised and challenged mouse enhances IL-25 
expression compared with either allergen exposure or viral infection alone 
ii.) RV infection increases allergen driven Th2-associated responses potentially 
regulated by IL-25  
4.2.2 Aims 
To investigate the effects of allergen and RV on IL-25 expression as well as characterise RV-
induced enhancement of Th2 inflammation potentially regulated by IL-25 using a mouse 
model of RV-induced allergic airways disease 
i.) To determine the magnitude and kinetics of IL-25 in the mouse lung by qPCR to 
measure gene expression and ELISA to detect protein  
ii.) To measure potential IL-25-regulated Th2 outcomes in mice including: 
 AHR using whole-body and double-chamber plethysmography 
 Viral load in the lung tissue using qPCR 
 Inflammatory airway leukocyte infiltration in the BAL via differential cell counts  
 Th2-associated cytokines and chemokines in the BAL and lung tissue by ELISA 
 Respiratory mucins including MUC5ac and MUC5b  in the BAL by ELISA 
 Total and allergen-specific IgE in mouse serum by ELISA 
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4.3 Results 
In this chapter, a mouse model of RV-induced allergic airways disease was employed and 
treatment groups, as previously described in section 2.2.4 are summarised in the table 
below for clarification.                 
 
Experimental 
groups 
Sensitisation  
(OVA/Alum i.p.) 
Challenge 
(OVA i.n) 
RV-1B infection 
(RV-1B i.n./UV-RV-1B control) 
RV OVA Yes Yes Yes 
UV OVA Yes Yes No  
RV PBS Yes No Yes 
UV PBS Yes No No 
Table 4.1  Treatment regime and nomenclature of groups in a model of RV-induced allergic airways 
disease 
 
4.3.1 Airway responses  
We employed whole-body (as measured by enhanced pause [Penh]) and double-chamber 
(as measured by specific airway resistance [SRaw]) plethysmography to assess the 
exacerbating effects of RV infection in OVA-sensitised and challenged mice on AHR. At d1 
p.i./allergen challenge, RV OVA mice showed enhancement in airway obstruction as 
assessed by Penh (Figure 4.2 A). Specifically, at a dose of 30mg/ml of methacholine, Penh 
was significantly greater in RV OVA-treated mice compared with UV PBS controls (P<0.05) 
while at 100mg/ml RV OVA mice displayed significantly greater Penh compared with PBS-
challenged groups (RV OVA vs RV PBS P<0.05; RV OVA vs UV PBS P<0.001.).There was a 
trend towards increased Penh in RV OVA groups vs UV OVA groups however this was not 
statistically significant.  Whole-body plethysmography data was confirmed by measurement 
of specific airway resistance (SRaw) using double-chamber plethysmography, which 
demonstrated increased AHR in RV OVA mice compared with UV PBS controls (P < 0.05) at a 
dose of 20mg/ml of methacholine (Figure 4.2 B).  Furthermore, RV OVA mice displayed 
significantly greater AHR compared with UV OVA mice, indicating that RV infection 
exacerbated allergen-induced allergic airways disease at a dose of 20mg/ml of 
methacholine.  
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Figure 4.2  Airway responses in a model of RV-induced allergic airways disease OVA-sensitised 
BALB/c mice were challenged i.n. with OVA or PBS control and infected with RV-1B or mock-infected 
with UV-inactivated virus. At d1 p.i./final allergen challenge, Penh (A) and SRaw (B) were measured in 
response to increasing doses (in mg/ml) of aerosolised methacholine (MCh). Penh and SRaw were 
measured over 5 minute periods after 1 minute aerosolisation challenge to methacholine. For both 
plethysmograph experiments, aerosolised water was used to determine baseline values. Data is 
represented as the mean (+/-SEM) of 5 mice per treatment and is representative of at least 2 
independent experiments (Penh data) or one experiment (sRaw data). + RV OVA vs UV OVA; # RV 
OVA vs RV PBS; *RV OVA vs UV PBS (*/#/+P < 0.05; *** P<0.001) 
 
4.3.2 RV-1B viral load 
To assess if enhanced AHR observed in RV OVA mice was associated with increase viral load, 
RV RNA copies were quantified by qPCR in the lung tissue of all treated groups of mice to 
compare viral load in the presence or absence of allergen challenge.  
RV-1B viral RNA was significantly increased at 10h p.i. in RV OVA mice compared with all 
other treated groups (RV OVA vs UV OVA P<0.001; RV OVA vs RV PBS P<0.001; RV OVA vs 
UV PBS P<0.001) (Figure 4.3). By d1 p.i., levels of viral RNA copies had decreased sharply in 
RV OVA mice and by d2 p.i. levels were comparable to viral RNA in RV PBS-treated mice 
which displayed a peak in viral load at this time-point. Thus, OVA challenge significantly 
enhanced early viral load in RV OVA mice compared with RV infection alone.   
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Figure 4.3  Viral load in a model of RV-induced allergic airways disease OVA-sensitised BALB/c 
mice were challenged i.n. with OVA or PBS control and infected with RV-1B or mock-infected with 
UV-inactivated virus. Lungs were harvested at 10h and days 1, 2, 4 and 7 p.i. and processed by 
extracting RNA and synthesizing cDNA to quantify viral RNA copies via qPCR.  Data is expressed as 
the number of RNA copies per μl of cDNA added per qPCR reaction.  Each group of mice (n=5) is 
represented as the mean (+/-SEM) and data is representative of at least 2 experiments. + RV OVA vs 
UV OVA; # RV OVA vs RV PBS; *RV OVA vs UV PBS (+++/###/*** P < 0.001) 
 
4.3.3 Airway leukocyte infiltration 
In human experimental infection models, RV infection has been reported to increase 
recruitment of neutrophils, lymphocytes and eosinophils in the asthmatic lung93. In 
accordance with this data, RV OVA mice displayed an early increase in neutrophilia and later 
enhanced eosinophilia as characterised by differential staining of BAL cell cytospins. 
Neutrophilia at d1 p.i. in RV OVA mice was approximately 5 fold higher compared with RV 
PBS mice (RV OVA vs RV PBS P<0.001) and remained significantly elevated until d2 p.i. 
compared with all other groups (RV OVA vs UV OVA P<0.001; RV OVA vs RV PBS P<0.001; RV 
OVA vs UV PBS P<0.001) (Figure 4.4 A). Eosinophilia was observed in OVA-challenged mice 
exclusively with RV OVA mice displaying the greatest levels at d4 and d7 p.i (Figure 4.4 B). A 
prolonged increase in lymphocytes from d2 to d7 p.i. was observed in RV OVA mice which 
were significantly increased compared with RV PBS and UV PBS mice but not compared with 
UV OVA groups (Figure 4.4 C). This kinetic analysis of BAL cells is consistent with previously 
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published data of this model indicating enhancement of allergic airways inflammation by RV 
infection202.   
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Figure 4.4  Airway leukocyte infiltration in a model of RV-induced allergic airways disease  OVA-
sensitised BALB/c mice were challenged i.n. with OVA or PBS control and infected with RV-1B or 
mock-infected with UV-inactivated virus. BAL cells from mice were fixed to cytospin slides and 
stained to quantify total numbers of neutrophils (A), eosinophils (B) and lymphocytes (C) at the 
indicated time-points p.i. All slides were blinded to experimental treatments. Each group of mice 
(n=5) is represented as the mean (+/-SEM) and data is representative of at least 2 experiments. + RV 
OVA vs UV OVA; # RV OVA vs RV PBS; *RV OVA vs UV PBS (##/** P<0.01; +++/###/*** P < 0.001) 
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4.3.4 BAL chemokines 
Given that eosinophil and Th2 lymphocyte recruitment and activation are associated with 
asthma pathogenesis, the chemokines CCL5/RANTES, CCL11/Eotaxin 1, CCL24/Eotaxin 2 and 
CCL17/TARC were measured in the BAL of all treated mice by ELISA.  
CCL5/RANTES, which has been demonstrated to be upregulated in virus-induced asthma 
exacerbation in humans, is a potent chemoattractant for eosinophils as well as memory T 
cells 206. Here, we showed that RV infection significantly induced early CCL5/RANTES 
expression in OVA-challenged mice (RV OVA vs UV OVA P<0.01, RV OVA vs RV PBS P<0.05, 
RV OVA vs UV PBS P<0.01) which persisted to d1 p.i. (RV OVA vs UV OVA P<0.05, RV OVA vs 
UV PBS P<0.01) (Figure 4.5 A). This was consistent with enhanced lymphocytosis and 
eosinophilia observed in RV OVA mice as illustrated in Figure 4.4. Similarly, the eosinophil 
chemoattractants, CCL11/Eotaxin 1 and CCL24/Eotaxin 2, were significantly upregulated in 
RV OVA mice with an early increase in CCL11/Eotaxin 1 at 10h p.i. (RV OVA vs UV OVA 
P<0.05, RV OVA vs UV PBS P<0.05) (Figure 4.5 C) and a comparatively delayed peak of 
CCL24/Eotaxin 2 protein at d1 p.i. (RV OVA vs UV OVA P<0.05, RV OVA vs RV PBS P<0.001, 
RV OVA vs UV PBS P<0.001) (Figure 4.5 D). Both groups of OVA-challenged mice displayed 
late enhancement of the Th2 cell chemoattractant, CCL17/TARC, at d7 p.i. and while levels 
were higher in RV OVA mice, these quantities were not significantly different (Figure 4.5 B).   
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Figure 4.5  BAL chemokines in a model of RV-induced allergic airways disease OVA-sensitised 
BALB/c mice were challenged i.n. with OVA or PBS control and infected with RV-1B or mock-infected 
with UV-inactivated virus. BAL from mice was collected at the indicated time-points and BAL 
supernatant was used to quantify CCL5/RANTES (A), TARC/CCL17 (B), CCL11/Eotaxin1 (C) and 
CCL24/Eotaxin2 (D) by ELISA. Data is represented as the mean (+/-SEM) of 5 mice per group and is 
representative of at least 2 independent experiments. + RV OVA vs UV OVA; # RV OVA vs RV PBS; 
*RV OVA vs UV PBS (+/#/* P<0.05; ++/##/** P<0.01; +++/###/*** P < 0.001) 
 
4.3.5 BAL IL-6  
Increases in the proinflammatory cytokine IL-6 have been reported in atopic asthmatics 
experimentally infected with RV which remained elevated during convalescence205. We 
measured BAL IL-6 in our mouse model of RV-induced allergic airways disease by ELISA and 
observed an approximate 6-fold increase in RV OVA mice compared with UV OVA mice at 
10h p.i. (RV OVA vs UV OVA P<0.001, RV OVA vs RV PBS P<0.001, RV OVA vs UV PBS 
P<0.001) (Figure 4.6). By d1 p.i., these levels had decreased but still remained significantly 
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elevated compared with all treated groups (RV OVA vs UV OVA P<0.001, RV OVA vs RV PBS 
P<0.001, RV OVA vs UV PBS P<0.001).   
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Figure 4.6  BAL IL-6 in a model of RV-induced allergic airways disease   OVA-sensitised BALB/c mice 
were challenged i.n. with OVA or PBS control and infected with RV-1B or mock-infected with UV-
inactivated virus. BAL from mice was collected at the indicated time-points and BAL supernatant was 
used to quantify IL-6 by ELISA. Data is represented as the mean (+/-SEM) of 5 mice per group and is 
representative of at least 2 independent experiments. + RV OVA vs UV OVA; # RV OVA vs RV PBS; * 
RV OVA vs UV PBS (+++/###/*** P < 0.001) 
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4.3.6     Th2 cytokine expression 
It is well established that asthma pathogenesis is largely mediated by the Th2 cytokines, IL-
4, IL-5 and IL-13207-209. Previously published data from our mouse model demonstrated 
significantly greater levels of IL-4 and IL-13 at d1 p.i. in the BAL of RV OVA mice compared 
with OVA-challenged mice alone202. Given the potential importance of IL-25-regulated Th2 
cytokines in the pathogenesis of RV-induced asthma exacerbations, we undertook a 
thorough investigation of Th2 cytokine production in the BAL and lung homogenate by ELISA 
and included an earlier time-point at 10h p.i. which has not previously been studied.  
 
4.3.6.1     BAL Th2 cytokines 
BAL Th2 cytokines were detectable only in allergen-sensitised and challenged mice. The 
combination of RV infection and OVA challenge induced significantly higher levels of BAL IL-
4 (RV OVA vs UV OVA P<0.001; RV OVA vs RV PBS P<0.001; RV OVA vs UV PBS P<0.001) 
(Figure 4.7 A) and IL-13 (RV OVA vs UV OVA P<0.05; RV OVA vs RV PBS P<0.001; RV OVA vs 
UV PBS P<0.001) (Figure 4.7 B) early on (10h p.i.). Furthermore, RV OVA mice produced 
approximately two-fold more IL-4 protein in the airways than OVA-challenged mice alone. 
By d1 p.i. quantities of IL-4 and IL-13 in RV OVA mice were comparable to OVA-challenged 
mice alone and by d4 and d7 p.i. levels in both groups were either low or undetectable. 
Concentrations of BAL IL-5 were comparable in both OVA-challenged groups at 10h p.i. 
while a later peak in RV OVA mice was observed at d1 p.i. (Figure 4.7 C). These levels were 
significantly increased compared with RV-infected (RV OVA vs RV PBS P < 0.001) and 
allergen-challenged groups (RV OVA vs UV OVA P<0.01). This data confirmed that RV 
infection enhances early Th2 production in the airways of allergen-challenged mice and 
identified 10h p.i. as a key time-point for analysis of these increases.  
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Figure 4.7  BAL Th2 cytokines in a model of RV-induced allergic airways disease   OVA-sensitised 
BALB/c mice were challenged i.n. with OVA or PBS control and infected with RV-1B or mock-infected 
with UV-inactivated virus. BAL from mice was collected at the indicated time-points and BAL 
supernatant was used to measure IL-4 (A), IL-5 (B) and IL-13 (C) by ELISA. Data is represented as the 
mean (+/-SEM) of 5 mice per group and is representative of at least 2 independent experiments. + 
RV OVA vs UV OVA; # RV OVA vs RV PBS; *RV OVA vs UV PBS (+ P<0.05; ++ P<0.01; +++/###/*** P < 
0.001) 
 
4.3.6.2     Th2 cytokines in lung homogenate 
To assess if Th2 cytokine profiles in the BAL reflected those in the lung parenchyma as well 
as gain a thorough profile of the magnitude and kinetics of expression, Th2 cytokines were 
also measured in lung homogenate by ELISA. Results indicated varied temporal peaks in 
cytokine expression in lung tissue compared with those observed in the BAL. Specifically, 
delayed peaks at d4 p.i. in both OVA-challenged groups were detected for all cytokines 
(Figure 4.8). Although levels were generally higher in RV OVA mice at d4 p.i., only IL-5 
amounts reached significance in RV OVA groups compared to UV OVA groups (RV OVA vs UV 
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OVA P<0.05) (Figure 4.8 B) . In addition, an earlier lower peak was observed at d1 p.i. in RV-
infected and OVA-challenged mice that was absent in OVA-challenged mice alone. At this 
time-point, RV infection significantly enhanced IL-4 (RV OVA vs UV OVA P<0.01) (Figure 4.8 
A), IL-5 (RV OVA vs UV OVA P<0.01) and IL-13 (RV OVA vs UV OVA P<0.05) (Figure 4.8 C) 
expression in RV-infected OVA-challenged mice compared with OVA-challenged mice alone.  
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Figure 4.8  Th2 cytokines in lung tissue in a model of RV-induced allergic airways disease OVA-
sensitised BALB/c mice were challenged i.n. with OVA or PBS control and infected with RV-1B or 
mock-infected with UV-inactivated virus. Lung tissue from mice was collected at the indicated time-
points and processed lung homogenate was used to measure IL-4 (A), IL-5 (B) and IL-13 (C) by ELISA. 
Data is represented as the mean (+/-SEM) of 5 mice per group and is representative of at least 2 
independent experiments. + RV OVA vs UV OVA; # RV OVA vs RV PBS; *RV OVA vs UV PBS (+/* 
P<0.05; ++/** P<0.01; +++/###/*** P < 0.001) 
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4.3.7   IL-25 expression  
Enhanced IL-25 expression in response to allergen exposure in vivo and in vitro has been 
reported in several studies and clinical findings have shown an increase in both IL-25 and its 
receptor mRNA in asthmatic tissue70,127,170. Findings from chapter 3 demonstrate increased 
IL-25 expression in RV-infected asthmatic cells compared with cells from healthy individuals 
suggesting an interaction between allergic inflammation and infection leading to increased 
IL-25 in asthma. To investigate the interaction between allergen-driven Th2 immunity and 
RV infection in vivo, IL-25 expression was measured in a mouse model of RV-induced allergic 
airways disease.  
IL-25 gene expression was quantified by qPCR in lung tissue while protein was detected in 
lung homogenate by ELISA as IL-25 was undetectable in the BAL.  RV infection induced 
significantly higher levels of IL-25 mRNA in OVA-challenged mice early on (10h p.i.) 
compared with all other treated groups (RV OVA vs UV OVA P<0.05; RV OVA vs RV PBS 
P<0.05; RV OVA vs UV PBS P<0.05) (Figure 4.9 A). By d1 and d2 p.i., mRNA levels in RV OVA 
mice had decreased and were comparable to UV OVA mice. IL-25 levels peaked in both UV 
OVA and RV PBS mice at d2 p.i. with ~10-fold more IL-25 expressed in the lungs of UV OVA 
mice compared with infection alone.  
IL-25 protein displayed a similar expression pattern as Th2 cytokines measured in mouse 
lung homogenate (Figure 4.8). Specifically, an early peak in IL-25 expression was observed 
exclusively in RV OVA mice at d1 p.i. (RV OVA vs UV OVA P<0.05; RV OVA vs UV PBS P<0.01) 
(Figure 4.9 B). This was followed by a second larger peak at d4 p.i. which was detected in 
both OVA-challenged groups, although levels were moderately higher in RV OVA mice.  
Consistent with results from chapter 3 (Figure 3.9), RV infection alone induced IL-25 protein 
which were comparable to levels measured in UV OVA mice. However, unlike sustained 
levels observed in our model of RV infection which employed a higher viral titre, levels had 
decreased to baseline by d7 p.i. in RV PBS mice suggesting that the lower titre used in this 
model may result in decreased, varied kinetics expression. 
In summary, we observed upregulation of IL-25 mRNA and protein in OVA-challenged mice 
further demonstrating that RV infection in OVA-challenged mice enhanced allergen-driven 
IL-25 production.  
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Figure 4.9  IL-25 gene and protein expression in a model of RV-induced allergic airways disease 
OVA-sensitised BALB/c mice were challenged i.n. with OVA or PBS control and infected with RV-1B or 
mock-infected UV-inactivated virus. Lung tissue from mice was collected at the indicated time-points and 
used to measure IL-25 mRNA (A) and protein expression (B). For measurement of IL-25 gene, RNA was 
extracted and cDNA synthesized by qPCR. Data is expressed as the number of mRNA copies per μl of 
cDNA added per qPCR reaction. IL-25 protein was detected in processed lung homogenate by ELISA. Data 
is represented as the mean (+/-SEM) of 5 mice per group and is representative of at least 2 independent 
experiments. + RV OVA vs UV OVA; # RV OVA vs RV PBS; *RV OVA vs UV PBS (+/#/* P<0.05; ##/** P<0.01; 
###/*** P < 0.001) 
 
4.3.8   IL-33 and TSLP expression  
Unpublished data from our laboratory indicates that IL-33 is significantly upregulated in 
atopic asthmatic patients experimentally infected with RV compared with healthy controls 
(Jackson, D. et al). In addition, asthmatic epithelial cells have been reported to generate 
increased amounts of the pro-Th2 cytokine, TSLP, in response to RV infection which was 
enhanced by supplementing IL-4 in the media in vitro210 . Based on the fact that IL-25, IL-33 
and TSLP are all epithelial-derived and have been reported to interact predominantly in the 
innate Th2 response, we aimed to measure IL-33 and TSLP in our model of RV-induced 
allergic airways disease.   
Like IL-25, IL-33 and TSLP protein was undetectable in the BAL, therefore levels were 
measured in lung homogenate by ELISA. Unlike Th2 cytokines measured in lung tissue above 
(Figures 4.8 and 4.9 B), IL-33 levels peaked in RV OVA mice at d1 p.i. with no subsequent 
larger peak at d4 p.i. (Figure 4.10 A). Though IL-33 levels were significantly higher in RV OVA 
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groups compared with both PBS-challenged groups at 10h (RV OVA vs RV PBS P<0.01; RV 
OVA vs UV PBS P<0.001) and d1 p.i. (RV OVA vs RV PBS P<0.001; RV OVA vs UV PBS 
P<0.001), no significant differences were observed between OVA-challenged groups. 
Interestingly, levels measured in OVA-challenged mice were in excess of ~9000pg/ml at d1 
p.i., an amount ~6-fold higher than other Th2 cytokine quantities in the lung homogenate 
(Figures 4.8 and 4.9 B).  
In contrast to results from Th2 cytokines measured thus far, TSLP protein expression 
appeared to be largely allergen-driven as indicated by increased levels in UV OVA mice at 
10h-d4 p.i (Figure 4.10 B).  At d7 p.i., RV infection induced a delayed peak in expression in 
OVA-challenged mice and though these levels were significant compared with UV PBS 
groups (P<0.01), levels between OVA-challenge mice were not significantly different.   
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Figure 4.10  IL-33 and TSLP in lung tissue in a model of RV-induced allergic airways disease   OVA-
sensitised BALB/c mice were challenged i.n. with OVA or PBS control and infected with RV-1B or 
mock-infected with UV-inactivated virus. Lung tissue from mice was collected at the indicated time-
points and processed lung homogenate was used to measure IL-33 (A) and TSLP (B) by ELISA. Data is 
represented as the mean (+/-SEM) of 5 mice per group and is representative of at least 2 
independent experiments. + RV OVA vs UV OVA; # RV OVA vs RV PBS; *RV OVA vs UV PBS (* P<0.05; 
##/** P<0.01; ###/*** P < 0.001) 
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4.3.9    BAL mucins 
Enhanced mucus secretion is associated with acute exacerbations and decreased lung 
function in asthmatic patients 211. The major respiratory mucins, Mucin5, subtypes a and c 
(MUC5ac and MUC5b), have been shown to be upregulated in response to RV infection 
alone while the combination of allergen and RV infection resulted in further 
enhancement202. Therefore, we measured MUC5ac and MUC5b in the BAL of all treated 
mice by ELISA. Both mucins were predominantly induced in the OVA-challenged groups as 
observed by comparable levels in RV OVA and UV OVA mice up until d4 p.i. for MUC5ac 
(Figure 4.11 A) and until d7 p.i. for MUC5b (Figure 4.11 B). Consistent with previously 
published results of this model, MUC5ac was significantly increased in RV OVA mice at d7 
p.i. compared with all other groups (RV OVA vs UV OVA P<0.001, RV OVA vs RV PBS P<0.001, 
RV OVA vs UV PBS P<0.001). There were no significant differences in MUC5b levels between 
OVA-challenged mice.    
 
1 2 4 7
0
1000
2000
3000
RV OVA
UV OVA
RV PBS
UV PBS
+++
###
***
###
***
 ##
***
###
***
Days post-infection
B
A
L
 M
U
C
5
a
c
(A
rb
it
ra
ry
 u
n
it
s
)
1 2 4 7
0
2000
4000
6000
RV OVA
UV OVA
RV PBS
UV PBS
 #
**
###
***
 ###
 ***
Days post-infection
B
A
L
 M
U
C
5
b
(A
rb
it
ra
ry
 u
n
it
s
)
A B
Figure 4.11  Mucins in a model of RV-induced allergic airways disease   OVA-sensitised BALB/c mice were 
challenged i.n. with OVA or PBS control and infected with RV-1B or UV-inactivated virus. BAL from mice 
was collected at the indicated time-points and BAL supernatant was used to quantify MUC5ac (A) and 
MUC5b (B) by ELISA. Data is represented as the mean (+/-SEM) of 5 mice per group and is representative 
of at least 2 independent experiments. + RV OVA vs UV OVA; # RV OVA vs RV PBS; *RV OVA vs UV PBS (# 
P<0.05; ** P<0.01; +++/###/*** P < 0.001) 
 
 
  
 117 
 
4.3.10   Serum IgE  
Elevated IgE levels to common environmental allergens is a general marker of atopic asthma 
and provides the trigger for the immediate allergic response upon allergen exposure55. In 
addition to allergen-specific IgE, viruses including RSV and RV have been demonstrated to 
enhance total IgE108,212.  Therefore, we measured OVA-specific and total IgE in serum from 
mice harvested at d7 p.i. by ELISA. Although differences between treated groups were not 
significant, total (Figure 4.12 A) and OVA-specific IgE (Figure 4.12 B) was generally higher in 
RV OVA mice with comparable levels of total IgE in UV OVA and RV PBS mice.   
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Figure 4.12  Total and OVA-specific IgE in a model of RV-induced allergic airways disease OVA-
sensitised BALB/c mice were challenged i.n. with OVA or PBS control and infected with RV-1B or UV-
inactivated virus. Blood was collected from the carotid artery of mice at d7 p.i. and serum was 
separated to measure total (A) and OVA-specific (B) IgE by ELISA. Data is represented as the mean 
(+/-SEM) of 5 mice per group and is representative of at least 2 independent experiments.  
 
4.4     Summary  
The studies described in this chapter were designed to utilise an established mouse model 
to identify RV-induced exacerbation-associated responses potentially regulated by IL-25 as 
well as the effects of infection and allergen on IL-25 expression.  
The combination of RV infection and OVA sensitisation and challenge in mice enhanced 
numerous read-outs of Th2 allergic inflammation compared with OVA treatment alone. One 
of the clearest indications of this effect was the significantly enhanced BAL Th2 cytokines, 
including IL-4, IL-5 and IL-13, in the airways and lungs of RV OVA mice shortly after infection 
(10h p.i.). In addition to the classical Th2 cytokines, IL-25 mRNA and protein was also 
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significantly induced over allergen-treated or infected mice alone. Though IL-25 was 
undetectable in the BAL, protein expression in the lung tissue followed a similar expression 
pattern as IL-4, IL-5, and IL-13; namely, a peak at d1 p.i. that was unique to RV OVA mice and 
significantly upregulated above OVA-treated mice alone. In contrast, the innate, epithelial-
derived Th2 cytokines, IL-33 and TSLP, were not significantly induced by RV infection and 
allergen treatment, with TSLP induction appearing to be predominantly allergen-driven.  
The combination of RV infection and OVA treatment also significantly enhanced early airway 
neutrophilia while eosinophilia and lymphocytosis was generally higher in RV OVA mice. This 
exacerbated airway inflammatory response was also confirmed by significantly upregulated 
levels of the eosinophil chemoattractants, CCL11/Eotaxin 1 and CCL24/Eotaxin 2, and the T 
cell and eosinophil chemokine, CCL5/RANTES, in the airways. Increased airway inflammation 
also coincided with enhanced AHR (as measured by SRaw) in RV OVA mice which was 
significantly greater than UV OVA groups in double-chamber plethysmography experiments. 
 RV infection also enhanced viral RNA copy numbers as well as early expression of the pro-
inflammatory cytokine, IL-6, in OVA-treated mice. A later augmentation in the respiratory 
mucin, MUC5ac, was also observed in RV OVA mice at d7 p.i. with no discernable 
differences in MUC5b expression between OVA-challenged groups. Total and OVA-specific 
IgE displayed a trend towards increased levels in RV OVA mice, however a time-point later 
than d7 p.i. may be required to distinguish greater differences in humoral immune 
responses between groups.    
In summary, RV infection of an allergen-sensitised and challenged mouse exacerbated Th2 
inflammation in addition to enhancing viral load and disease severity as demonstrated by 
augmented AHR. The interaction of virus and allergen resulted in the greatest induction of 
IL-25 gene and protein expression compared with either factor alone verifying our 
hypothesis. To further investigate the resultant effects of enhanced IL-25 in our model of 
RV-induced allergic airways disease, we aimed to characterise IL-25-responsive cells via flow 
cytometry as demonstrated in the next chapter.  
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Chapter 5: Results 
IL-25-responsive cell populations in a model of RV-induced allergic airways disease 
5.1 Introduction  
 
The ability of IL-25 to amplify Th2 immunity is dependent on non-covalent binding to its 
principal receptor, IL-17RB, which forms a heterodimer with IL-17RA179. Several cell types 
including airway smooth muscle cells, invariant natural killer T cells, Th9 cells and Th2 
memory cells have been demonstrated to express IL-17RB in the lung127,185,187,189,213. In 
addition, the majority of recent IL-25-based studies have focussed on characterising IL-
17RB-expressing ILC2 populations which secrete Th2 cytokines upon IL-25 binding77,78,193. 
Grouped under this heading, and of particular interest, are the IL-25-responsive novel 
population termed nuocytes which have been reported to infiltrate the mouse lung in 
response to OVA sensitisation and challenge and induce AHR via the secretion of IL-1376. 
Furthermore, OVA sensitisation and challenge in mice has been demonstrated to enhance 
adaptive Th2 immunity via IL-25-dependant recruitment of CD4+ cells to the lung169. Wang 
et al. further established that Th2 memory cells secrete IL-4, IL-5 and IL-13 upon IL-25 
binding127. In this chapter, we aimed to characterise potential IL-25-responsive cells by 
measuring expression of IL-17RB in our mouse model of RV-induced allergic airways disease 
by flow cytometry analysis.  
We hypothesised that RV-induced IL-25 acts on IL-17RB+ innate cell populations and IL-
17RB+ adaptive cells which are recruited into the mouse lung by OVA sensitisation and 
challenge resulting in exacerbated Th2 inflammation. We also hypothesised that enhanced 
levels of IL-25 previously observed in RV-infected and OVA-challenged mice would cause 
increased recruitment of IL-17RB-expressing leukocytes to the lung providing a potential 
mechanism whereby RV infection may exacerbate allergen-driven Th2 immunity. To test 
this, IL-17RB-expressing cells were characterised by flow cytometry in our model of RV-
induced allergic airways disease.  
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5.2 Hypotheses and Aims 
5.2.1 Hypotheses 
i.) Significantly enhanced IL-25 levels measured in RV-infected and allergen-
sensitised and challenged mice correspond with recruitment of IL-17RB 
expressing cells to the lung 
ii.) RV infection in an allergen-sensitised and challenged mouse results in 
recruitment of both innate and adaptive IL-25-responsive cell populations  
 
5.2.2 Aims 
To investigate the effects of RV infection and OVA sensitisation and challenge on IL-17RB-
expressing cell populations using a mouse model of RV-induced allergic airways disease 
i.) To determine the magnitude and kinetics of total IL-17RB+ cell numbers  in the 
mouse lung and airways by flow cytometry  
ii.) To characterise the magnitude and kinetics of  innate and adaptive IL-25-
responsive cell populations by analysing: 
 Expression of IL-17RB and co-expression of markers associated with 
innate cell populations  and Th2-associated markers in the lungs and 
airway using flow cytometry analysis 
 Adaptive cells expressing IL-17RB and co-expressing Th2-associated 
markers in the lungs and airways using flow cytometry analysis 
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5.3 Results 
5.3.1 Total IL-17RB+ lymphocyte populations 
Using a mouse model of RV-induced allergic airways disease, we sought to determine the 
effects of infection and OVA-sensitisation and challenge on IL-17RB-expressing cells by 
staining for IL-17RB in whole lung cell preparations and BAL cells and analysing by flow 
cytometry.  
Approximately 99% of IL-17RB+ lungs cells were encompassed within the ‘lymphocyte’ gate 
based on forward scatter (FSC) vs side scatter (SSC) analysis. The data represented is 
annotated as percentages and total cell numbers of IL-17RB+ lymphocytes, with the 
understanding that this gating strategy also incorporated non-lymphocyte populations 
including basophils and other innate cell populations.  
The greatest number of IL-17RB-expressing cells in whole lung cell preparations were 
observed in RV OVA mice at d7 p.i. (RV OVA vs UV OVA P<0.001; RV OVA vs RV PBS P<0.001; 
RV OVA vs UV PBS P<0.001) (Figure 5.1 A and 5.2.1). These cells comprised approximately 
14% of the total lung lymphocyte population in RV OVA mice which was significantly higher 
compared with all other treated groups (RV OVA vs UV OVA P<0.001; RV OVA vs RV PBS 
P<0.001; RV OVA vs UV PBS P<0.001) (Figure 5.1 B). At d1 p.i., RV OVA mice displayed a 
small elevation in total IL-17RB+ cell numbers compared with other treated groups which 
represented ~1% of total lung lymphocytes. In BAL IL-17RB+ cells, this peak was more 
pronounced and was significant compared with UV PBS control groups (RV OVA vs UV PBS 
P<0.05) (Figure 5.1 C and 5.2.2). Consistent with findings in lung cells, the highest peak in 
BAL IL-17RB+ cells was observed at d7 p.i. in both OVA-challenged groups as well as in RV-
infected mice alone.  
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Figure 5.1  Total IL-17RB+ cells in a model of RV-induced allergic airways disease OVA-sensitised 
BALB/c mice were challenged i.n. with OVA or PBS control and infected with RV-1B or mock-infected 
with UV-inactivated virus. Cells were stained for IL-17RB and total live, single cells per whole mouse 
lung (A) and the percentage of IL-17RB+ lung cells within the ‘lymphocyte’ gate (B) are represented, 
as well as total BAL IL-17RB+ cells (C).  Data is represented as the mean (+/-SEM) of 5 mice per group 
and is representative of 2 independent experiments. + RV OVA vs UV OVA; # RV OVA vs RV PBS; *RV 
OVA vs UV PBS (* P<0.05; +++/###/*** P < 0.001) 
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Figure 5.2.1  Representative flow plots of total IL-17RB+ cells in whole lung tissue in all treated groups at 
d7 p.i. After gating live, single lymphocytes as demonstrated in figure 2.4.1, lung cells stained with all 
markers with the exclusion of IL-17RB were used as a control to set gates (A) and define IL-17RB+ cells (B) in 
the lungs of RV OVA , UV OVA , RV PBS and UV PBS mice. Results are representative of 3 independent 
studies.   
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Figure 5.2.2  Representative flow plots of total BAL IL-17RB+ cells in all treated groups at d7 p.i. 
After gating live, single lymphocytes as demonstrated in figure 2.4.1, BAL cells stained with all 
markers with the exclusion of IL-17RB were used as a control to set gates (A)  and define IL-17RB+ 
cells (B) in the lungs of RV OVA , UV OVA , RV PBS and UV PBS mice. Results are representative of 3 
independent studies.   
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5.3.2 Innate cell populations 
To gain a greater understanding of IL-17RB-expressing innate cell populations, a panel of 
various Th2-associated markers were used in conjunction with anti-IL-17RB to define cell 
phenotypes. These markers included the pan-NK cell and basophil marker, CD49b, the high 
affinity IgE receptor, FcεRI and the mast cell, basophil and Th2 cell marker, T1/ST2. We were 
also interested in characterising the newly termed ILC2 populations therefore a marker for 
ICOS in addition to the T cell markers, CD3 and CD4, were included to define T and non-T cell 
populations. Intracellular staining for IL-4 was also carried out. Using this panel, the cell 
populations listed below were identified.  
 
5.3.2.1  Innate lymphoid cells (ILC) 2    
Of the total IL-17RB+ lymphocytes in the lung and BAL, a population of T1/ST2+ ICOS+ IL-4-
FcεRI-CD49b-CD3-CD4- were identified. Based on this expression, we hypothesised these 
cells represented one of the innate lymphoid cell populations recently grouped under the 
heading ILC2. Though additional markers to confirm a lineage negative phenotype would be 
required for definitive characterisation, this classification fitted most accurately based on 
recently published findings and will be defined as ILC2s throughout76,78.  
In lung tissue, this cell population was significantly elevated early on (6h p.i.) (RV OVA vs RV 
PBS P<0.001; RV OVA vs UV PBS P<0.001) and at d7 p.i.(RV OVA vs RV PBS P<0.001; RV OVA 
vs UV PBS P<0.001) in OVA-treated mice (Figure 5.3 A and 5.4.1). In between these 2 time-
points, cell numbers were reduced to levels close to baseline at d1 and d4 p.i. in all treated 
groups. Where the highest levels were observed in OVA-challenged mice (d7 p.i.), cells 
represented a mere 0.45% of the total lymphocyte population (Figure 5.3 B).  
In contrast to decreased levels observed in whole lung tissue at d1 p.i., ILC2s in the airways 
of RV OVA mice were significantly upregulated compared with all other treated groups (RV 
OVA vs UV OVA P<0.05; RV OVA vs RV PBS P<0.01; RV OVA vs UV PBS P<0.01) (Figure 5.3 C 
and 5.4.2). Measurements at later time-points p.i. emulated trends observed in whole lung 
cell preparations; namely, decreased ILC2s in all treated mice at d4 p.i. and a delayed 
increased at d7 p.i. Though levels were elevated in both OVA-challenged groups at d7 p.i., 
significant differences were only recorded between RV OVA and UV PBS groups.     
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Figure 5.3  ILC2s in a model of RV-induced allergic airways disease OVA-sensitised BALB/c mice 
were challenged i.n. with OVA or PBS control and infected with RV-1B or mock-infected with UV-
inactivated virus. Cells were stained for CD3, CD4, IL-17RB, T1/ST2, ICOS+, FcεRI, CD49b, and 
intracellular IL-4. The total cell numbers per whole mouse lung (A) and the percentage of ILC2s (CD3-
CD4-IL-17RB+T1/ST2+ICOS+) lung cells within the ‘lymphocyte’ gate (B) are represented, as well as 
total BAL ILC2s (C).  Data is represented as the mean (+/-SEM) of 5 mice per group and is 
representative of 2 independent experiments. + RV OVA vs UV OVA; # RV OVA vs RV PBS; *RV OVA 
vs UV PBS (+/# P<0.05; ##/** P<0.01; ###/*** P < 0.001)  
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Figure 5.4.1  Representative flow plots of ILC2s in whole lung tissue in all treated groups at d7 p.i. Flow 
plots represent gated CD3-/CD4- (A) cells. In addition, lung cells stained with all markers with the exclusion 
of T1/ST2 were used as a control to set gates (B) and define T1/ST2+ cells (C), which were then gated on 
positive IL-17RB/ICOS expression (D) in the lungs of RV OVA , UV OVA , RV PBS  and UV PBS  mice. Numbers 
indicated on the plots reflect the percentage of cells that are present with the gated areas.  Results are 
representative of 3 independent studies.   
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Figure 5.4.2  Representative flow plots of BAL ILC2s in all treated groups at d7 p.i. Flow plots represent 
gated CD3-/CD4- (A) cells. In addition, BAL cells stained with all markers with the exclusion of T1/ST2 were 
used as a control to set gates (B) and define T1/ST2+ cells (C), which were then gated on positive IL-
17RB/ICOS expression (D) in the lungs of RV OVA , UV OVA , RV PBS  and UV PBS  mice. Numbers indicated 
on the plots reflect the percentage of cells that are present with the gated areas.  Results are representative 
of 3 independent studies.   
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5.3.2.2 IL-4+ basophils 
Based on the empirical observation that RV infection induced an early increase in IL-4 in the 
airways of OVA-challenged mice which was two-fold higher than levels in OVA-challenged 
mice alone (Figure 4.7 A), we sought to identify any IL-17RB+ cells that co-expressed IL-4. 
Though no non-T cell IL-4+IL-17RB+ cells were observed, we did identify an FSClo/SSCloCD3-
CD4-FcεRI+T1/ST2+CD49b+ cell population in whole lung cell preparations and BAL 
leukocytes which produced IL-4, a surface marker and cytokine expression profile consistent 
with basophils.214,215 216.  
Both OVA-challenged groups had increased levels of IL-4+basophils in whole lung tissue at 
6h p.i. (RV OVA vs RV PBS P<0.01) and by d1 p.i. levels in RV OVA mice were significantly 
higher compared with other treatment groups (RV OVA vs UV OVA P<0.05; RV OVA vs RV 
PBS P<0.001; RV OVA vs UV PBS P<0.001) (Figure 5.5 A and 5.6.1). This peak in expression in 
RV OVA mice represented ~0.6% of total cells within the ‘lymphocyte’ gate (Figure 5.5 B). A 
similar trend was observed in the BAL; RV OVA mice displayed a peak in IL-4+basophils at d1 
p.i. which was significantly elevated compared with PBS-challenged groups (RV OVA vs RV 
PBS P<0.001; RV OVA vs UV PBS P<0.001) but not compared with UV OVA mice (Figure 5.5 C 
and 5.6.2). Consistent with results from whole lung tissue, IL-4+basophils in the airways had 
declined by d4 and d7 p.i. in all groups.   
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Figure 5.5  IL-4+ basophils in a model of RV-induced allergic airways disease OVA-sensitised BALB/c 
mice were challenged i.n. with OVA or PBS control and infected with RV-1B or UV-inactivated virus. 
Cells were stained for IL-17RB, CD3, CD4, FcεRI, CD49b, T1/ST2, ICOS and intracellular IL-4. Total cell 
numbers per whole mouse lung (A) and the percentage of IL-4+ basophil (CD3-CD4-
FcεRI+CD49b+T1/ST2+) lung cells within the ‘lymphocte’ gate (B) are represented, as well as total IL-
4+ basophils in BAL (C).  Data is represented as the mean (+/-SEM) of 5 mice per group and is 
representative of 2 independent experiments. + RV OVA vs UV OVA; # RV OVA vs RV PBS; *RV OVA 
vs UV PBS (+P<0.05; ## P<0.01; ###/*** P < 0.001)  
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Figure 5.6.1  Representative flow plots of IL-4+ basophils in whole lung tissue in all treated groups 
at d1 p.i. Flow plots represent gated CD3-/CD4- cells (A), T1/ST2+/FcεRI+ (B) and CD49b+/IL-4+ (C) 
cells in the lungs of RV OVA , UV OVA , RV PBS  and UV PBS  mice. Numbers indicated on the plots 
reflect the percentage of cells that are present with the gated areas.  Results are representative of 2 
independent studies.   
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Figure 5.6.2  Representative flow plots of BAL IL-4+ basophil lung cells in all treated groups at d1 
p.i. Flow plots represent gated CD3-/CD4- cells (A), T1/ST2+/FcεRI+ (B) and CD49b+/IL-4+ (C) BAL 
cells in the lungs of RV OVA , UV OVA , RV PBS and UV PBS mice. Numbers indicated on the plots 
reflect the percentage of cells that are present with the gated areas.  Results are representative of 2 
independent studies.   
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5.3.3  IL-17RB+ T cell populations 
5.3.3.1 IL-4+IL-17RB+CD4+ T cells 
Next we measured IL-4+IL-17RB+ CD4+ T cells by staining lung and BAL leukocytes for IL-
17RB, CD3, CD4 and intracellular IL-4. 
In whole lung tissue, a robust increase in IL-4+IL-17RB+ CD4+ T cells was observed at d7 p.i. 
in RV OVA mice which was significantly enhanced compared with UV OVA and PBS-
challenged mice (RV OVA vs UV OVA P<0.001; RV OVA vs RV PBS P<0.001; RV OVA vs UV PBS 
P<0.001) (Figure 5.7 A and 5.8.1). This increase accounted for the largest proportion of total 
IL-17RB-expressing cells at d7 p.i., making up approximately 5% of total cells within the 
‘lymphocyte’ gate (Figure 5.7 B).   
In the airways, an early increase in IL-4+IL-17RB+ CD4+ T cells was observed in RV OVA mice 
which increased up to d7 p.i (Figure 5.7 C and 5.8.2). Although levels in RV OVA mice were 
significantly elevated above PBS-challenged mice at d7 p.i., levels in OVA-challenged groups 
were not significantly different in the BAL.  
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Figure 5.7  IL-4+IL-17RB+ CD4+ T cells in a model of RV-induced allergic airways disease OVA-
sensitised BALB/c mice were challenged i.n. with OVA or PBS control and infected with RV-1B or 
mock-infected UV-inactivated virus. Cells were stained for IL-17RB, CD3, CD4, FcεRI, CD49b, T1/ST2, 
ICOS and intracellular IL-4. The total cells numbers per whole mouse lung (A) and percentage of IL-
4+ CD4+ T cells in lung cells within the ‘lymphocyte’ gate (B) are represented, as well as total IL-4+ 
CD4+ T cells in BAL (C).  Data is represented as the mean (+/-SEM) of 5 mice per group and is 
representative of 2 independent experiments. + RV OVA vs UV OVA; # RV OVA vs RV PBS; *RV OVA 
vs UV PBS (#/*P<0.05; +++/###/*** P < 0.001)  
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Figure 5.8.1  Representative flow plots of IL-4+IL-17RB+ CD4+ T cells in whole lung tissue in all treated 
groups at d7 p.i. Flow plots represent gated CD3+/CD4+ (A) cells while lung cells stained with all markers 
with the exclusion of IL-4 and IL-17RB were used as a control to set gates (B) and used to define IL-4+/IL-
17RB+ (C) in the lungs of RV OVA , UV OVA , RV PBS and UV PBS mice. Numbers indicated on the plots reflect 
the percentage of cells that are present with the gated areas.  Results are representative of 3 independent 
studies.   
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Figure 5.8.2  Representative flow plots of BAL IL-4+IL-17RB+ CD4+ T cells in all treated groups at d7 p.i. 
Flow plots represent gated CD3+/CD4+ (A) cells while BAL cells stained with all markers with the exclusion of 
IL-4 and IL-17RB were used as a control to set gates (B) and used to define IL-4+/IL-17RB+ (C) in the lungs of 
RV OVA , UV OVA , RV PBS  and UV PBS  mice. Numbers indicated on the plots reflect the percentage of cells 
that are present with the gated areas.  Results are representative of 3 independent studies.   
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5.4 Summary 
In this chapter, we identified non-T (ILC2s) and T cell (Th2) populations that expressed the 
IL-25 receptor, IL-17RB. In accordance with our hypothesis, RV infection in OVA-sensitised 
and challenged mice resulted in recruitment of IL-17RB-expressing cells in the total lung 
which coincided with increased IL-25 expression as demonstrated in chapter 4. Based on 
findings that activation of ILC2s and Th2 cells by IL-25 induces amplification of Th2 
inflammation via the release of Th2 cytokines, this provides a potential mechanism whereby 
RV-induced IL-25 may enhance disease severity and exacerbate Th2 inflammation.  
Of the total IL-17RB-expressing cells, an early infiltrating population that expressed IL-17RB, 
T1/ST2 and ICOS but was negative for CD3, CD4, CD49b, FcεRI and IL-4 was identified in the 
lung and airways of allergen-challenged mice. Based on their similarity to the newly grouped  
innate lymphoid populations, they were classified as ILC2s81.  OVA-challenged mice also 
displayed a delayed peak at d7 p.i. which complemented published reports that nuocytes, 
which represent a cell subset grouped within ILC2s, persist through the adaptive response76. 
Despite similar cell numbers in OVA-challenged mice in the lung, ILC2s were significantly 
enhanced in the BAL of RV OVA mice at d1 p.i. Due to their ability to amplify Th2 
inflammation via the release of IL-5 and IL-13 in response to IL-25, upregulation of these 
innate cells in the BAL in response to RV and/or allergen together with increased expression 
of IL-25 may suggest a potential role in enhanced allergic inflammation.   
An early source of IL-4+ cells that did not express IL-17RB was identified predominantly in 
the lungs and airways of RV OVA mice at d1 p.i. This cell subset was characterised as 
FSClo/SSCloCD3-CD4-FcεRI+T1/ST2+CD49b+ and accounted for approximately 85% of IL-4+ 
lymphocytes at 6h and d1 p.i. These cells closely resembled basophils and based on the fact 
that they made up the majority of IL-4+ cells, we speculated that they were a major source 
of IL-4 in the airways of OVA-challenged mice as demonstrated in chapter 4.  
Characterisation of IL-17RB+ adaptive cells demonstrated that Th2  cells were enhanced in 
the lungs of OVA-challenged mice at d7 p.i. RV infection had a striking effect on Th2 cell 
populations in allergen-sensitised and challenged mice resulting in a significant increase 
over allergen-treated mice alone which accounted for approximately 5% of total IL-17RB+ 
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lymphocytes. This is pertinent given that asthma pathogenesis is largely mediated by Th2 
cells.  
The studies described in this chapter facilitated identification of cell populations that IL-25 
may mediate its biological effects through in RV-induced exacerbation. Using the same anti-
IL-17RB antibody to block IL-25-mediated signalling in vivo, we sought to investigate any 
inhibitory effects on IL-17RB-expressing cell populations as well as on RV-mediated Th2 
responses measured in chapter 4 with the aim of defining a functional role of RV-induced IL-
25 in a model of allergic airways disease. 
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Chapter 6: Results 
6.1 Blocking IL-25 signalling in a model of RV-induced allergic airways disease 
RV infections are the principal cause of asthma exacerbations8,98. It remains unclear how, in 
the atopic asthmatic lung, RV interacts with the pulmonary Th2 environment to trigger an 
exacerbation. In previous chapters, we have identified a pro-Th2 cytokine, IL-25, which is 
induced by RV infection in vivo and in vitro. In addition, allergen exposure and RV infection 
synergistically upregulated IL-25 and its receptor, IL-17RB, which was associated with 
disease severity as demonstrated by augmented AHR. To our knowledge, this is the first 
study to demonstrate the upregulation of IL-25 by RV, with or without exposure to allergen. 
In this chapter, we aimed to define the functional role of IL-25 in a model of RV-induced 
allergic airways disease by blocking the biological activity of RV-induced IL-25 using a 
neutralising antibody against IL-17RB.  
Several studies have demonstrated the therapeutic benefit of blocking allergen-induced IL-
25 by inhibiting Th2 inflammation in mice70,169,170. Specifically, neutralising IL-25 before 
sensitisation in an allergen-induced asthma model prevented Th2 inflammation, including 
AHR, Th2 cytokine production and eosinophilia, with some of these inhibitory effects 
persisting even when the antibody was administered 4 hours before allergen challenge in 
previously sensitised mice170. Furthermore, Camelo et al. demonstrated that blocking IL-25 
signalling, using the same anti-IL-17RB antibody employed in this study, decreased nuocyte 
and NKT cell mucosal infiltration and decreased IL-13 in a type-2 model of colitis in mice171. 
These findings demonstrated that blocking IL-25 either directly or via receptor blocking was 
similarly effective at inhibiting biological activity of IL-25.   
We aimed to investigate interactions between infection and allergic inflammation by 
transiently blocking RV-induced IL-25 signalling in OVA-sensitised and challenged mice and 
assess the effects on disease severity and immune response predominantly by measuring 
Th2-related outcomes.  As we were specifically interested in the effect of IL-25 activity on 
RV-induced exacerbation of allergic airways inflammation we administered an anti-IL-17RB 
blocking antibody to allergen-sensitised and challenged mice at the time of RV infection and 
compared with responses in allergen-challenged mice alone as well as isotype-matched 
groups. Isotype antibody was also administered to all other treatment groups to control for 
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the effects of anti-IL-17RB while mice challenged with PBS and dosed with UV-inactivated 
RV (UV PBS) served as negative controls. Th2-related innate and adaptive responses were 
then measured in all groups by assessing early (8h and d1 p.i.) and later (d7 p.i.) responses 
after infection. 
 
6.2 Hypotheses and Aims:  
6.2.1 Hypotheses 
i.) Blocking IL-25 signalling prior to RV infection reduces early disease-associated 
end-points including:  
 Decreased Th2 cytokines in the airways 
 Decreased airway obstruction 
 Decreased Th2-associated innate cell populations 
ii.) Maintaining IL-17RB neutralisation post-RV infection reduces ongoing Th2-
associated responses in an OVA-sensitised and challenged mouse, predominantly 
indicated by: 
 Decreased eosinophilia and lymphocytosis infiltration in the airways 
 Decreased Th2 cells in the lungs and airways 
6.2.2 Aims  
To investigate the functional role of RV-induced IL-25 and interactions between infection 
and allergic inflammation in a model of RV-induced allergic airway disease by transiently 
blocking IL-25 receptor signalling  
i.) To define the function of RV-induced IL-25 by neutralising IL-17RB in RV-infected 
and OVA-challenged mice and compare read-outs in Th2 inflammation to IL-17RB-
treated OVA-challenged mice alone as well as identically treated isotype control 
groups. Any potential effects of IL-17RB neutralisation will be assessed by 
measuring: 
 Airway obstruction using whole-body plethysmography  
 Inflammatory airway leukocyte infiltration in the BAL via differential cell counts  
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 Th2-associated cytokine and chemokine proteins in the BAL and lung tissue by 
ELISA 
 IL-25 mRNA  by qPCR and IL-25, IL-33 and TSLP protein by ELISA in the lung tissue  
 Respiratory mucin proteins including MUC5ac and MUC5b  in the BAL by ELISA 
 Total and allergen-specific IgE in mouse serum by ELISA 
ii.) To examine the effect of blocking IL-25 signalling on innate and adaptive Th2-
associated cell populations by flow cytometry analysis 
 
6.3 Results  
In this chapter, an IL-17RB neutralising antibody was administered to treatment groups in a 
model of RV-induced allergic airways disease (described in detail in section 2.2.5). The RV 
PBS treatment group was excluded due to the fact we were primarily interested in the 
effects of RV-induced IL-25 during allergic inflammation and the comparative differences 
between RV OVA and UV OVA groups and equivalent isotype-treated groups.  An anti-IL-
17RB antibody (Clone D9.2) was administered 4h pre-RV infection and at d3 and d5 p.i. and 
compared with identically treated groups administered isotype control antibody (anti-c-myc 
mouse IgG1 [Clone 9e10.2]). Treatment regime and nomenclature of all groups are 
summarised in the table below for clarification. 
 
Experimental groups Sensitisation 
(OVA/Alum 
i.p.) 
Challenge 
(OVA i.n) 
RV-1B infection 
(RV-1B i.n./UV-RV-1B) 
Antibody treatment 
 
RV OVA (anti -IL-17RB) Yes Yes Yes Anti-IL-17RB 
UV OVA (anti-IL-17RB) Yes Yes No  Anti-IL-17RB 
UV PBS  (anti-IL-17RB) Yes No  No  Anti-IL-17RB 
RV OVA (ISO) Yes Yes Yes Isotype control  
UV OVA (ISO) Yes Yes No   Isotype control 
UV PBS (ISO) Yes No No  Isotype control 
Table 6.1 Summarised treatment regime and nomenclature of antibody-treated groups (represented 
as ‘anti-IL-17RB’ and ‘ISO’) in model of RV-induced allergic airways disease.  
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6.3.1 Airway responses 
We employed whole-body plethysmography to assess if blocking RV-induced IL-25 signalling 
affected airway obstruction in a model of RV-induced allergic airways disease. Enhanced 
pause (Penh) was measured in anti-IL-17RB and isotype-treated groups at d1 p.i. As 
previously observed, RV OVA (ISO) groups displayed significantly augmented Penh levels 
compared with UV PBS (ISO) controls at a dose of 30mg/ml (P<0.01) and 100mg/ml 
(P<0.001) of methacholine (Figure 6.2). Treatment of OVA-challenged mice with anti-IL-17RB 
resulted in equivalent Penh values in RV OVA (anti-IL-17RB) and UV OVA (anti-IL-17RB) mice, 
which were also similar in values in UV OVA (ISO) groups. However, comparison of anti-IL-
17RB and isotype-treated RV OVA groups revealed no significant differences.  
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Figure 6.2  Effect of blocking IL-25 signalling on airway responses BALB/c mice were treated as 
described in section 2.2.5 and administered anti-IL-17RB antibody (groups represented as ‘anti-IL-
17RB’) or isotype antibody (groups represented as ‘ISO’)  at 4h pre-infection as well as at d3 and d5 
p.i. At d1 p.i., Penh was measured in response to increasing doses (in mg/ml) of aerosolised 
methacholine (MCh). Penh was measured over 5 minute periods after 1 minute aerosolisation 
challenge to methacholine. Aerosolised water was used to determine baseline values. Data is 
represented as the mean (+/-SEM) of 5 mice per treatment and is representative of 2 independent 
experiments. * RV OVA (anti-IL-17RB) vs UV PBS (anti-IL-17RB); + RV OVA (ISO) vs UV PBS (ISO) 
(**/++ P<0.01;***/ +++ P<0.001) 
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6.3.2 RV-1B viral load 
To determine if neutralisation of IL-17RB affected viral replication, RV-1B RNA copies were 
measured in lung tissue. RV RNA levels were significantly reduced in RV OVA (anti-IL-17RB) 
mice compared with RV OVA (ISO) mice at 8h p.i. (Figure 6.3).  At d1 p.i. RV RNA copies in RV 
OVA (ISO) mice were reduced to levels below those of RV OVA (anti-IL-17RB) mice, though 
these differences were not significant.  
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Figure 6.3  Effect of blocking IL-25 signalling on viral load  BALB/c mice were treated as described in 
section 2.2.5 and administered anti-IL-17RB antibody (groups represented as ‘anti-IL-17RB’) or 
isotype control antibody (groups represented as ‘ISO’)  at 4h before infection as well as at d3 and d5 
post-infection. Lungs were harvested at the indicated time-points and processed by extracting RNA 
and synthesizing cDNA to quantify viral RNA copies via qPCR.  Data is expressed as the number of 
RNA copies per μl of cDNA added per qPCR reaction.  Each group of mice (n=5) is represented as the 
mean (+/-SEM) and data is representative of 2 experiments. * RV OVA (anti-IL-17RB) vs all other 
groups; + RV OVA (ISO) vs ISO groups (*/+ P<0.05). 
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6.3.3 Airway leukocyte infiltration 
The effect of IL-17RB neutralisation on airway leukocyte infiltration was determined by 
differential staining of BAL cell cytospins in our mouse model. In accordance with data from 
chapter 4, RV OVA (ISO) mice displayed significantly enhanced neutrophilia at d1 p.i. and 
delayed eosinophilia and lymphocytosis at d7 p.i. compared with all other isotype-treated 
groups. 
In RV OVA (anti-IL-17RB) mice, airway neutrophilia was significantly decreased compared 
with RV OVA (ISO) (P<0.001) and UV OVA (ISO) groups (P<0.001) at d1 p.i. (Figure 6.4 A).   
Furthermore, RV OVA (anti-IL-17RB) mice had significantly reduced eosinophilia compared 
with RV OVA (ISO) groups (P<0.001) at d7 p.i (Figure 6.4 B). Similarly, anti-IL-17RB treatment 
in RV OVA mice significantly decreased infiltration of lymphocytes into the airways 
compared with RV OVA (ISO) groups (P < 0.001) at d7 p.i (Figure 6.4 C). Analysis of UV OVA 
groups indicated that IL-17RB neutralisation had no significant effect on allergen-induced 
eosinophilia and lymphocytosis based on comparable levels in anti-IL-17RB and isotype-
treated mice at d7 p.i.  
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Figure 6.4  Effect of blocking IL-25 signalling on airway leukocyte infiltration BALB/c mice were 
treated as described in section 2.2.5 and administered anti-IL-17RB antibody (groups represented as 
‘anti-IL-17RB’) or isotype control antibody (groups represented as ‘ISO’)  at 4h before infection as 
well as at d3 and d5 post-infection. BAL cells from mice were fixed to cytospin slides and stained to 
quantify total numbers of neutrophils (A), eosinophils (B) and lymphocytes (C) at the indicated time-
points p.i. All slides were blinded to experimental treatments. Data is represented as the mean (+/-
SEM) of 5 mice per group and is representative of 2 independent experiments. * RV OVA (anti-IL-
17RB) vs all groups; + RV OVA (ISO) vs ISO groups (* P<0.05; ++ P<0.01; ***/+++ P < 0.001). 
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6.3.4   BAL chemokines 
Based on our findings that blocking IL-25 signalling decreased eosinophilic and lymphocytic 
infiltration in the airways of RV-infected and allergen-challenged mice, we sought to 
measure specific chemoattractants for these cell types. Specifically, the chemokines 
CCL17/TARC, CCL5/RANTES, CCL11/Eotaxin1 and CCL24/Eotaxin2 were measured in the BAL.  
Comparing responses in isotype-treated groups confirmed the exacerbation phenotype 
represented in chapter 4; namely RV infection significantly induced chemokine expression in 
OVA-challenged mice compared with OVA-treated mice alone. In contrast, CCL5/RANTES, a 
potent chemoattractant of eosinophils and memory T cells, was significantly reduced in RV 
OVA (anti-IL-17RB) mice compared with RV OVA (ISO) mice (P<0.001) at d1 p.i (Figure 6.5 A). 
Blocking IL-17RB also resulted in lower levels of CCL17/TARC, which was significant 
compared with RV OVA (ISO) groups (P<0.01) at d7 p.i (Figure 6.5 B). In accordance with 
data displaying decreased eosinophila, the eosinophil chemoattractants, CCL11/Eotaxin1 
(Figure 6.5 C) and CCL24/Eotaxin2 (Figure 6.5 D), were significantly reduced in RV OVA (anti-
IL-17RB) mice. Specifically, CCL11/Eotaxin1 protein was downregulated at 8h p.i. compared 
with RV OVA (ISO) groups (P<0.05) while CCL24/Eotaxin2 levels were significantly decreased 
compared with RV OVA (ISO) groups (P<0.05) at d1 p.i. IL-17RB neutralisation marginally 
downregulated allergen-induced CCL24/Eotaxin2 levels as indicated by decreased levels in 
UV OVA (anti-IL-17RB) mice compared with UV OVA (ISO) mice at d1 p.i., however these 
changes were not significant. Similar levels of chemokines and cytokines in OVA-challenged 
alone anti-IL-17RB and isotype-treated mice suggested that blocking the IL-25 receptor 
following allergen challenge had minimal effects on Th2 mediators in the airways.  
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Figure 6.5 Effect of blocking IL-25 signalling on BAL chemokines BALB/c mice were treated as 
described in section 2.2.5 and administered anti-IL-17RB antibody (groups represented as ‘anti-IL-
17RB’) or isotype control antibody (groups represented as ‘ISO’)  at 4h before infection as well as at 
d3 and d5 post-infection. BAL from mice was collected at the indicated time-points and BAL 
supernatant was used to quantify CCL5/RANTES (A), TARC/CCL17 (B), CCL11/Eotaxin1 (C) and 
CCL12/Eotaxin2 (D) by ELISA. Data is represented as the mean (+/-SEM) of 5 mice per group and is 
representative of 2 independent experiments. * RV OVA (anti-IL-17RB) vs all other groups; + RV OVA 
(ISO) vs ISO groups (* P<0.05; ***/+++ P<0.001). 
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6.3.5   BAL IL-6  
As previously stated, RV infection of human epithelial cells induces the proinflammatory 
cytokine IL-6. Although this pleiotropic cytokine has a broad range of effects including 
immunomodulatory properties, whether it is beneficial or harmful during infection remains 
unclear217. Results from isotype-treated groups confirmed previous finding that RV infection 
significantly enhanced early IL-6 protein production at 8h p.i. in OVA-challenged mice 
compared with allergen challenge alone (P<0.001). We found that neutralising IL-17RB, in 
contrast to Th2-promoting chemokines, resulted in a profound enhancement of BAL IL-6 
protein in RV OVA (anti-IL-17RB) mice which was significant compared with all groups of 
anti-IL-17RB and isotype-treated RV and/or OVA-challenged mice at 8h p.i. (RV OVA (anti-IL-
17RB) vs RV OVA (ISO) P<0.001; RV OVA (anti-IL-17RB) vs UV OVA (ISO) P<0.001) (Figure 
6.6). 
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Figure 6.6  Effect of blocking IL-25 signalling on BAL IL-6  BALB/c mice were treated as described in 
section 2.2.5 and administered anti-IL-17RB antibody (groups represented as ‘anti-IL-17RB’) or 
isotype control antibody (groups represented as ‘ISO’)  at 4h before infection as well as at d3 and d5 
post-infection. BAL from mice was collected at the indicated time-points and BAL supernatant was 
used to quantify IL-6 by ELISA. Data is represented as the mean (+/-SEM) of 5 mice per group and is 
representative of 2 independent experiments. * RV OVA (anti-IL-17RB) vs all other groups; + RV OVA 
(ISO) vs ISO groups (*/+ P<0.05; ***/+++ P<0.001). 
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6.3.6    Th2 cytokine expression 
6.3.6.1 BAL Th2 cytokines 
Due to their central role in mediating asthma pathogenesis, we sought to investigate 
whether RV-induced enhancement of Th2 cytokines in OVA-challenged mice (reported in 
chapter 4) was affected by blocking IL-25 signalling. Therefore, BAL IL-4, IL-5 and IL-13 were 
measured in our mouse model of disease. Th2 cytokine responses in isotype-treated groups 
were consistent with previous data and confirmed an early exacerbation at 8h p.i. of Th2 
cytokines in RV OVA mice compared with UV OVA mice (IL-4 P<0.001; IL-5 P<0.01; IL-13 
P<0.05). Strikingly, levels of IL-4 (Figure 6.7 A), IL-5 (Figure 6.7 B) and IL-13 (Figure 6.7 C) 
protein in the airways were significantly reduced early on (8h p.i.) in RV OVA (anti-IL-17RB) 
mice compared with RV OVA (ISO) mice (IL-4 P<0.001; IL-5 P<0.05; IL-13 P<0.05). At d1 p.i., 
IL-5 was the only Th2 cytokine to remain significantly reduced in RV OVA (anti-IL-17RB) mice 
compared with isotype-matched groups.  
By blocking IL-25 signalling, BAL Th2 cytokines levels in RV OVA (anti-IL-17RB) mice were 
reduced to levels similar to that in UV OVA (ISO) groups at 8h p.i. indicating specific 
inhibition of RV-induced Th2 inflammation. A modest decrease in IL-13 levels in UV OVA 
(anti-IL-17RB) groups compared with UV OVA (ISO) groups at 8h p.i. was observed, however 
these differences were not significant. The minimal decreases in Th2 cytokines in UV OVA 
(anti-IL-17RB) compared with isotype-matched groups further indicate that blocking the IL-
25 receptor after allergen challenge had minimal effect on allergic inflammation. 
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Figure 6.7  Effect of blocking IL-25 signalling on BAL Th2 cytokines  BALB/c mice were treated as 
described in section 2.2.5 and administered anti-IL-17RB antibody (groups represented as ‘anti-IL-
17RB’) or isotype control antibody (groups represented as ‘ISO’)  at 4h before infection as well as at 
d3 and d5 post-infection. BAL from mice was collected at the indicated time-points and BAL 
supernatant was used to measure IL-4 (A), IL-5 (B) and IL-13 (C) by ELISA. Data is represented as the 
mean (+/-SEM) of 5 mice per group and is representative of 2 independent experiments. * RV OVA 
(anti-IL-17RB) vs all other groups; + RV OVA (ISO) vs ISO groups (*/+ P<0.05; ++/** P<0.01; ***/+++ P 
< 0.001). 
 
6.3.6.2   Th2 cytokines in lung homogenate 
To assess if Th2 cytokine profiles in the BAL reflected those in the lung parenchyma, IL-4, IL-
5 and IL-13 were also measured in lung homogenate from anti-IL-17RB and isotype-treated 
mice by ELISA.  In contrast with IL-4 and IL-5 measurements in the BAL, there were no 
significant differences in IL-4 (Figure 6.8 A) and IL-5 (Figure 6.8 B) expression in lung 
homogenate between RV OVA (anti-IL-17RB) and RV OVA (ISO) groups at any time-points 
p.i. However, IL-13 protein expression in lung homogenate closely matched early IL-13 
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expression in the BAL and resultant blocking of IL-25 signalling significantly reduced protein 
in RV OVA (anti-IL-17RB) at all time-points p.i. compared with isotype-matched groups 
(Figure 6.8 C). Furthermore, blocking allergen-induced IL-25 signalling in UV OVA (anti-IL-
17RB) groups decreased IL-13 level to those measured in RV OVA (anti-IL-17RB) mice at all 
time-points p.i.   
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Figure 6.8  Effect of blocking IL-25 signalling on Th2 cytokines in lung tissue  BALB/c mice were 
treated as described in section 2.2.5 and administered anti-IL-17RB antibody (groups represented as 
‘anti-IL-17RB’) or isotype control antibody (groups represented as ‘ISO’)  at 4h before infection as 
well as at d3 and d5 post-infection. Lung tissue from mice was collected at the indicated time-points 
and processed lung homogenate was used to measure IL-4 (A), IL-5 (B) and IL-13 (C) by ELISA. Data is 
represented as the mean (+/-SEM) of 5 mice per group and is representative of 2 independent 
experiments. * RV OVA (anti-IL-17RB) vs all other groups; + RV OVA (ISO) vs ISO groups (*/+ P<0.05; 
++/** P<0.01; ***/+++ P < 0.001). 
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6.3.7    IL-25 expression  
The effect of IL-17RB neutralisation on IL-25 expression was investigated in all antibody-
treated groups. As IL-25 protein was undetectable in the BAL, lung homogenate was used to 
detect protein by ELISA while mRNA was quantified by qPCR in lung tissue.  The early effects 
of receptor neutralisation did not significantly alter IL-25 mRNA (Figure 6.9 A) and protein 
expression (Figure 6.9 B) in any treatment groups at 8h p.i., indicated by similarities 
between anti-IL-17RB and isotype-matched mice. However, gene and protein levels were 
significantly reduced in RV OVA (anti-IL-17RB) mice compared with RV OVA (ISO) groups at 
d1 p.i. (mRNA P<0.05; protein P<0.5). In both instances, expression was reduced to similar 
quantities in UV OVA (ISO) and UV OVA (anti-IL-17RB) groups. Though differences in mRNA 
between RV OVA groups were no longer significant at d7 p.i., protein levels remained lower 
in anti-IL-17RB-treated mice compared with isotype-treated groups while mRNA levels in all 
treatment groups were sharply decreased. Allergen-induced IL-25 was not significantly 
altered by IL-17RB neutralisation indicated by similar levels in UV OVA (anti-IL-17RB) and UV 
OVA (ISO) groups at all time-points. 
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Figure 6.9  Effect of blocking IL-25 signalling on IL-25 expression in lung tissue BALB/c mice were 
treated as described in section 2.2.5 and administered anti-IL-17RB antibody (groups represented as 
‘anti-IL-17RB’) or isotype control antibody (groups represented as ‘ISO’)  at 4h before infection as 
well as at d3 and d5 post-infection. Lung tissue from mice was collected at the indicated time-points 
and used to measure IL-25 mRNA (A) and protein expression (B). Data is represented as the mean 
(+/-SEM) of 5 mice per group and is representative of 2 independent experiments. * RV OVA (anti-IL-
17RB) vs all other groups; + RV OVA (ISO) vs ISO groups (* P<0.05; ** P<0.01; ***/+++ P<0.001). 
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6.3.8 IL-33 and TSLP expression  
Due to the related roles that IL-33 and TSLP have with IL-25 in the innate Th2 response, 
protein levels of IL-33 and TSLP were measured in lung homogenate from anti-IL-17RB and 
isotype-treated mice by ELISA. By d1 p.i., IL-33 (Figure 6.10 A) and TSLP levels (Figure 6.10 B) 
in RV OVA (anti-IL-17RB) groups were significantly reduced compared with RV OVA (ISO) 
groups. By d7 p.i., IL-33 levels in anti-IL-17RB and isotype-treated mice were still decreased 
while TSLP protein in RV OVA (anti-IL-17RB) groups was significantly upregulated compared 
to UV OVA (anti-IL-17RB) groups and matched levels in RV OVA (ISO) and UV OVA (ISO) 
groups. Notably, allergen-induced IL-33 and TSLP protein was downregulated by neutralising 
IL-17RB in UV OVA groups at d1 as well as d7 p.i. indicated by reduced amounts in UV OVA 
(anti-IL-17RB) mice compared with UV OVA (ISO) mice.  
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Figure 6.10  Effect of blocking IL-25 signalling on IL-33 and TSLP  protein expression in lung tissue  
BALB/c mice were treated as described in section 2.2.5 and administered anti-IL-17RB antibody 
(groups represented as ‘anti-IL-17RB’) or isotype control antibody (groups represented as ‘ISO’)  at 
4h before infection as well as at d3 and d5 post-infection. Lung tissue from mice was collected at the 
indicated time-points and processed lung homogenate was used to measure IL-33 (A) and TSLP (B) 
by ELISA.  Data is represented as the mean (+/-SEM) of 5 mice per group and is representative of 2 
independent experiments. * RV OVA (anti-IL-17RB) vs all other groups; + RV OVA (ISO) vs ISO groups; 
(* P<0.05; ** P<0.01; ***/+++ P<0.001) 
 
 
  
 154 
 
6.3.9   BAL mucins 
Levels in the BAL of the two major respiratory mucins, MUC5ac and MUC5b, were measured 
to assess the effects of blocking IL-25 signalling. Results recorded in isotype-treated groups 
substantiated data from chapter 4; namely, MUC5ac was significantly enhanced in RV OVA 
mice compared with OVA-challenged mice alone at d7 p.i. (P<0.001) (Figure 6.11 A), 
whereas there were no differences in MUC5b protein levels between OVA-challenged 
groups at any time-points (Figure 6.11 B). IL-17RB neutralisation caused a significant 
reduction in MUC5ac protein in RV OVA (anti-IL-17RB) mice compared with RV OVA (ISO) 
groups (P<0.001) at d7 p.i. In contrast, MUC5b levels between both groups of antibody-
treated OVA-challenged mice remained largely unchanged at all time-points p.i.      
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Figure 6.11  Effect of blocking IL-25 signalling on BAL mucins  BALB/c mice were treated as 
described in section 2.2.5 and administered anti-IL-17RB antibody (groups represented as ‘anti-IL-
17RB’) or isotype control antibody (groups represented as ‘ISO’)  at 4h before infection as well as at 
d3 and d5 post-infection. BAL from mice was collected at the indicated time-points and BAL 
supernatant was used to quantify MUC5ac (A) and MUC5b (B) by ELISA. Data is represented as the 
mean (+/-SEM) of 5 mice per group and is representative of 2 independent experiments. * RV OVA 
(anti-IL-17RB) vs all other groups; + RV OVA (ISO) vs ISO groups (** P<0.01; ***/+++ P<0.001). 
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6.3.10   Measurement of serum IgE  
Total and OVA-specific IgE in serum from both antibody-treated groups at d7 p.i. was 
measured by ELISA. Neutralisation of IL-17RB caused a trend towards decreased total serum 
IgE levels in RV OVA (anti-IL-17RB) groups compared with RV OVA (ISO) groups though these 
differences were not significant (Figure 6.12 A). No clear differences in OVA-specific IgE 
levels were observed between anti-IL-17RB and isotype-treated groups (Figure 6.12 B). 
Allergen-induced IgE was largely unaltered by anti-IL-17RB treatment indicated by similar 
OVA-specific and total IgE levels in UV OVA (anti-IL-17RB) and UV OVA (ISO) groups. 
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Figure 6.12  Effect of blocking IL-25 signalling on total and OVA-specific IgE  BALB/c mice were 
treated as described in section 2.2.5 and administered anti-IL-17RB antibody (groups represented as 
‘anti-IL-17RB’) or isotype control antibody (groups represented as ‘ISO’)  at 4h before infection as 
well as at d3 and d5 post-infection. Blood was collected from the carotid artery of mice at d7 p.i. and 
serum was separated to measure total (A) and OVA-specific (B) IgE by ELISA.  Data is represented as 
the mean (+/-SEM) of 5 mice per group and is representative of 2 independent experiments.  
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6.3.11 Effect of blocking IL-25 signalling on innate (non-T) and adaptive CD4+ T cell 
populations 
Flow cytometry was used to characterise the effects of IL-17RB neutralisation on the 
magnitude and kinetics of non-T and T cell populations associated with Th2 immunity in a 
model of RV-induced allergic airways disease. An identical panel of markers (as described in 
chapter 5 and table 2.10) was used to identify cell populations. Due to the fact that the 
same antibody clone (Clone D9.2) was used for in vivo neutralisation and for previous 
identification of IL-17RB+ cells, flow cytometry detection of IL-17RB expressing populations 
could not be carried out in blocking antibody experiments. 
 
6.3.11.1    Innate cell populations 
i.)          Innate lymphoid cells (ILC) 2    
Based on an enhanced infiltration of ILC2s into the airways of RV OVA mice at d1 p.i. 
reported in chapter 5, we sought to investigate the effects of blocking IL-25 signalling on this 
IL-25-responsive cell population in our model of RV-induced allergic airways disease. 
Furthermore, due to the fact that ILC2s are reported as an early source of IL-5 and IL-13 in 
the airways of allergen-sensitised and challenged mice, we hypothesized that reduced BAL 
IL-5 and IL-13 levels demonstrated in section 6.3.7.1 may be caused by inhibition of cytokine 
release due to IL-17RB neutralisation.  
A population of T1/ST2+ICOS+IL-4-FcεRI-CD49b-CD3-CD4- cells was characterised in the lung 
and BAL of IL-17RB-neutralised mice and isotype-treated controls, which matched the 
surface phenotype of previously identified ILC2s (predominantly indicated by the fact that 
identified populations were non T cells yet expressed ICOS). There was a trend towards a 
reduction in cell populations in the airways of RV OVA (anti-IL-17RB) groups compared with 
RV OVA (ISO) groups at all time-points p.i.; however analysis revealed no significant 
differences between groups (Figure 6.13 A). With regard to whole lung tissue, cell numbers 
in both antibody-treated groups were similar with no significant variations at any time-point 
p.i. (Figure 6.13 B).  
Cell populations in the airways of isotype-treated OVA-challenged mice displayed similar 
results to those recorded in chapter 5; namely a peak in number at d1 p.i. that was 
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significantly enhanced in RV OVA groups compared with UV PBS groups. In addition, cells in 
whole lung tissue from OVA-challenged isotype-treated mice peaked at 8h and d7 p.i. with a 
sharp decrease between time-points at d1 p.i. which was also consistent with findings in 
chapter 5.   
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Figure 6.13  Effect of blocking IL-25 signalling on ILC2s  BALB/c mice were treated as described in 
section 2.2.5  and administered anti-IL-17RB antibody (groups represented as ‘anti-IL-17RB’) or 
isotype control antibody (groups represented as ‘ISO’)  at 4h before infection as well as at d3 and d5 
post-infection.  The left lung lobe was harvested at the indicated time-points p.i. (after collecting the 
BAL) and lung cells were processed as previously described. Cells were stained for CD3, CD4, T1/ST2, 
ICOS, FcεRI, CD49b and intracellular IL-4. Total BAL ILC2s (T1/ST2+ICOS+IL-4-FcεRI-CD49b-CD3-CD4-) 
(A) and total cells numbers per whole mouse lung (B) are represented. Data is represented as the 
mean (+/-SEM) of 5 mice per group and is representative of 2 independent experiments.  
 
ii.) IL-4+ basophils 
Due to a significant early decrease in BAL IL-4 in anti-IL-17RB-treated RV OVA mice, we also 
investigated intracellular sources of IL-4 and the effects of blocking IL-25 signalling by flow 
cytometer analysis.    
Analysis of the IL-4+ basophils (FSClo/SSCloCD3-CD4-FcεRI+T1/ST2+CD49b+) in anti-IL-17RB 
and isotype-treated mice revealed varied profiles in the airways and in whole lung tissue. 
Specifically, RV OVA (anti-IL-17RB) groups had significantly reduced BAL IL-4+ basophils 
compared with RV OVA (ISO) at d1 p.i (Figure 6.14 A and 6.15). In contrast, cell numbers 
measured in whole lung tissue from RV OVA (anti-IL-17RB) and RV OVA (ISO) groups were 
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similar at 8h and d1 p.i. (Figure 6.14 B) with no significant differences between any other 
treatment groups.  
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Figure 6.14  Effect of blocking IL-25 signalling on basophils  BALB/c mice were treated as described 
in section 2.2.5 and administered anti-IL-17RB antibody (groups represented as ‘anti-IL-17RB’) or 
isotype control antibody (groups represented as ‘ISO’) at 4h before infection as well as at d3 and d5 
post-infection.  The left lung lobe was harvested at the indicated time-points p.i. (after collecting the 
BAL) and lung cells were processed as previously described. Cells were stained for CD3, CD4, FcεRI, 
CD49b, T1/ST2, ICOS and intracellular IL-4. The total IL-4+ basophils (CD3-CD4-
FcεRI+CD49b+T1/ST2+) in BAL lung cells (A) and total cells numbers per whole mouse lung (B) are 
represented.  Data is represented as the mean (+/-SEM) of 5 mice per group and is representative of 
2 independent experiments.  
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Figure 6.15  Representative flow plots of BAL IL-4+ basophils  in a model of RV-induced allergic airways 
disease at d1 p.i. Flow plots represent gated T1/ST2+/FcεRI+ and CD49b+/IL-4+ BAL cells in anti-IL-17RB 
antibody (groups represented as ‘anti-IL-17RB’) or isotype control antibody (groups represented as ‘ISO’)-
treated RV OVA, UV OVA and UV PBS mice. Numbers indicated on the plots reflect the percentage of cells 
that are present with the gated areas.  Results are representative of 2 independent studies. 
 
6.3.11.2   Adaptive Th2 cell populations 
 i.)      IL-4+ CD4+ T cells 
Based on the effects of RV-induced enhancement of Th2 cells in OVA-challenged mice 
reported in chapter 5, we aimed to investigate the effect of blocking IL-25 signalling in our 
mouse model of disease.  
In isotype-treated mice, RV infection in OVA-challenged and sensitised groups significantly 
enhanced IL-4+CD4+ T cells compared with OVA-challenge alone at d7 p.i. as demonstrated 
in chapter 5. Analysis of the effects of blocking IL-25 signalling demonstrated that IL-17RB 
neutralisation had a striking effect on IL-4+CD4+ T cells in the airways and in whole lung cell 
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preparations of RV-infected and OVA-challenged mice.  Specifically, levels of BAL (Figure 
6.16 A and 6.17.1) and lung IL-4+ CD4+ T cells (Figure 6.16 B and 6.17.2) in RV OVA (anti-IL-
17RB) mice were significantly reduced compared with RV OVA (ISO) groups (BAL P<0.01; 
Lung P<0.001) at d7 p.i. These levels were reduced to quantities observed in UV OVA (ISO) 
groups and were also similar to amounts in UV OVA (anti-IL-17RB) groups, indicating that IL-
17RB neutralisation had minimal effect on allergen-induced IL-4+ CD4+ T cells.  
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Figure 6.16  Effect of blocking IL-25 signalling on IL-4+ CD4+ T cells  BALB/c mice were treated as 
described in section 2.2.5 and administered anti-IL-17RB antibody (groups represented as ‘anti-IL-
17RB’) or isotype control antibody (groups represented as ‘ISO’)  at 4h before infection as well as at 
d3 and d5 post-infection.  The left lung lobe was harvested at the indicated time-points p.i. (after 
collecting the BAL) and lung cells were processed as previously described. Cells were stained for CD3, 
CD4, FcεRI, CD49b, T1/ST2, ICOS and intracellular IL-4. Total IL-4+ CD4+ T cells in the BAL (A) and 
total cells numbers per whole mouse lung (B) are represented.  Data is represented as the mean (+/-
SEM) of 5 mice per group and is representative of 2 independent experiments. * RV OVA (anti-IL-
17RB) vs all other groups; + RV OVA (ISO) vs ISO groups (** P<0.01; ***/+++ P<0.001). 
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Figure 6.17.1  Representative flow plots of BAL IL-4+ CD4+ T cells in a model of RV-induced allergic airways 
disease  at d7 p.i. Flow plots represent gated CD3+/CD4+ and IL-4+ BAL cells in anti-IL-17RB antibody 
(groups represented as ‘anti-IL-17RB’) or isotype control antibody (groups represented as ‘ISO’)-treated RV 
OVA, UV OVA and UV PBS mice. Numbers indicated on the plots reflect the percentage of cells that are 
present with the gated areas.  Results are representative of 2 independent studies. 
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Figure 6.17.2 Representative flow plots of IL-4+ CD4+ T cells in whole lung tissue in a model of RV-induced 
allergic airways disease  at d7 p.i. Flow plots represent gated CD3+/CD4+ and IL-4+ cells in anti-IL-17RB 
antibody (groups represented as ‘anti-IL-17RB’) or isotype control antibody (groups represented as ‘ISO’)-
treated RV OVA, UV OVA and UV PBS mice. Numbers indicated on the plots reflect the percentage of cells 
that are present with the gated areas.  Results are representative of 2 independent studies. 
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 Early/innate effects of IL-17RB 
neutralisation in RV OVA mice 
Later/adaptive effects of 
sustained IL-17RB neutralisation in 
RV OVA mice 
 8h p.i. d1 p.i. d7 p.i. 
Airway obstruction - - - 
RV viral load       ↓(*) - - 
Airway neutrophilia - ↓ (***) - 
Airway eosinophilia & 
lymphocytosis 
- - ↓ (***) 
BAL IL-4 protein       ↓ (***) - - 
BAL IL-5 protein   ↓ (*)       ↓ (*) - 
BAL IL-13 protein   ↓ (*) - - 
Lung  IL-4 protein - - - 
Lung  IL-5 protein - - - 
Lung IL-13 protein        ↓ (***)       ↓ (***)   ↓ (***) 
Lung IL-25 protein and mRNA -       ↓ (*) - 
Lung IL-33 protein - ↓ (***) - 
Lung TSLP protein -       ↓ (**) - 
BAL CCL5/RANTES protein -       ↓ (***) - 
BAL CCL17/TARC protein -        -                          ↓ (**) 
BAL CCL11/Eotaxin 1  ↓ (*) - - 
BAL CCL24/Eotaxin 2 -       ↓ (*) - 
BAL MUC5ac protein  - - ↓ (***) 
BAL MUC5b protein - - - 
BAL IL-6 protein ↑ (***) - - 
Total and OVA-specific IgE  - - - 
BAL ILC2s  - - - 
Lung ILC2s - - - 
BAL basophil -      ↓ (*) - 
Lung basophil - - - 
BAL  IL-4+ CD4+ T cells - -                           ↓ (**) 
Lung IL-4+ CD4+ T cells - -     ↓ (***) 
Table 6.2   A summary of relative statistically significant increases and decreases for RV OVA (anti-IL-
17RB) vs RV OVA (ISO). *P<0.05; **P<0.01; ***P<0.001; - no significant changes 
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6.4   Summary 
By blocking IL-25 signalling, RV-mediated enhancement of several key Th2-associated 
allergic responses were inhibited as indicated by reductions in anti-IL-17RB-treated RV OVA 
groups compared with isotype-treated RV OVA groups. In some instances, these responses 
were reduced to levels measured in allergen-treated mice alone therefore indicating a 
reversal of the exacerbating effect of RV infection. The most striking examples of abrogated 
Th2 inflammation was a dramatic early reduction in airway IL-4, IL -5 and IL-13 protein levels 
and a later decrease in BAL and lung  IL-4+ CD4+ T cells in RV OVA mice administered anti-IL-
17RB antibody. In contrast, blocking allergen-induced IL-25 signalling had a minimal effect 
on several key features of Th2 inflammation in established allergic airways disease 
specifically indicating a role for RV-induced IL-25 in the exacerbation phenotype.  
Additional early reductions in Th2-related mediators in anti-IL-17RB-treated RV OVA mice 
included CCL5/RANTES, CCL11/Eotaxin 1 and CCL24/Eotaxin 2 in the airways as well as 
decreased IL-25, IL-33, TSLP and IL-13 in lung tissue. All these read-outs were significantly 
reduced at 8h and/or d1 p.i. compared with isotype-matched groups. Notably, neutrophilic 
inflammation, which has previously been associated with symptom severity205, was also 
significantly diminished in the airways of RV OVA (anti-IL-17RB) mice at d1 p.i.   
Repeated doses of anti-IL-17RB antibody administered at d3 and d5 p.i. sustained inhibition 
in RV OVA mice resulting in reduced airway eosinophilia and lymphocytosis at d7 p.i., which 
coincided with decreased levels in the Th2 cell chemokine, CCL17/TARC. Later effects of IL-
17RB neutralisation also included reduced levels of respiratory mucin, MUC5ac, in RV OVA 
mice.  Again, these observations were all significantly decreased compared with isotype-
treated RV OVA mice.  
Reduction of early BAL IL-5 and IL-13 observed in RV OVA (anti-IL-17RB) mice coincided with 
a trend towards decreased ILC2 numbers in the airways. However, future work will focus on 
measurement of intracellular expression of IL-5 and IL-13 by flow cytometry to establish an 
association between cell numbers and cytokine expression. We were able to demonstrate 
that reduced IL-4 in the airways was partly due to a lack of infiltrating IL-4+ basophils as cell 
numbers were reduced in the airways of RV OVA (anti-IL-17RB) mice at 8h and d1 p.i.  In 
contrast, IL-4+ basophils in the whole lung tissue were similar in anti-IL-17RB and isotype-
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treated groups potentially indicating that blocking IL-17RB resulted in a decrease in IL-4-
expressing basophil recruitment into the airways.  
Despite a predicted decrease in a number of Th2-associated read-outs in anti-IL-17RB-
treated RV OVA groups, some results were in contradiction with our original hypotheses. For 
example, despite significantly reduced levels of IL-13 and airway leukocyte infiltration in the 
lungs and airways in anti-IL-17RB-treated mice, aiway responses as measured by whole-
body plethysmography were not inhibited. An intriguing finding was that blocking IL-25 
signalling significantly reduced viral load at 8h p.i. which coincided with upregulated BAL IL-
6 levels in RV OVA mice, potentially indicating an increased Th1 response as a result of a 
dampened Th2 responses caused by IL-17RB neutralisation.  
In summary, blocking IL-25 signalling negated RV-induced enhancement of Th2 immunity 
suggesting that RV-induced IL-25 plays a role in enhancement of Th2 inflammation in a 
mouse model of RV-induced allergic airways disease. 
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Chapter 7: Discussion and future work 
RV infections are the principal cause of asthma exacerbations. While Th2-mediated 
inflammation is clearly implicated in the asthmatic response, it is unknown how the immune 
response to RV infection interacts with Th2 immunity to enhance disease 
pathogenesis92,95,218. Epithelial-derived IL-25 has been identified in several studies as an 
initiator and regulator of Th2 immunity and plays a role in asthma pathogenesis70,127,170. 
Given that bronchial epithelial cells are the primary site of RV infection, it may be 
hypothesised that RV infection of the airway epithelium induces the pro-Th2 cytokine, IL-25, 
providing a link between infection and Th2 driven allergic inflammation.  
In this study, we aimed to: 
 investigate RV-induced IL-25 expression in human airway epithelial cell lines and 
HBECs obtained from bronchoscopic brushings from atopic asthmatics and healthy 
patients  
 examine induction of IL-25 to RV infection in the otherwise untreated mouse airway 
 employ a mouse model of RV-induced allergic airways disease to assess the effects 
of infection and allergen on IL-25, Th2-associated mediators and IL-17RB-expressing 
cell populations  
 define a mechanistic role for RV-induced IL-25 by blocking signalling mediated by IL-
25 in our model of disease and measure key Th2 mediators associated with the 
exacerbation phenotype  
These objectives were carried out to facilitate the characterisation of the role of IL-25 in RV-
induced asthma exacerbations.  
 
7.1 RV-induced IL-25 expression in vitro  
Based on the pivotal role the airway epithelium plays in shaping immune responses to 
various stimuli including RV infection, we investigated RV-induced expression of IL-25 in 
human airway epithelial cell lines and HBECs obtained from atopic asthmatics and non-
asthmatic healthy controls.  
Of major significance was the finding that RV infection induced epithelial-derived IL-25 
mRNA and protein in vitro. Furthermore, HBECs from asthmatics exhibited a greater 
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capacity to produce IL-25 than cells from healthy controls. The finding that RV upregulates a 
driver of Th2 inflammation represents a mechanistic link between the antiviral response and 
Th2 induction and potentially a role for IL-25 in the initiation of RV-induced exacerbation of 
allergic inflammation. Previous in vitro studies have reported IL-25 gene expression in 
response to the allergens, Aspergillus oryzae and ragweed, in the human alveolar basal 
epithelial cells, A549, and mouse primary lung epithelial cells and cell lines70. Xu et al. also 
demonstrated IL-25 induction in cultured HNECs in response to the dsRNA analogue, poly 
I:C,  mimicking viral infection160. To our knowledge this is the first study to demonstrate RV-
induced IL-25 from HBECs in vitro.   
The differential response of HBECs from asthmatics and healthy controls in response to RV 
infection also highlights intrinsic differences in the bronchial epithelium between groups. 
Employing similar conditions for ex vivo culturing of HBECs from asthmatic and healthy 
patients, a separate study demonstrated that RV-infected cells from asthmatics produced 
less type I and type III IFNs which was associated with enhanced viral load102,103; therefore 
innate deficiencies may result in increased viral replication accounting for increased 
proinflammatory mediators including upregulated IL-25 production in the asthmatic 
epithelium. Similar findings were reported relating to the Th2 promoting cytokine, TSLP; 
HBECs from asthmatic children were shown to express more TSLP in response to RSV 
infection compared with cells from healthy children137. These results also suggest a greater 
propensity of the asthmatic epithelium to drive Th2 inflammation via the augmented 
release of virus-induced mediators.  
Enhanced IL-25 protein expression was also associated with clinical outcomes of disease; 
increased protein levels at 24h p.i. significantly correlated with sensitisation to a greater 
number of common environmental allergens in asthmatic patients while there was also an 
association with increased numbers of recorded asthma exacerbations per year. This is 
intriguing given that clinical studies indicate that the combination of allergic sensitisation, 
exposure to high levels of allergen and viral infections are strongly associated with the risk 
of hospital admittance with acute asthma92,95. The fact that atopy (as indicated by the 
presence of allergen-specific IgE) was associated with a tendency to produce more RV-
induced IL-25 in atopic asthmatics further suggests that RV interacts with the allergic 
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phenotype potentially increasing susceptibility to initiation of acute asthma mediated by IL-
25. 
RV-induced IL-25 gene expression was also detected in the human bronchial epithelial cell 
line, BEAS-2B. Based on an absence of IL-25 mRNA in response to UV-inactivated virus and a 
robust infection-dependant induction of IL-6 protein, IL-25 expression was dependant on 
viral replication. However, gene expression levels in RV-infected BEAS-2B cells were 
comparatively low compared with HBECs infected ex vivo as indicated by undetectable IL-25 
protein levels. Furthermore, additional airway epithelial cell lines (including A549s and 
H292s) were a poor model for RV-induced IL-25 compared with robust expression in HBECs 
from asthmatics and, to a certain extent, healthy controls. Varying responses between 
primary cells and cell lines is not an uncommon phenomenon and disparities in responses to 
stimuli between primary HBECs and airway epithelial cell lines have been reported219. 
Modifications of cell lines via transformation or derivation from human lung carcinoma to 
allow unlimited cell division indicate a tendency for genetic drift and therefore models are 
less physiologically relevant compared with primary cells219. Ex vivo models of HBECs from 
asthmatics and healthy controls represent not only the most accurate physiological 
conditions, but also enable direct comparisons of varying responses to stimuli in the 
diseased and healthy state.  
In our study, submerged cultures were employed on the basis that this enabled 
measurement of IL-25 expression after 2-3 passages as opposed to air-liquid interface 
cultures where cells are continuously cultured for a number of weeks. This was important 
for our purposes as it was theorised that extended culture may result in loss of any intrinsic 
variations between asthmatic and healthy cells. In addition, the fact that cell lines as well as 
commercially purchased HBECs (which were frozen down and passaged 5-6 times before 
harvest) expressed very limited amounts of IL-25 gene may be as a result of multiple 
passages/extended time in culture. As a result, cells from bronchial brushings were grown as 
submerged monolayer cultures.  
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7.2 RV-induced IL-25 expression in vivo  
Based on the findings that RV induced IL-25 in vitro, we sought to characterise IL-25 
expression in a mouse model of RV infection. Using this model, we confirmed a release of 
mediators in BALB/c mice that have been measured in patients experimentally infected with 
RV as well as in vitro studies of RV-infected HBECs40,205. These read-outs included an early 
robust neutrophilic response at 10h p.i. followed by lymphocytic inflammation as well as 
strong induction of the mouse CXCR2-specific chemokine, CXCL1/KC, the proinflammatory 
cytokines, IL-6, IFN-λ and CCL5/RANTES in the airways of RV-infected mice which were 
consistent with published results for this model202.  
In accordance with findings in vitro, RV infection significantly upregulated IL-25 gene and 
protein expression in the otherwise untreated mouse airway. Increased levels of IL-25 in RV-
infected mice demonstrated that production was predominantly virus replication 
dependent. However, mice treated with UV-inactivated virus also expressed comparatively 
reduced levels which mimicked patterns of IL-25 expression observed in RV-infected mice 
indicating that a component of IL-25 induction was also dependant on virus-receptor 
binding220.  The induction of IL-25 in response to viral infection in naive BALB/c mice has also 
been demonstrated by Siegle et al. However, this study employed a chronic asthma model 
in neonatal mice infected with a species-specific form of RSV. In this instance, measurement 
of IL-25 gene was limited to two time-points after infection only, namely 2 weeks and 4 
weeks p.i177. In contrast, we investigated the acute effects of RV infection on IL-25 gene and 
protein over several time-points up until d7 p.i. We reported a significant early increase in 
IL-25 gene expression in the lungs which decreased steadily while protein levels in RV-
infected mice remained elevated till d7 p.i. Based on these findings, future assessment of 
the duration that IL-25 protein levels remain upregulated after infection as well as what 
effects re-infection may have on further IL-25 enhancement may be noteworthy.  
IL-25 gene expression was also significantly upregulated at 10h p.i. in the BAL cells of RV-
infected mice and, like total gene expression levels, gradually decreased till d7 p.i. The fact 
that neutrophils comprised over 80% of the total BAL cells early after infection may 
implicate these cells as a source of IL-25. In support of this, we identified immunoreactive IL-
25 cells in the airway lamina propria that were morphologically similar to neutrophils. 
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Previous identification of neutrophils as IL-25 producers has not been reported; however it 
is pertinent that IL-25 has been shown to enhance neutrophil infiltration via upregulation of 
the neutrophil chemoattractant, CXCL8/IL-8, possibly indicating a positive self-feedback 
loop225. Furthermore, IL-25-induced CXCL8/IL-8 production was shown to be mediated by 
activation of NF-κB in vitro, representing a common transcription factor activated in 
response to RV and IL-25 following CXCL8/IL-8 production152. Accordingly, IL-25 in 
conjunction with RV infection may have an additive effect on neutrophil recruitment via 
upregulated CXCL8/IL-8 levels. This is of relevance as RV-induced neutrophilia has been 
associated with disease severity while neutrophil deficiency in mice was related to 
decreased AHR and BAL mucins221. An observed decrease in neutrophilia in the airways of IL-
17RB-neutralised RV-infected and OVA-challenged mice supports this premise which will be 
discussed in greater detail in section 7.5.   
IL-25 immunoreactivity in the bronchial epithelium of RV-infected mice confirmed in vitro 
findings, demonstrating the epithelium to be a major source of early RV-induced IL-25 
expression. Comparable with findings in HBECs from patients, epithelial-derived IL-25 
protein levels were highest at 24h p.i. Similarly, Kaiko et al. demonstrated RSV-induced IL-25 
in the respiratory epithelium of NK cell/IFN-γ-depleted mice by IHC analysis at 4 days p.i. In 
this instance, IL-25 upregulation was attributed to a deficiency in IFN-γ which was 
demonstrated to have a suppressive effect on IL-25 production157. In contrast, here we 
report the acute induction of IL-25 gene and protein by virus in the bronchial epithelium of a 
naive BALB/c mouse which, to our knowledge, has not previously been demonstrated.  
Kinetic expression of IL-25 as measured by IHC indicated initial secretion by the bronchial 
epithelium which was followed by infiltration of IL-25-expressing inflammatory cells. 
Specifically, preliminary analysis of IL-25+ cells in the airway lamina propia identified 
macrophages (based on cellular morphology) as a potential source of IL-25 in RV-infected 
mice. Using the environmental irritant, titanium dioxide, Kang et al. validated alveolar 
macrophages to be a source of IL-25 in rats165. In addition, immunostaining indicated the 
presence of RV-induced infiltrating IL-25-producing lymphocytes in the airway lamina 
propia. A mixed profile of CD4+ and CD8+ T cells have been reported as the main 
lymphocyte populations in the airways of patients experimentally infected with RV83,89; 
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therefore it is of interest that Owyang et al. demonstrated that IL-25 was constitutively 
expressed by CD4+ and CD8+ T cells163. It was this constitutive expression in naive mice 
which imparted immunity to Trichuris infection; when tested in strains deficient in IL-25, 
mice failed to clear the infection and developed severe intestinal inflammation.  Trichuris 
infection studies were also carried out in mice deficient in NF-κB1 (p50) which developed 
very similar symptoms of disease163.   
In light of similarities between NF-κB and IL-25 deficiencies in relation to disease symptoms, 
it is also of interest that RV, in addition to propagating in the airway epithelium, has also 
been reported to replicate in macrophages and that both cell types require the transcription 
factor, NF-κB, for RV-induced release of proinflammatory mediators37,38,222. Specifically, RV 
infection of epithelial cells was shown to increase NF-κB activation required for CXCL8/IL-8, 
IL-6, ICAM-1 and MMP-9 expression37,38,220,223,224 while TNF-α production by macrophages 
was reported to be dependent on RV-induced NF-κB signalling222. Based on the findings that 
IL-25 induction was largely dependent on virus replication as well as the presence of an NF-
κB binding site upstream of the IL-25 encoding region, investigation of a potential role for 
this transcription factor in RV-induced IL-25 regulation is noteworthy156. Analysis would also 
be valuable based on the fact that very little is known about regulation of IL-25 gene 
expression. 
It is of importance that despite expression of IL-25, Th2 inflammation (including IL-4, IL-5 
and IL-13 and airway eosinophilia) was absent in our model of RV infection. By contrast, the 
intranasal and intraperitoneal administration of recombinant IL-25 has been reported to 
induce allergic inflammation marked by IL-4, IL-5 and IL-13, eosinophilia and epithelial cell 
hyperplasia in the lungs and digestive tract of mice153,225. Additional studies have also shown 
that overexpressing IL-25 in the lung epithelium of transgenic mice displayed increased 
CCL11/eotaxin-1, CCL24/eotaxin-2, CCL22/MDC and MUC5ac gene expression in lung tissue 
as well as increased epithelial hyperplasia and eosinophils in the lung parenchyma70. 
Comparison of the amount of recombinant protein used to initiate allergic inflammation in 
these instances indicated that the smallest dose used was in the order of a 1000 fold more 
than the amount of IL-25 induced by RV infection in this study70,77,78,153,225. Furthermore, 
these studies administered repeated treatments on consecutive days, and in some cases, 
 172 
 
mice were dosed daily for up to ten days, clearly not reflecting accurate physiological 
conditions70. Similarly, measurement of IL-25 in the BAL of transgenic mice indicated 
amounts approximately 10 fold more than IL-25 levels upregulated in RV-infected mice169.  
Based on these findings, we suggest that the amount of IL-25 induced by RV infection was 
insufficient to initiate Th2 inflammation in the pulmonary environment.  
In addition to insufficient levels, it may be that in a skewed Th1 environment, demonstrated 
by a robust induction of antiviral and proinflammatory cytokines in our model of RV 
infection, the absence of Th2-associated cell populations could account for a lack of IL-25-
induced allergic inflammation. Numerous studies have indicated that IL-25 has the potential 
to act directly on both innate and adaptive Th2 cytokine-producing cells in the lung77,127,172. 
Hence, in a Th2 pulmonary environment (such as in the allergic asthmatic lung), RV-induced 
IL-25 may activate recruited cells resulting in Th2 cytokine release and enhanced allergic 
inflammation. In support of this, Tamachi et al. reported that transgenic overexpression of 
IL-25 in the lung failed to initiate a Th2 response in mice. However, following OVA 
sensitisation and challenge which induced recruitment of OVA-activated CD4+ T cells to the 
lung, IL-25 induced significant enhancement of allergic airways disease169.  
Therefore, after confirming the suitability of this mouse model for the detection of RV-
induced IL-25, we aimed to investigate the effect of RV infection on IL-25 in a Th2 allergic 
environment shaped by allergen sensitisation and challenge.   
 
7.3 IL-25 induction in response to allergic and viral interactions in a model of RV-
induced allergic airways disease 
To investigate mechanisms of interplay between allergen exposure and RV infection in 
relation to IL-25 expression, a mouse model of RV-induced allergic airways disease was 
developed in our laboratory and employed in these studies202.  One of our primary 
objectives was to investigate potential synergistic effects of allergen in conjunction with RV 
infection on IL-25 expression. We first confirmed the suitability of our model by comparing 
results to published findings as well as comparison with clinical aspects of acute asthma. We 
also carried out a thorough analysis of RV-induced enhancement of Th2 responses to 
allergen to define end-points potentially regulated by IL-25 which could be measured 
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subsequent to blocking IL-25 signalling. These findings will be discussed below before 
examining the combined effect of RV infection and allergen treatment on IL-25 gene and 
protein expression.  
Infiltration of a mixed profile including early neutrophilia and later eosinophilic 
inflammation was significantly enhanced in RV-infected and allergen-challenged mice which 
corresponded with cellular profiles measured in induced sputum samples in patients with 
acute asthma88. In accordance with previously published results of this model, RV infection 
also enhanced lymphocytic airway inflammation in allergen-sensitised and challenged mice 
in addition to increasing cholinergic hyperresponsiveness indicating increased disease 
symptoms89,202. We also confirmed that augmented airway inflammation coincided with 
upregulated T cell and eosinophil chemoattractants; specifically, the T cell chemoattractant, 
CCL5/RANTES, as well as CCL11/Eotaxin 1 and CCL24/Eotaxin 2 were upregulated in the 
airways of RV OVA mice early after infection which corresponded with recently published 
results of this model226. Furthermore, RV OVA treatment resulted in an increase of the Th2 
cell chemoattractant, CCL17/TARC, which corresponded with upregulated Th2 (IL-4+CD4+) 
cells observed at d7 p.i. Also in accordance with published results from this model, RV-
infected and allergen-treated mice exhibited enhanced expression of the major respiratory 
mucin, MUC5ac202. Although the mucin, MUC5b, was not significantly upregulated above 
other treated groups, RV-infected and allergen-treated groups had the greatest 
accumulative mucus secretion at d7 p.i. This indicates an additional hallmark of acute 
exacerbation recorded in patients where mucus plugging of the airways has been 
demonstrated in fatal asthma cases65,83.   
A primary aim was to carry out a thorough analysis of Th2 cytokines at various time-points 
after infection and compare expression with IL-25 induction in this model of disease. We 
were particularly interested in investigating early events after infection with the aim of 
characterising the innate effects of virus and allergen on all cytokines; therefore, an earlier 
time-point at 10h p.i. was incorporated which has not previously been studied in this model. 
Analysis of the BAL indicated RV infection induced an early source of IL-4 and IL-13 in OVA-
sensitised and challenged mice at 10h p.i. and IL-5 at d1 p.i. that was significantly 
upregulated compared with mice treated with OVA or RV alone. By d2 p.i. levels of IL-4, IL-5 
and IL-13 were low or undetectable in all treated groups. In stark contrast, analysis of 
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cytokines in harvested lobes from the right lung (excluding the apical lobe) indicated 
sustained expression of IL-4, IL-5 and IL-13 until d4 p.i. in both groups of OVA-challenged 
mice. Analysis of cytokine expression in lung tissue indicated that RV infection enhanced all 
Th2 cytokines in allergen-treated mice at d1 p.i. above OVA-treated mice alone; this was 
followed by a later peak in expression at d4 p.i. that was predominantly allergen-driven. 
Both peaks may suggest an early and late phase response to RV infection and OVA 
treatment which has been well characterised in allergen challenge studies in mouse models 
and humans69,73,74. In line with this theory, preliminary analysis of IL-4-producing cells by 
flow cytometry indicated that basophils accounted for the majority of early IL-4 expression 
at d1 p.i. while an enhanced population of Th2 cells were present in the lung tissue of RV 
OVA mice at d4 and d7 p.i66,73. With regard to differences recorded in the airways and lung 
tissue, several reports have demonstrated that cellular profiles in the BAL fluid do not 
always reflect cell populations in the lung parenchyma and that variable cytokine expression 
can occur in different lung compartments227 228-230. Although previously published results 
from this model validated sharp reductions in BAL Th2 mediators at d1 p.i. to d2 p.i202, 
comparison of cytokine expression from different lung compartments has not previously 
been investigated. Furthermore, the robust induction of IL-4 and IL-13 in response to RV 
infection and OVA treatment as early as 10h p.i. has not previously been reported. The fact 
that the predominant source of IL-4 was from basophils and not Th2 cells suggests the 
presence of innate cellular sources of Th2 cytokines in the airways early after infection. 
Particularly striking were the large quantities of IL-4 levels in the airways of RV OVA mice at 
10h p.i.; not only were amounts in RV OVA mice ~2 fold more than OVA-treated mice alone 
but were also ~2 fold higher than those measured in lung tissue. Given its integral role in 
inducing differentiation towards the Th2 phenotype as well as its function in isotype 
switching of B cells to IgE synthesis73, investigation of innate sources and the potential 
effects of upregulated IL-4 levels in RV-infected and OVA-challenged mice in the airways was 
noteworthy and will be discussed in detail in section 7.4 and 7.5.   
 
Due to the fact that the epithelial-derived Th2 cytokines, TSLP and IL-33, have been shown 
to interact with IL-25 predominantly in the innate Th2 response, protein expression was 
measured in lung tissue in our mouse model of disease130. Both cytokines displayed  
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different kinetic protein expression compared with other measured Th2 cytokine profiles; 
though an early peak in IL-33 expression was observed at d1 p.i., a later characteristic peak 
at d4 p.i. was absent in both IL-33 and TSLP. 
In line with published findings which demonstrated that allergen treatment in the form of 
HDM upregulated IL-33 in mice, we showed that OVA induced IL-33 expression in our 
model67. Though RV infection enhanced expression in OVA-treated mice in our studies, 
there were no significant differences between OVA-challenged groups. In contrast with 
reports that have documented upregulation of IL-33 in response to viruses including 
influenza A in the mouse lung122, RV infection failed to significantly induce IL-33 above 
negative controls. Of interest was the fact that, compared with other Th2 mediators 
measured in lung tissue, IL-33 levels remained comparatively low in OVA-challenged groups 
after d2 p.i., indicating a more predominant role in the early allergic response. Recently, 
several papers have highlighted an important role for IL-33 as a crucial amplifier of innate 
Th2 responses in the lung and gut as opposed to adaptive immunity231 232. Namely, a 
prominent role in the proliferation and activation of basophils and mast cells has been 
demonstrated in mouse and human studies233 131,234  An early peak in expression and 
absence of a later peak at d4 p.i. may support these findings as well as the fact that both 
innate cell populations characterised by flow cytometry in this mouse model expressed the 
IL-33 receptor, T1/ST2. 
In contrast, TSLP expression was predominantly driven by allergen exposure until d4 p.i. 
after which levels in RV OVA groups were upregulated above levels in UV OVA groups at d7 
p.i. A recent study demonstrated that TSLP played a prominent role in the adaptive 
response by promoting virus-specific CD8+ T-cells in response to influenza A infection; levels 
in this model were found to peak at d5 p.i. 235. Therefore, characterisation of a potential 
adaptive function for TSLP in RV OVA mice after d7 p.i would be of interest. However, 
contrasting with these results, though the combination of RV infection and allergen 
sensitisation in RV PBS groups enhanced TSLP levels above UV PBS controls, viral infection 
alone, as demonstrated in our model of RV infection, failed to induce TSLP expression (data 
not shown). Human in vitro studies have demonstrated that TSLP was upregulated in normal 
HBECs infected with RV and that supplementing the cell media with IL-4 was shown to 
enhance RV-induced TSLP121. These results are in conflict with observations in RV-infected 
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and OVA-challenged mice i.e. in an IL-4-enriched milieu, RV infection failed to upregulate 
TSLP levels compared with OVA-treated mice alone.  
In accordance with our hypothesis, allergen challenge and RV infection following 
sensitisation enhanced IL-25 production compared to induction by allergen or RV alone. This 
was confirmed by significantly enhanced mRNA and protein at 10h and d1 p.i. respectively 
in RV OVA mice. As demonstrated in our mouse model of RV infection, induction of IL-25 in 
response to infection in RV PBS groups was also confirmed. Comparison of IL-25 protein 
expression with IL-4, IL-5 and IL-13 measured in lung tissue from RV OVA mice revealed a 
similar trend; namely, an early and late response that was most pronounced in OVA-treated 
mice infected with RV at d1 p.i. Again, this suggests an early source of IL-25 as well as a 
later, adaptive cellular source. In contrast with all other measured Th2 cytokines, amounts 
of IL-25 induced by RV alone and OVA alone were equivalent at d1 p.i. and were significantly 
upregulated above double-negative controls. These novel findings indicate that both RV and 
allergen are capable of independently inducing IL-25, a property unique to this Th2 cytokine.  
As previously discussed, several reports have demonstrated upregulation of IL-25 in 
response to allergen in the lungs of mice and humans71,158,169. In line with findings from our 
study, Tamachi et al. reported that OVA sensitisation and challenge induced IL-25 gene 
expression which was measured at 4h, 8h and d1 after the final OVA challenge. Expression 
was slightly elevated at 8h p.i. compared with d1 p.i. which was similar to our observations. 
However based on a thorough kinetic analysis of gene expression up until d7 p.i., we were 
also able to identify a second higher peak in expression at d2 p.i. Furthermore, as opposed 
to measurement of protein expression at a single time-point at d1 as reported by others, we 
demonstrated that induction by allergen was most pronounced at d4 p.i.169. This detailed 
kinetic analysis of IL-25 expression in response to OVA treatment has not previously been 
demonstrated and allowed us to draw parallels between peaks in allergen-induced IL-25 
compared to IL-4, IL-5 and IL-13 expression in lung tissue.  
Although a detailed analysis of the antiviral response was not characterised in our study, 
enhanced viral load was found to coincide with augmented Th2 cytokines, increased airway 
inflammation and enhanced AHR in RV-infected and OVA-treated mice. In accordance with 
these findings, Message et al. demonstrated that RV load in asthmatics was related to 
enhanced lower airway inflammation and increased bronchial hyperreactivity while 
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augmented Th2 cytokines were associated with greater disease severity93. Therefore, these 
clinical findings draw parallels with findings in our mouse model of disease. In addition, a 
strong induction of IL-6 was also demonstrated in RV-infected and allergen-treated mice. In 
line with these results, elevated IL-6 levels in sputum have been reported in atopic 
asthmatic patients experimentally infected with RV205. Similar to BAL Th2 cytokines, the 
highest levels of IL-6 in the airways were measured at 10h p.i. in RV OVA mice, which was 
~2.5 fold greater than amounts observed at d1 p.i., again suggestive of an early cellular 
source. This is a striking example of the enhancing effects of RV infection and allergic 
inflammation; virus and allergen alone induced ~8 fold less IL-6 than when both 
components were administered, highlighting the complex interactions between the antiviral 
and allergic response. Possible implications for increased IL-6 levels as well as the fact that 
blocking IL-25 signalling further enhanced levels are discussed further in section 7.5.  
In summary, RV infection of an allergen-sensitised and challenged mouse predominantly 
enhanced Th2 inflammation as well as viral load and disease severity as demonstrated by 
augmented AHR. The interaction of virus and allergen resulted in the greatest induction of 
IL-25 gene and protein expression compared with either factor alone verifying our 
hypothesis. We then investigated whether IL-25 levels measured in RV-infected and 
allergen-treated mice corresponded with enhanced recruitment of IL-17RB-expressing cells 
to the lung in addition to characterising cell populations potentially activated by enhanced 
IL-25 in our mouse model of disease. 
 
7.4 IL-17RB-expressing cell populations in a model of RV-induced allergic airways 
disease 
On the basis that IL-25 has been demonstrated to mediate its biological effects through a 
multitude of innate and adaptive cell populations77,78,127,187,193, we employed several Th2-
associated markers to characterise IL-17RB-expressing non-T and T cell populations 
recruited to the lung in our mouse model of disease. We also investigated the effects of 
virus and/or allergen on the magnitude and kinetics of total IL-17RB-expressing cells in the 
lungs and airways of treated mice hypothesising that enhanced levels of IL-25 in RV OVA 
mice correlated with increased receptor expression.  
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7.4.1 Total IL-17RB+ cell populations 
In line with previous findings, we observed that allergen exposure increased pulmonary IL-
17RB expression in the lung71,236. Specifically, Petersen et al. have demonstrated that 
repeated treatment with cockroach allergen in mice upregulated IL-17RB and reciprocally 
increased IL-25 gene expression71. Other studies reported that ex vivo PBMCs from patients 
with allergic rhinitis challenged with allergen extract for a week expressed significantly 
enhanced IL-17RB after 4 days of culture as determined by flow cytometry236. In addition to 
confirming these findings, we demonstrated that RV infection enhanced allergen-induced IL-
17RB-expressing cells in lung tissue. In line with our hypothesis, this coincided with the 
greatest induction of IL-25 in RV OVA groups, indicating that IL-25 may serve as an 
amplification factor in Th2 inflammation. The greatest number of IL-17RB-expressing cells, 
which comprised approximately 14% of the total lung lymphocyte population, was observed 
in RV OVA mice at d7 p.i.  Further analysis revealed that ~40% of IL-17RB+ cells at this time-
point were IL-4+ Th2 cells. Analysis of flow cytometry plots indicated that a large population 
of IL-17RB+ CD4+ T cells did not express IL-4. These cells may represent IL-5 or IL-13-
expressing Th2 cells or, alternatively, Th9 cells which have also been shown to express IL-
17RB187. In addition, a population of cells which we classified as ILC2s comprised a further 
~3% of IL-17RB-expressing cells at d7 p.i. Future flow cytometry analysis of this model will 
aim to incorporate intracellular staining (ICS) for IL-5, IL-9 and IL-13 as well as employ 
reporter mouse strains expressing GFP at the IL-4 and IL-13 loci to gain detailed information 
on potential IL-25-responsive Th2 cytokine-secreting cells.    
In contrast to results in lung tissue, interaction of RV infection and OVA treatment in mice 
induced an early infiltration of IL-17RB+ cells into the airways representing ~20% of ILC2s 
and ~10% IL-4+Th2 cells at d1 p.i. However, IL-17RB+ cells in the airways at d7 p.i. exhibited 
no discernable differences between OVA-challenged groups or RV-infected mice alone.  The 
majority of IL-17RB+ cells in OVA-challenged groups at this time-point were again identified 
as IL-4+ Th2 cells which accounted for ~25% while ILC2s made up ~9%.  
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7.4.2 IL-17RB+ ILC2s 
Due to the large variety of IL-25-responsive innate cell populations that have been 
characterised and the vast range of markers used to phenotype them68,71,77,78,192,193,237, we 
employed a selective panel that was phenotypical of innate lymphoid cells. Using these 
markers, we identified an early IL-17RB+T1/ST2+ICOS+IL-4-FcεRI-CD49b-CD3-CD4- 
population in OVA-challenged mice which we termed ILC2s, representing the newly grouped 
subset made up of nuocytes, Ih2 and NH cells which share expression of IL-17RB, T1/ST2 and 
ICOS, in addition to exhibiting a lin- phenotype81. Other IL-17RB-expressing innate cells that 
did not fall within this subset were excluded based on a process of elimination of published 
findings,; specifically, the IL-25-responsive T2M cells, which have been demonstrated to be 
induced in the lungs of allergen-challenged mice and in response to IL-25 administration, 
were excluded based on the fact that they do not express T1/ST2 and are representative of 
a myeloid subset71. Similarly, IL-17RB+ MPPtype2 cells, reported to confer immunity to T. 
muris infection in Il-25-/- mice, were also previously characterised as T1/ST2-77.  
Based on published findings of ILC2 subsets, nuocytes represented the most likely candidate 
for IL-17RB+ innate cells identified in our model of disease. Namely, nuocytes are the only 
group of innate lymphoid cells reported to infiltrate the lung in response to OVA challenge 
in a mouse model of allergic airways disease where they provided a major source of innate 
IL-13 upon IL-25 activation. Furthermore, using a day 12 and day 25 OVA-induced lung 
allergy model, nuocytes were not only detected in the BAL at the start of the allergic 
response but also persisted through the adaptive response with greater numbers detected 
at day 25 post-sensitisation76. In line with these findings, OVA-challenge induced ILC2s at 6h 
and later at d7 p.i. in lung tissue in our model. A significant early induction at d1 p.i. was also 
measured in the airways of RV-infected and OVA-challenged mice; however all other time-
points measured in the BAL and lung p.i. revealed no enhancing effect of RV infection in 
OVA-challenged mice indicating that this cell population may be predominantly allergen-
driven. Of note, the amount of ILC2 numbers recruited into the airways in response to OVA-
challenged in the early response at d1 p.i. and the later response at d7 p.i. were very similar 
to those measured in the day 12 and day 25 OVA-induced lung allergy model i.e. ~2000 cells 
per mouse in the early response and ~4000 cells enumerated at the later time-point post-
allergen challenge76. Future studies will aim to confirm these preliminary findings by 
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confirming a lin- phenotype in cells as well as ascertain whether this cell population is a 
contributing source of IL-13 expression as previously demonstrated by nuocytes in the 
lung76.   
7.4.3 IL-4+ basophils 
A striking effect of RV infection in the allergic lung was a very robust induction of IL-4 in the 
airways early after infection. Based on these findings, we sought to identify potential IL-
17RB-expressing cellular sources that co-expressed IL-4 by flow cytometry analysis. Though 
no IL-4+IL-17RB+ cells were observed early after infection, we did identify an 
FSClo/SSCloFcεRI+T1/ST2+CD49b+CD3-CD4- cell population in whole lung cell preparations 
and BAL leukocytes which produced IL-4. While there exists divided opinion as to a definitive 
panel of markers for basophil characterisation, analysis of the literature revealed that these 
cells fitted the basophil phenotype most accurately214,215,134,216,238. Namely, mast cells were 
discounted based on the fact they do not express CD49b while eosinophils were also 
excluded based on SSChighFcεRIlo properties238. Other studies have recently characterised 
FcεRI-expressing DCs which were demonstrated to infiltrate the mouse lung in response to 
viral infection as well as inhaled allergen238,239. Specifically, paramyxoviral infection of mice 
induced high expression of FcεRI on resident lung DCs which were reported to be regulated 
by type I IFN receptor and not IgE. However, identification of these myeloid cells was based 
on isolation of SSChigh/FSChigh populations which excluded FSClo/SSClo FcεRI+ cells identified in 
our model239. In addition, IL-4-expressing FcεRI+ DCs, characterised by Hammad et al., were 
reported to infiltrate the mouse lung in response to HDM allergen. Based on the fact this 
population exhibited a varied forward/side scatter profile and did not express CD49b, these 
cells were also excluded as potential candidates238. As a result, we concluded that basophils 
most accurately represented characterised IL-4-producing non-T cells in our mouse model of 
disease. 
Others have demonstrated that in a model of OVA-induced allergic airways inflammation, 
basophils comprised the largest proportion of non-T IL-4-producing cells which were shown 
to infiltrate the lung after allergen challenge240. Our findings demonstrated similar results 
with IL-4-expressing basophils accounting for ~85% of innate IL-4 producers at d1 p.i. in both 
OVA-challenged groups suggesting that they were the principal early source of IL-4 in the 
airways of RV OVA mice. In line with their role in the innate allergic response, basophils 
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peaked at d1 p.i. in the airways and lung tissue of OVA-challenged mice and rapidly declined 
after this time-point.  Peak levels in OVA-challenged mice accounted for ~0.5% of total cells 
from lung tissue within the ‘lymphocyte’ gate. These findings are in accordance with other 
studies which have reported that basophils represent a relatively small population of 
leukocytes during the allergic response; however they have also been demonstrated to 
generate greater amounts of IL-4 on a per-cell basis than Th2 cells implicating them as an 
important source of IL-4241, 242.  
Studies of respiratory viruses and basophil activation have demonstrated that RSV induced 
basophil accumulation in the lungs of BALB/c mice and that these cells were the primary 
early source of IL-4215. In vitro studies have also reported that RV-infected cell lines from 
human mast cells and basophils  can enhance IgE/anti-IgE-induced histamine release in both 
cell types as well as IL-4 and IL-6 protein in basophil supernatant106. Demonstrating 
interaction between virus and allergic inflammation, RV infection augmented total serum 
IgE in asthmatic patients which correlated with reduced lung function while RV-infected 
allergic rhinitis patients displayed elevated total serum IgE and histamine compared with 
infected non-allergic controls107,108.  Due to the fact that serum was taken at a single time-
point at d7 p.i. in our study, we could not demonstrate a temporal relationship between IgE 
levels and FcεRI-expressing cells. In addition to allergen-induced cross-linking of IgE, 
activation of basophils can occur via stimulation with IL-33 together with IL-3 which has 
been shown to directly induce IL-4 production243, 244.  Though amounts were not significantly 
elevated above OVA-challenged mice alone, the greatest levels of IL-33 at d1 p.i. were 
measured in RV OVA mice which coincided with peak basophil levels in the lung tissue and 
the airways. Confirmation of T1/ST2 expression on cells was also consistent with a potential 
effector function of IL-33 in the induction of basophil activation245.  
In summary, we identified IL-17RB-expressing Th2-associated cell populations as well as an 
early source of IL-4-producing basophils in our mouse model of disease which have not 
previously been characterised. Finally, to define a role for IL-25 in RV-induced allergic 
airways disease, RV-induced IL-25 signalling was blocked to investigate potential outcomes 
on identified cell populations as well as on RV-enhanced Th2 responses.   
 
 182 
 
7.5 Blocking IL-25 signalling in a model of RV-induced allergic airways disease 
It is unclear how, in the asthmatic lung, RV infection interacts with the pulmonary Th2 
environment to trigger an exacerbation. We have demonstrated that IL-25 is induced by RV 
infection in vivo and in vitro. In addition, the combination of allergen exposure and RV 
infection enhanced expression of IL-25 and its receptor, IL-17RB, which was associated with 
disease severity as measured by AHR. To define a functional role of RV-induced IL-25 in a 
model of allergic airways disease we systemically blocked the biological activity of RV-
induced IL-25 using a neutralising antibody against IL-17RB, which was previously employed 
in flow cytometry analysis. To achieve these aims, anti-IL-17RB antibody was administered 
to treatment groups pre-RV infection. An additional 2 doses were administered to mice at 
d3 and d5 p.i. and groups compared with isotype-matched controls.  
Using the same antibody clone utilised in this study, Camelo et al. demonstrated its efficacy 
in decreasing Th2 inflammation in a type 2 model of colitis. By blocking IL-25 signalling, mice 
displayed decreased IL-13 levels, blood eosinophilia and IgE which correlated with reduced 
IL-4, IL-5 and IL-13 production by cultured mesenteric lymph node (MLN) cells171. 
Furthermore, symptoms of disease were lessened and mucosal infiltration of NKT cells and 
nuocytes was reduced. Antibody binding was shown to be specific for mouse and human IL-
17RB and exhibited no cross-reactivity with other members of the IL-17 receptor family171. 
Using an identical dose of blocking antibody administered i.p. (as reported by Camelo et al.) 
we also observed reduced Th2 inflammation in our mouse model of disease, which has not 
previously been demonstrated in the lung.  
Blocking IL-25 signalling attenuated RV-mediated enhancement of airway inflammation and 
granulocyte numbers in OVA-sensitised and challenged mice, a key feature of acute asthma 
in human disease83,88. Administration of anti-IL-17RB antibody in RV OVA mice significantly 
reduced airway neutrophilia at d1 p.i. and eosinophilia and lymphocytosis at d7 p.i. 
compared with isotype-treated RV OVA mice, clearly implicating a role for RV-induced IL-25 
in airway leukocyte infiltration. As previously stated, this significant decrease in airway 
neutrophilia in anti-IL-17RB-treated RV OVA mice may be explained by the inability of IL-25 
to induce the neutrophil chemoattractant, CXCL1/KC, in accordance with studies of human 
renal cells which produced CXCL8/IL-8 in response to IL-25 stimulation152. Furthermore, 
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human eosinophils treated with IL-25 were reported to secrete CXCL8/IL-8 in an NF-κB-
dependant manner in vitro84. Therefore, a significant reduction of total eosinophil numbers 
as well as the inability of IL-25 to act on potential responsive cells may account for a 
CXCL1/KC-dependent decrease in neutrophilic inflammation mediated by IL-25. As 
preliminary characterisation of the effects of IL-17RB neutralisation on this mouse model of 
disease was predominantly focused on Th2-associated read-outs, future studies will center 
on evaluation of Th1 immune responses including measurement of CXCL1/KC as a 
mechanism for reduced neutrophilia. The fact that IL-25 may also mediate virus-associated 
inflammatory responses such as neutrophil recruitment implicates IL-25 receptor 
neutralisation as a promising therapeutic target for virus-induced allergic disease, 
particularly in light of the fact RV-induced neutrophilia has been associated with disease 
severity88,221.  
Eosinophilic inflammation was also reduced in the airways of anti-IL-17RB-treated RV OVA 
mice at d7 p.i. Previous studies reported that IL-25 can act indirectly and directly on 
eosinophils to increase viability and induce infiltration into the lung respectively70,188,199.  
Angkasekwinai et al. demonstrated that treatment of mouse lung epithelial cells with IL-25 
strongly induced expression of CCL11/Eotaxin-1 and CCL5/RANTES as well as TSLP and 
MUC5ac gene expression70. In line with these findings, the eosinophil chemoattractants, 
CCL11/Eotaxin-1 and CCL5/RANTES, as well as CCL24/Eotaxin-2 were significantly 
downregulated in anti-IL-17RB-treated RV OVA mice compared with isotype-matched 
groups, while reduced levels of BAL IL-5 in the airways at 8h and d1 p.i. may also have 
contributed to decreased eosinophil recruitment73. However, eosinophil chemoattractants 
in OVA-challenged mice alone were lower than anti-IL-17RB-treated RV OVA groups even 
though their total BAL eosinophil numbers were higher, indicating an additional pathway 
contributing to reduced eosinophilia. IL-25 has also been reported to bind directly to 
eosinophils enhancing cell viability and therefore promoting eosinophilia in allergic 
inﬂammation199. Therefore, it is plausible that blocking RV-induced IL-25 signalling 
decreased eosinophilic survival in the late-phase allergic response.  
Lymphocytic inflammation was also dramatically reduced in anti-IL-17RB-treated RV OVA 
groups; this was in line with results demonstrating decreased levels of the memory T cell 
chemoattractant, CCL5/RANTES, as well as the Th2 cell chemoattractant, CCL17/TARC. In 
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addition, flow cytometry data corroborated results demonstrating a striking decrease in Th2 
cells in anti-IL-17RB-treated RV OVA.  
In contrast with these results, the anti-IL-17RB dosing regime used in this study had minimal 
effects on allergen-induced eosinophilia and lymphocytosis. Other studies have 
demonstrated that blocking IL-25 reduced recruitment of eosinophils and CD4+ T cells into 
the airways as well as decreased Th2 cytokines and IgE in OVA-sensitised and challenged 
mice.  In these instances, antibody was administered before allergen sensitisation or before 
mice were challenged169,170. Therefore, it is most probable that because anti-IL-17RB 
antibody was administered after 2 allergen challenges in our model, treatment was unable 
to suppress ongoing inflammatory responses. The fact that other read-outs of Th2 
inflammation, including BAL Th2 cytokines, chemokines, mucin proteins and Th2 cells, were 
also largely unchanged by blocking IL-17RB in UV OVA mice further indicates that once the 
allergic response was initiated, IL-25 may not be required for propagation of allergen-
induced Th2 inflammation.  
One of the most striking examples of abrogated Th2 inflammation was a dramatic early 
reduction in BAL IL-4, IL-5 and IL-13 in RV OVA mice administered anti-IL-17RB antibody. 
Based on the fundamental role these mediators play in Th2 cell differentiation, IgE 
synthesis, mucus secretion, bronchioconstriction and cellular recruitment, this finding was 
of great relevance73. These results further indicated that RV-induced IL-25 was implicated in 
augmentation of allergic airways disease as blocking allergen-induced IL-25 signalling again 
had minimal effects. In contrast, analysis of IL-4 and IL-5 expression in the lung homogenate 
of all treated mice revealed no significant differences between anti-IL-17RB and isotype-
matched groups indicating IL-25-mediated signalling had negligible effects in total lung 
tissue. These differences between cytokine expression in the lung parenchyma and BAL may 
suggest that blocking IL-17RB resulted in a direct or indirect decrease in IL-4 and IL-5-
expressing cells recruited into the airways. For example, IL-4+ basophil levels in the lung 
tissue of RV OVA and UV OVA mice were not significantly altered by IL-17RB neutralisation 
compared with isotype-matched groups. However, infiltrating IL-4+ basophils were 
significantly reduced in the airways of RV OVA (anti-IL-17RB) mice at d1 p.i compared with 
isotype-treated RV OVA mice. Several chemokines, including CCL5/RANTES, have been 
reported to promote basophil chemotaxis to the site of allergic inflammation246. The fact 
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that others demonstrated that CCL5/RANTES was induced by the epithelium in response to 
IL-2570 as well as findings from our study that showed levels were significantly decreased in 
the BAL of IL-17RB-treated RV OVA mice at d1 p.i. may represent an indirect mechanism of 
decreased basophil infiltration in the airways. Furthermore, additional basophil 
chemoattractants, including CCL2/MCP-1 and CCL3/MIP-1α, have also been reported to be 
secreted by IL-25-stimulated eosinophils 188,247.  
The reduction of early BAL IL-5 and IL-13 observed in RV OVA (anti-IL-17RB) mice coincided 
with a reduced trend in ILC2 numbers in the airways. However, future studies will focus on 
employing reporter mouse strains expressing GFP at the IL-13 loci as well as ICS staining for 
IL-5 to explore if identified ILC2s represent an IL-25-responsive source of Th2 cytokines that 
may be reduced as a result of neutralising IL-17RB.  Alternatively, cytokine profiles of ILC2s 
harvested from treated groups in our model could be measured after ex vivo culturing in the 
presence of anti-IL-17RB or isotype controls to assess potential abrogation of cytokine 
release. Further characterisation of ILC2s would be of value based on findings from Camelo 
et al. who demonstrated that blocking IL-25 signalling in a model of type 2 colitis resulted in 
a significant reduction in infiltrating nuocytes and NKT cells into the mucosa which 
correlated with decreased IL-5 and IL-13 levels171.  
Blocking IL-25 signalling resulted in a significant reduction of IL-13 in the BAL and lung tissue 
in both groups of anti-IL-17RB-treated OVA-challenged mice compared with isotype-
matched controls. Barlow et al. recently demonstrated that by inhibiting IL-25 before 
allergen challenge in mice, IL-13 levels were significantly decreased with a reciprocal 
increase in IL-17A that was shown to be important for protection against Th2 
inflammation172. Furthermore, transgenic overexpression of IL-13 in mice that were 
administered IL-25 blocking antibody failed to upregulate IL-17A. This suggests that IL-13, 
acting downstream of IL-25, plays a role in suppressing IL-17A and that IL-25 acts as a key 
regulator of this IL-13/IL-17A axis. Pertinent to our study was the fact that although IL-17A 
has been documented to induce neutrophilia, the reciprocal elevation of IL-17A in anti-IL-
25-treated mice did not induce significant neutrophil infiltration in the blood or BAL of 
mice172. It is also interesting to speculate that, based on findings that IL-13 blocks in vitro 
differentiation of Th17 cells by inhibiting IL-6, IL-1β and IL-23, the large increase in IL-6 
observed in anti-IL-17RB-treated RV OVA mice may be as a result of enhanced IL-17A 
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production166. Corroborating a beneficial role for IL-17A in allergic disease, a separate study 
demonstrated that, when administered to allergen-sensitised mice, IL-17A could suppress 
allergic inflammation and AHR248.  
Based on these findings, IL-25 may well act as a regulator of the IL-13/IL-17A axis in RV-
induced exacerbation of allergic airways disease and future studies will focus on measuring 
IL-17A and related Th17-promoting cytokines; however, certain read-outs in our model were 
in contradiction with published findings. For example, Barlow et al. reported that blocking 
IL-25 resulted in complete abrogation of AHR which was dependent on IL-17A production172. 
We found that although blocking IL-25 signalling reduced numerous mediators of Th2 
inflammation including IL-13 and granulocytes in the airways of anti-IL-17RB-treated RV OVA 
mice, airway obstruction as measured by whole-body plethysmography (WBP) was not 
significantly reduced. Future studies will aim to corroborate airway obstruction data with 
measurement of AHR by double-chamber plethysmography (DCP) as previously carried out 
in our model of RV-induced allergic airways disease. Although experiments to investigate 
the effects of blocking IL-25 signalling were repeated twice, due to the amount of 
techniques employed to measure read-outs at each time-point and the large number of 
mice per study, WBP was considered the most practical system for measurement of airway 
responses. This is largely due to the fact that DCP is more time-consuming, requiring several 
rounds of acclimation to familiarise mice with the restraining neck seals to prevent 
confounding reading as a result of stress249. However, DCP permits measurement of sRaw 
(indicating the sum of lung volume and upper airway or nasal resistance), a more relevant 
read-out of airway mechanics249. This fact together with the finding that employing DCP in 
our previous study showed significantly greater AHR in RV OVA mice compared with OVA 
treatment alone (a difference that was not reflected in WBP), represents a rationale for 
repeating these studies with a specific focus on measuring this important read-out of 
disease severity via DCP.  
Gregory et al. recently demonstrated that blocking IL-25 in mice exposed to HDM 
completely abrogated  IL-33 and TSLP production suggesting that IL-25 drives both IL-33 and 
TSLP in the lung201. In contrast, we reported that blocking IL-25 signalling had no effect on 
TSLP and IL-33 at 8h p.i., indicating induction of both mediators in response to RV infection 
and/or OVA exposure by the epithelium. However, IL-17RB neutralisation in both OVA-
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challenged groups resulted in a significant decrease in IL-33 and TSLP at d1 p.i. indicating a 
later IL-25-regulated cellular source. It has been reported that stimulation of the mouse lung 
epithelium with IL-25 induced TSLP expression70; therefore, IL-25 may activate a later source 
of epithelial-derived TSLP as indicated by reduced expression in IL-17RB-neutralised mice at 
d1 p.i. In a similar way, IL-33 is produced by structural cells including airway smooth muscle 
cells, endothelial cells and lung fibroblasts which have been reported to express the IL-25 
receptor; therefore these structural cells may represent a source of IL-33 regulated by IL-
25126,142,189-191. While levels of IL-33 were reduced in all treated groups by d7 p.i., TSLP levels 
were in fact elevated in IL-17RB-neutralised RV OVA mice. These results indicated that 
adaptive sources of TSLP were not regulated by RV-induced IL-25. In contrast, a reduction in 
allergen-driven TSLP was indicative of a cellular source dependent on IL-25 activation.  
Based on the fundamental role that Th2 cells play in mediating asthma pathogenesis, it was 
of major relevance that blocking RV-induced IL-25 resulted in a significant reduction in cells 
in the airways and lung of RV OVA mice. This was apparent from cell numbers in IL-17RB-
neutralised RV OVA mice that were restored to levels measured in UV OVA mice and the 
fact that Th2 cells were largely unchanged in anti-IL-17RB and isotype-treated UV OVA 
groups. At this preliminary stage of characterising IL-25 signalling blockade in our disease 
model, there are numerous mechanisms that could be postulated to describe this striking 
reduction. For example, significant decreases in the Th2 chemoattractant, CCL17/TARC, 
which were exclusively reduced in RV OVA groups at d7 p.i. could have contributed to 
decreased recruitment of Th2 cells expressing CCR4; this is in accordance with other studies 
that demonstrated blocking CCL17/TARC in a mouse model of allergic disease reduced CD4+ 
T cell infiltration and Th2 cytokines250. Furthermore, the absence of an early source of IL-4 
as measured in the airways of RV OVA mice may play a role in reduced Th2 cell 
differentiation contributing to decreased total Th2 cell numbers251. In a previous study, IL-25 
was shown to induce early IL-4 expression in naive CD4+ T cells from mice via upregulation 
of NFATc1 and JunB which resulted in increased GATA3 expression and Th2 cell 
differentiation in vitro. Therefore, the lack of IL-4 observed in RV OVA mice may be directly 
related to blocking RV-induced IL-25 signalling which may result in reduced Th2 cell 
differentiation70. IL-25 has also been demonstrated to enhance proliferation and induce 
activated IL-17RB-expressing Th2 memory cells to acquire an effector-memory phenotype 
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by directly binding to its receptor. Therefore blocking RV-induced IL-25 signalling may 
directly reduce Th2 cell proliferation and activation. Our observation of decreased Th2 cells 
in RV OVA mice is in support of this127.  
In view of the fact that Kaiko et al. demonstrated a reciprocal relationship between IL-25 
and IFN-γ, it may be suggested that blocking IL-25 signalling increased levels of IFN-γ 
resulting in an augmented antiviral response as indicated by reduced viral load in IL-17RB-
neutralised RV OVA mice at 8h p.i.  However, measurement of IFN-γ in our model of disease 
revealed no significant differences between treatment groups (data not shown). Prospective 
measurement of the type I (IFN-β and IFN-α) and type III (IFN-λ) IFNs in our disease model 
would be relevant based on their ability to disrupt viral replication resulting in reduced viral 
load in the innate immune response. Furthermore, the fact that enhanced viral shedding 
due to deficiencies in IFN-β and IFN-λ were highlighted as potential mechanisms of 
exacerbation of disease in HBECs from atopic asthmatics indicates characterisation of these 
innate responses are of particular importance102,103.  
Of interest was the fact that decreased viral load in IL-17RB-neutralised RV OVA mice 
coincided with significantly upregulated levels of BAL IL-6 early after infection. Whether this 
pleiotrophic cytokine is beneficial or harmful in respiratory disease is largely unknown. Its 
ability to activate B cells and proliferate cytotoxic T cells indicates a potential antiviral 
role252; of interest, mice deficient in IL-6 that were exposed to aerosolised endotoxin 
displayed enhanced levels of airway neutrophilia, TNFα and MIP-2253. Therefore, further 
characterisation of this cytokine and its ability to upregulate Th1 as well as Th17 responses 
will be carried out in future studies.  
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7.6 Summary of findings  
RV infection of HBECs induced IL-25 gene and protein expression. Importantly, HBECs from 
atopic asthmatics demonstrated a greater propensity to express IL-25 which may represent 
a mechanism whereby RV interacts with the allergic phenotype to drive Th2 inflammation in 
RV-induced asthma exacerbation. In a similar way, RV infection of the untreated mouse 
airway induced IL-25 expression in the airway epithelium as well as in inflammatory cells in 
the airway lamina propia. However this expression was not sufficient to initiate Th2 
inflammation. It may be this system models RV infection in an otherwise healthy individual. 
That is, despite the fact that IL-25 is upregulated, a beneficial antiviral response (as 
indicated by increased type III IFN production) is induced and Th2 inflammation is not 
initiated due to the absence of allergen sensitisation and challenge. Based on clinical studies 
that have demonstrated that allergen exposure increases the risk of acute asthma in 
conjunction with viral infection in sensitised asthmatics, our primary aim was to investigate 
the role of RV-induced IL-25 in a model of RV-induced allergic airways disease. Using this 
model, we first demonstrated that RV infection enhanced allergen-induced IL-25 levels as 
well as key features of Th2 inflammation and pathogenesis in the lung (Figure 7.1). We also 
showed that enhanced IL-25 in RV-infected and allergen-treated mice corresponded with 
increased recruitment of IL-17RB-expressing non-T (ILC2s) and T cells (Th2 cells) to the lung 
suggesting that IL-25 may serve as an amplification factor in RV-induced Th2 inflammation. 
Finally, to investigate the role of RV-induced IL-25 on enhancement of Th2 inflammation, we 
blocked RV-induced IL-25 signalling in our mouse model of disease. Neutralising IL-17RB 
reduced several key features of the exacerbation phenotype in RV OVA mice including 
airway leukocyte infiltration, BAL Th2 cytokines and chemokines, Th2 cells and total mucin 
production. In contrast, Th2-associated responses were largely unchanged by blocking IL-25 
signalling in established allergic inflammation. These findings suggest that RV-induced IL-25 
plays a role in augmenting Th2 inflammation associated with the exacerbation phenotype 
which it mediates through binding to its receptor, IL-17RB.  
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Figure 7.1 (A) A Venn diagram illustrating the enhancing effects of OVA and RV infection (overlapping space 
between both circles) as opposed to characteristic responses of each factor alone. (B) Representation of the 
role of RV-induced IL-25 in our model of RV-induced allergic airways disease based on findings from blocking 
IL-25 signalling. RV-induced IL-25 increased key aspects of the exacerbation phenotype including 
A 
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neutrophils, eosinophils, Th2 cells and basophils into the airways. Furthermore, RV-induced IL-25 
upregulated Th2 cytokines and chemokines as well as mucus secretion and possibly viral load.  
7.7 Potential therapeutic applications 
The findings that blocking IL-25 signalling in a system that models RV-induced asthma 
exacerbations not only dramatically reduced several key symptoms of allergic inflammation 
in the lung but also, surprisingly, decreased early viral load as well as virus-induced airway 
neutrophilia highlights a strong therapeutic potential. The benefits of blocking IL-25 to 
reduce disease severity in a model of allergic airways disease have been previously 
demonstrated70,169,170. However, this is the first study that indicates that neutralising IL-
17RB is able to reduce immunopathogenic mechanisms relating to both virus and allergen in 
a model of RV-induced allergic airways disease. Therapies for viral-induced asthma are 
largely limited due to its mixed Th1/Th2 phenotype characterised by neutrophilic 
inflammation that has been demonstrated to be resistant to corticosteroid treatment83,90. 
Moreover, therapeutic targeting of allergic inflammation using oral corticosteroids has, in 
some instances, proven detrimental due to reciprocal interference of antiviral immunity 
resulting in increases in viral titre91. Therefore the observation that blocking the IL-25 
receptor resulted in reduced viral load and virus-driven inflammation (neutrophilia) as well 
as reduced Th2 inflammation is novel.  Furthermore, findings from our study as well as 
others show that IL-25 is produced by the respiratory epithelium suggesting that it acts 
upstream of Th2 inflammation and that targeting this cytokine may be more efficacious in 
reducing disease progression than inhibiting specific cytokines further downstream of the 
Th2 immune cascade70,157. However, it will also be necessary to comprehensively assess 
what effects blocking IL-25 signalling may have on immune homeostasis in the respiratory 
mucosa. Based on the findings that a deficiency in IL-25 resulted in autoimmune disorders 
including inflammatory bowel disease as a result of a reciprocal increase in Th17-associated 
immunity, a thorough investigation of potential secondary effects in other organs will be 
necessary130,166. The results obtained in this study are promising and indicate that 
transiently blocking IL-25 signalling is beneficial in reducing the exacerbation phenotype and 
may enhance antiviral responses in a model of RV-induced allergic airways disease. 
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7.8 Future work  
7.8.1 Cellular sources of IL-25 protein in the lung 
As our findings are the first to detect RV-induced IL-25, we included IHC to measure IL-25 
immunoreactivity to corroborate protein data as measured by ELISA. Preliminary analysis of 
IL-25 immunoreactive cells in our model of RV infection demonstrated novel findings; in 
particular, the fact that neutrophils are a potential source of IL-25. Future work will focus on 
a more detailed analysis of cellular sources using double staining IHC for phenotypic 
markers such as ly-6G and ly-6C to identify neutrophils.  Alternatively, flow cytometry may 
be employed to characterise cells expressing IL-25 via intracellular staining as well as co-
expression of additional surface phenotypes.  
Furthermore, a primary aim of future studies will be to assess IL-25-producing cells in our 
mouse model of RV-induced allergic airways disease again either employing double staining 
IHC or flow cytometry.  
 
7.8.2 Characterisation of regulation of IL-25 expression 
Very little is known about the regulation of IL-25 gene expression. Based on the presence of 
a putative NF-κB binding site upstream of the IL-25 encoding region as well as the fact that 
RV infection of epithelial cells was shown to increase NF-κB activation37, we have carried out 
preliminary analysis of the role of NF-κB in IL-25 regulation by pharmacological inhibition of 
the IκB kinase complex (IκK2) (a crucial signalling component of the NF-kB pathway) in RV-
infected mice. Future studies will aim to confirm these findings, however initial results are 
promising indicating decreased IL-25 gene expression in IκK2-treated mice infected with RV.   
 
7.8.3 Characterisation of Th2 cytokine expression and confirmation of cell populations 
Preliminary flow analyses demonstrated the presence of IL-17RB-expressing ILC2s and Th2 
cells in the lung and BAL of mice in our model of RV-induced allergic airways disease. To 
explore a mechanistic function for these cells via the secretion of Th2 cytokines, we aim to 
employ reporter mouse strains expressing GFP or alternatively the Tomato fluorescent gene 
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at the IL-4 and IL-13 loci to determine cytokine expression together with our panel of 
selective surface markers in mice treated with anti-IL-17RB and isotype controls.   
In addition, investigation of the effects of IL-25 stimulation as well as anti-IL-17RB inhibition 
on relevant cell populations in in vitro cultures harvested from our mouse model would also 
allow us to gain a greater understanding of what cell types are responsive to IL-25. Of 
particular interest, IL-17RB-expressing ILC2s and Th2 cells will be assessed for their ability to 
secrete Th2 cytokines in response to IL-25 stimulation and similarly the ability of anti-IL-
17RB to inhibit cytokine release. 
Future work will also involve a thorough characterisation of identified IL-17RB-expressing 
cells. Specifically, a lineage negative panel to confirm the absence of T and B cell, 
macrophage, DC, neutrophil, eosinophil, mast cell, basophil, NKT cell or NK cell markers will 
be assembled to definitively classify ILC2s in our disease model.  
 
7.8.4 Development of RV-induced allergic airways disease model 
OVA, which does not contain protease activity, largely induces Th2 inflammation via 
interaction with DCs and subsequent presentation to T cells.  The fact that a large 
proportion of allergens shown to induce IL-25 from the respiratory epithelium have been 
reported to possess proteolytic activity67,70, indicates that the investigation of concomitant 
treatment with RV together with a more complex physiologically relevant allergen is 
noteworthy. For example, employing the common human aeroallergen HDM together with 
RV infection would be of interest given that HDM was demonstrated to trigger TLR4 on lung 
structural cells in mice inducing IL-25 expression67.  As carried out in our mouse model of 
disease in relation to OVA challenge, a thorough titration of the allergen dose will be 
required to optimise treatment regime. Based on a demonstrated role for IL-25 in airway 
remodelling, it would also be of relevance to carry out a chronic allergen challenge protocol 
over a number of weeks and assess the effects on IL-25 expression over an extended 
duration. 
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7.8.5 Variation of treatment regime for blocking IL-25 signalling  
Given that we were primarily focussed on investigating the role of RV-induced IL-25 in our 
model of disease, we administered a blocking antibody 4 hours before infection. Future 
studies will investigate varied treatment regimes by administering the blocking antibody at 
different points before and after infection. For example, administering the blocking 
antibody prior to sensitisation and assessing the effect on allergen-induced and RV-induced 
IL-25 would be of great interest.  
 
7.8.6 Investigation of mechanisms of suppression of Th2 responses by blocking IL-25 
signalling 
A primary aim of future work will be to characterise a mechanism for reduced Th2 
inflammation as well as reduced viral load and neutrophilia measured as a result of blocking 
IL-25 signalling in RV-infected and OVA-challenged mice. This will include analysis of 
potentially augmented Th1 and Th17-associated mediators. Specifically, the innate type I 
and type III interferons will be measured as a possible mechanism for reduced viral load on 
the basis of their ability to enhance antiviral responses. Previous studies have reported that 
IL-25 induced CXCL8/IL-8 in human renal cells via NF-κB activation152. Therefore, 
measurement of neutrophil chemoattractants including CXCL1/KC will be carried out in our 
disease model. This would be of particular interest since enhanced neutrophilia in the 
airways is a hallmark of RV-induced asthma in patients which has been associated with 
augmented disease severity; therefore a reduction in neutrophilic inflammation via IL-17RB 
neutralisation may be of therapeutic benefit.  
In addition, IL-17A will be measured to ascertain whether IL-25 plays a role in regulating the 
IL-13/IL-17A axis and if reduced IL-13 levels measured in our model of disease are a result of 
reciprocally increased IL-17A production. Additional Th17 associated mediators, including 
the Th17-promoting cytokines IL-1β and IL23, will also be measured to assess if they 
coincide with upregulated IL-6 and whether they play a role in inducing Th17 cell 
differentiation. Also of interest is whether these Th17-associated factors are beneficial to 
the exacerbation phenotype which could be investigated by antibody-mediated blocking of 
relevant cytokines and measuring read-outs of Th2 inflammation. 
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